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ABSTRACT 
 
One of the research areas that has gained interest in recent years in order to explain 
diabetes-related complications is the accumulation of a group of compounds called 
advanced glycation end products (AGEs). AGEs can be formed in the body and 
contribute to vascular damage in diabetes. In addition, AGEs can be found in some 
foods rich in protein and fat (high cooking temperatures increases its formation) and 
some research shows that they can also accumulate in the body and could have a role 
in diabetes complications. Some studies also have shown that higher intake of AGEs 
could increase the risk of diabetes-related complication by elevating inflammatory and 
oxidation markers even in states when glucose levels are normal. However, the 
association between AGEs consumption and diabetes-related complications has not 
been demonstrated.  
In this study, we tried to identify if high intake of AGEs results in an increased risk for 
complications in patients with DM type 2 in two different ethnicities (Mexicans and non-
Hispanic Whites). Because the association between AGEs consumption and diabetes-
related complications has not been studied due to the long-term data needed for AGE 
intake. In addition, we were also interested in developing an assessment tool (a food 
frequency questionnaire) to categorize whether AGEs intake is high, moderate or low in 
order to assess AGEs intake related to DM complications in the different populations 
studied. 
This study showed that for each unit increase in the transformed dietary AGEs 
(LogAGEs), participants were 3.7 times more likely to have moderate-high risk for 
cardiovascular disease. The present study also found that the food frequency 
questionnaire is comparable to 7 days of Food Records to measure dAGEs. In 
conclusion, dietary AGEs were associated with the risk level for diabetes-related 
cardiovascular complications, which should be explored in future research. 
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Chapter 1 
Introduction 
 
Recent data show an increase in the prevalence of diabetes mellitus (DM) in the United 
States (US) from 10.7 in 2007 to 11.3% in 2011 in adults 20 years of age and older. A 
closer analysis of the 2011 data shows important differences by race/ethnicity; the 
prevalence in non-Hispanic whites is 7.1% while in Mexican-Americans it is 13.3 %, just 
below the prevalence of DM in Mexico (14.4%) according to the 2006 national survey 
[1,2]. A recent survey in Mexico (ENSANUT 2012) reveals that 9.1% of the total 
population has been diagnosed with diabetes, and a rough estimation for the total 
prevalence (adding those without confirmed diagnosis) could be as high as 18% [3]. In 
addition, complications of diabetes are the 7th leading cause of death in the US, and it 
is estimated that the average medical expenditure for people with diabetes is 2.3 times 
higher than people without the disease [2]. Understanding the factors that could have a 
role in diabetes complications is important to improve the individual’s quality of life and 
reduce the economic burden caused by diabetes complications. One of the research 
areas that has gained interest in recent years is the accumulation of a group of 
compounds called advanced glycation end products (AGEs). AGEs can be formed in 
the body and contribute to vascular damage in diabetes [4]. In addition, AGEs can be 
found in some foods rich in protein and fat (high cooking temperatures increases its 
formation) and some research shows that they can also accumulate in the body with 
subsequent impact on health [5]. Most of the studies with dietary AGEs (dAGEs) are 
clinical research studies, where a high or a low AGEs diet is assigned to a treatment or 
to a control group, and the effects of these diets are measured in terms of levels of 
blood AGEs, and levels of inflammation markers. In these studies, AGEs intake has 
been assessed with 3-day food records. However, there is still not a standardized 
assessment method for AGEs quantification in the diet, and the association between 
AGEs consumption and diabetic complications has not been studied due to the lack of 
longitudinal data on both AGEs intake and complications development.  
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It must be noted that my research to date has included Mexicans, non-Hispanic whites, 
and Mexicans in Illinois because this dissertation is a continuation of my research for 
my Master’s degree at the University of Guanajuato, Mexico. That work included a 
randomized six week prospective study in two groups of patients: one with a standard 
diet (n=13), and another with low dAGEs (n=13), both with similar amounts of calories, 
carbohydrates, lipids, and proteins. At the beginning and the end of study, we collected 
anthropometric measures, and circulating glucose, hemoglobin A1c (HbA1c), lipids, 
insulin, serum fluorescent AGEs, protein C-reactive (CRP), tumor necrosis factor alpha 
(TNF-α) and malondialdehyde (MDA), insulin, and the homeostatic assessment model 
was calculated to measure insulin resistance (HOMA-IR). Adherence to diet was 
reviewed weekly. Changes in TNF-α levels were different for the standard diet 
(12.5±14.7) as compared with low dAGEs (−18.36±17.1, p<0.00001). Also, changes in 
MDA were different in the standard versus the low dAGEs group (2.0±2.61 and 
−0.83±2.0, p<0.005), and no changes were found for insulin levels or HOMA-IR. In 
conclusion, dAGEs restriction decrease significantly TNF-α and MDA levels [6].    
For this dissertation, the differences and similarities among two ethnic groups in AGEs 
intake and differences in complications of diabetes and possible relationships with level 
of AGEs in diet were investigated.                                                           
 
1.1 Objectives 
The long-term goal of my research is to delay the onset of diabetes complications that 
could be secondary to dAGEs. As a first step towards accomplishing this goal, the 
objective of this research is to investigate whether there is an association between 
different levels of AGEs intake and the extent of severity of complications in subjects 
with DM.  
 
1.2 Hypothesis 
My central hypothesis is that subjects with DM type 2 and with diabetes related 
complications would have a higher intake of dAGEs when compared with subjects 
without complications.  
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A review of the literature indicates that dAGEs increase circulating AGEs, accumulate in 
tissues, and act as a ligand for the advanced glycation end products receptor (RAGE). 
My previous work showed that by decreasing dAGEs the pro-inflammatory cytokine 
TNF-α and the oxidation marker MDA decreased as well [6].  
The rationale for developing this research is that no previous study has shown a 
relationship between high intake of dAGEs and presence of complications in type 2 DM. 
In addition, there is evidence that Mexican-Americans have higher prevalence of 
diabetes and higher risk for diabetes-related complications than non-Hispanics whites. 
We are interested in knowing if differences in AGEs intake could explain this higher risk 
for complications independent of long-term healthcare. 
 
1.3 Specific Aims  
In order to test our central hypothesis the following 3 specific aims are proposed:  
Specific Aim 1: Examine the dietary intake of AGEs in non-Hispanic white, Mexicans 
living in Mexico and Mexicans living in Illinois with DM that may vary due to different 
foods eaten and cooking methods. Also, explore the potential relation of AGEs intake 
and complications in diabetes. 
The working hypothesis is that dAGEs intake is different in these 3 ethnic groups. This 
difference could explain the differences in diabetes related complications among these 3 
groups. This would involve establishing differences between dietary intakes in the 3 
groups, setting categories of AGEs intake and determining a score for categories for 
diabetes complications.   
 
Specific Aim 2: Develop an assessment tool to categorize whether AGEs intake is 
high, moderate or low in order to assess AGEs intake related to DM complications in the 
different populations studied.  
The working hypothesis is that a food frequency questionnaire is comparable to food 
records to establish categories of dAGEs intake. This would involve designing a food 
frequency questionnaire to assess and categorize AGEs intake, and measuring the 
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relative validity and reliability of this food frequency for future use in epidemiological 
studies. 
 
Specific Aim 3: Identify if high intake of AGEs results in an increased risk for 
complications in patients with DM type 2. 
The working hypothesis is that subjects with diabetes related complications have a 
higher AGEs intake when compared with subjects without complications. This would 
involve assessing actual and past intake of dAGEs in a control group (subjects without 
complications) and in a case group (subjects with complications).  
 
1.4 Scope and statement of the problem  
Diabetes-related complications are the 7th cause of death in the US, and, in Mexico, 
they are the leading cause of death [1,2]. Patients with diabetes-related complications 
have a diminished quality of life and the economic toll of the disease is becoming a real 
challenge. Longitudinal studies showed that glycemic control is the best strategy to 
delay diabetes-related complications. However, some studies also have shown that 
higher intake of AGEs could increase the risk of diabetes-related complications by 
elevating inflammatory and oxidation markers even in euglycemic states [7]. Because 
the association between AGEs consumption and diabetes-related complications has not 
been studied due to the long-term data needed for AGEs intake, we believe that this 
research could help to answer this research question.  
 
1.5 Significance  
At the completion of this research, we will have established if dietary AGEs represents a 
risk for complications in DM. These results will encourage the development of further 
research to establish a direct association between dietary intake of AGEs and 
complications. In addition, the results of this research could help in establishing the 
pertinent recommendations for AGEs intake in patients with DM with the purpose to 
decrease the health care burden that complications for diabetes represent in the actual 
health care system in developed as well developing countries. 
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For this thesis Chapter 2 and Chapter 3 served as literature review. The methodology 
and results for specific aim 1 are presented on Chapter 4, and additional results are 
presented on Appendix A. The methodology and results for specific aim 2 are presented 
on Chapter 5, and the methodology and preliminary results for specific aim 3 are 
presented on Chapter 6. Conclusions and future directions are presented on Chapter 7. 
The questionnaires used for the different studies are presented on Appendix B, C and 
D. 
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  Chapter 2 
Dietary Advanced Glycation End Products and Aging1 
 
 
Abstract: Advanced glycation end products (AGEs) are a heterogeneous, complex 
group of compounds that are formed when a reducing sugar reacts in a non-enzymatic 
way with amino acids in proteins and other macromolecules. This occurs both 
exogenously (in food) and endogenously (in humans) with greater concentrations found 
in older adults. While higher AGEs occur in both healthy older adults and those with 
chronic diseases, research is progressing to both quantify AGEs in food and in people, 
and to identify mechanisms that would explain why some human tissues are damaged, 
and others are not. In the last twenty years, there has been increased evidence that 
AGEs could be implicated in the development of chronic degenerative diseases of 
aging, such as cardiovascular disease, Alzheimer’s disease and with complications of 
diabetes mellitus. Results of several studies in animal models and humans show that 
the restriction of dietary AGEs has positive effects on wound healing, insulin resistance 
and cardiovascular diseases. Recently, the effect of restriction in AGEs intake has been 
reported to increase the lifespan in animal models. This paper will summarize the work 
that has been published for both food AGEs and in vivo AGEs and their relation with 
aging, as well as provide suggestions for future research. 
Keywords: advanced glycation end products; aging; Maillard reaction. 
 
 
 
 
 
  
 
1 This chapter appeared in its entirety in Nutrients and it is referred as to Luevano-Contreras C, Chapman-
Novakofski. Dietary Advanced Glycation End Products and Aging. Nutrients, 2010, 2, 1247-1265.  
This article is © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution license and it can 
be found at http://www.mdpi.com/2072-6643/2/12/1247 with DOI: 10.3390/nu2121247. 
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2.1 Introduction  
Advanced glycation end products (AGEs) are a heterogeneous, complex group of 
compounds that are formed mainly via the Maillard reaction. The Maillard reaction 
occurs when reducing sugar reacts in a non-enzymatic way with amino acids in 
proteins, lipids or DNA. This reaction has been studied for years in the food industry 
because its products add a desirable color and taste to foods. However, the study of the 
products of this reaction in vivo have received increasing attention in recent years due 
to association of AGEs with certain chronic diseases, such as diabetes mellitus, 
cardiovascular diseases, and Alzheimer’s disease, as well as during the aging process. 
 
2.2 Formation of AGEs  
The formation of AGEs through the Maillard reaction occurs in three phases (Figure 
2.1). First, glucose attaches to a free amino acid (mainly lysine and arginine) of a 
protein, lipid or DNA, in a non-enzymatic way to form a Schiff base. A Schiff base is a 
compound that has a carbon to nitrogen double bond where the nitrogen is not 
connected to hydrogen. The initiation of this first step depends on glucose concentration 
and takes place within hours. If the concentration of glucose decreases, this reaction is 
reversible. During the second phase, the Schiff base undergoes chemical 
rearrangement over a period of days and form Amadori products (also known as early 
glycation products). The Amadori products are more stable compounds (hemoglobin 
A1c is the most well known), but the reaction is still reversible. If there is accumulation 
of Amadori products, they will undergo complicated chemical rearrangements 
(oxidations, reductions, and hydrations) and form crosslinked proteins. This process 
takes place in weeks or months and it is irreversible. The final brownish products are 
called AGEs and some of them have fluorescent properties. They are very stable, and 
accumulate inside and outside the cells and interfere with protein function [1,2]. Besides 
the Maillard reaction, other pathways can also form AGEs. For instance, the 
autoxidation of glucose and the peroxidation of lipids into dicarbonyls derivatives by an 
increase in oxidative stress is another pathway described for the formation of AGEs [3]. 
These dicarbonyl derivatives known as α-oxaldehydes (glyoxal, methylglyoxal (MG), 
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and 3-deoxyglucosone) can interact with monoacids and form AGEs. The other well-
studied mechanism for the formation of AGEs is the polyol pathway, where glucose is 
converted to sorbitol by the enzyme aldose reductase and then to fructose by the action 
of sorbitol dehydrogenase. Fructose metabolites (as fructose 3-phosphate) then are 
converted into α-oxaldehydes and interact with monoacids to form AGEs [4]. Thus, at 
least three pathways may form AGEs: The Maillard reaction; oxidation of glucose; and 
peroxidation of lipids and through the polyol pathway. Given these differing pathways, it 
is not surprising that AGEs are diverse in their chemical structure. Among the most 
widely studied AGEs are carboxymethyl-lysine (CML), pentosidine, and pyrraline, and, 
together with methylglyoxal (an α-oxaldehyde), they have been used as biomarkers for 
in vivo formation of AGEs [2,5,6]. CML (not fluorescent, not cross-linked AGEs) has 
been consistently used also as a biomarker for long-term protein damage and can be 
formed by the Maillard reaction and by α-oxaldehydes. As well as CML, pentosidine (a 
fluorescent protein crosslink) is formed by the Maillard reaction and by the α-dicarbonyl 
glyoxal, while pyrraline (not fluorescent, not cross-linked AGEs) is formed by the 
Maillard reaction [7].  
 
The deleterious effects of AGEs in different tissues are attributed to their chemical, pro-
oxidant, and inflammatory actions [1,2]. The biological effects of AGEs are exerted by 
two different mechanisms: One independent of the receptor (damage of protein 
structure and extracellular matrix metabolism); or one involving the receptor for 
advanced glycation end products (RAGE) [2,8] (Figure 2.2). The interaction of AGEs 
with the receptor RAGE triggers the activation of the mitogen-activated protein kinases 
(MAPKs) and the phosphatidylinositol-3 kinase (PI3-K) pathways that will lead to the 
activation of the transcription factor NF-κB (nuclear factor kappa B). After activation, NF-
κB translocates to the nucleus where it will activate the transcription of genes for 
cytokines, growth factors and adhesive molecules, such as tumor necrosis factor α 
(TNF-α), interleukin 6 (Il-6), well known inflammation promoters, and vascular cell 
adhesion molecule 1 (VCAM1) [8-12]. NF-κB activation increases RAGE expression, 
creating a positive feedback cycle that enhances the production of inflammation 
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promoters. In addition, AGE-RAGE interaction activates NAD(P)H oxidase (a complex of 
enzymes which produces superoxide) and when this complex is upregulated, it 
increases intracellular oxidative stress. The sudden increase in oxidative stress by 
NAD(P)H oxidase in response to AGE-RAGE interaction will also activate NF-κB [13-
15].  
 
2.3 Implications for Health 
Accumulation of AGEs has been found in healthy aging persons, and this accumulation 
is higher during high glucose concentrations. Microvascular and macrovascular 
damage, seen in diabetes, is attributed to the accumulation of AGEs in tissues, but it is 
also associated with atherosclerosis, Alzheimer’s disease, end stage renal disease, 
rheumatoid arthritis, sarcopenia, cataracts, and other degenerative ophthalmic 
diseases, Parkinson’s disease, vascular dementia and several other chronic diseases 
[16-19]. For instance, Bar et al. have demonstrated differential increases of AGEs 
products in Alzheimer’s dementia and vascular dementia compared to controls [20]. It 
has also been suggested that AGEs are involved in the loss of bone density and 
muscular mass associated with aging [21]. We discuss briefly some of the health 
implications described in the older population. 
 
2.3.1 Cardiovascular Diseases 
The in vivo accumulation of AGEs over time contributes to changes in the structure and 
function of the cardiovascular system and presents as arterial stiffening, myocardial 
relaxation abnormalities, atherosclerotic plaque formation and endothelial dysfunction. 
Several authors have described some of the mechanisms for these changes. One of the 
proposed mechanisms involves additional cross-linking on collagen (whose normal 
structure already contains crosslinking) by glycation of its free amino acids. The 
collagen-AGEs cross-linking will produce stiffness of blood vessels. Sims et al. 
completed a histological study on 27 samples of post-mortem aortas from people with 
diabetes and controls and found a correlation between AGEs accumulation and aortic 
stiffness [22]. Another mechanism by which AGEs exert damage to the cardiovascular 
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system is reduction of low-density lipoproteins (LDL) uptake by cell receptors. This 
occurs through glycation of the LDL particle on the apolipoprotein B and in the 
phospholipid components of LDL. The glycated LDL is more susceptible to cross-linking 
with collagen on the arterial wall than non-glycated LDL, and it is not taken up into the 
cell and accumulates. Macrophages uptake of these modified LDL lead to foam cell 
formation, and the development of atheroma [23,24]. Furthermore, decreasing in nitric 
oxide (NO) activity is another mechanism described by AGEs damaging the 
cardiovascular system. NO (a vasodilator) biosynthesis in the endothelium counteracts 
some of the mechanisms for atherosclerosis. Some authors proposed that AGEs reduce 
NO synthase (eNOS) half-life in the endothelium. For instance, Xu et al. found a 
decreased in eNOS activity after exposure to CML. They also found that after 30 
minutes of exposure with CML-albumin, there was a reversible inhibition of endothelium 
and vascular response dependent on NO in vivo and in vitro [25-28]. Additional work 
supports the role of increased androgens during and after menopause as a risk factor 
for cardiovascular events in women, with an associated increase in AGEs. A study of 
106 postmenopausal women found significant correlations between testosterone and 
free androgen indices versus AGEs after adjustment for age, body mass index, insulin 
resistance indices, and fasting glucose and insulin levels [29]. 
 
Therefore, the accumulation of AGEs could be explained by some of the cardiovascular 
changes associated with aging, such as vascular stiffening, diastolic dysfunction and 
endothelial dysfunction [24]. A study with long-term (24–30 weeks) administration of 
aminoguanidine (an inhibitor of AGE formation) showed prevention of the age-related 
cardiac hypertrophy and arterial stiffness [30]. It has also been found that CML, a 
predominant AGE, can serve as a predictor of cardiovascular mortality. Semba et al. 
studied a group of 559 women aged 65 and older for 4.5 years from the Women’s 
Health and Aging Study I (WHAS I). During this time 22% of the population died; 43.9% 
from cardiovascular disease. They measured CML as a marker for AGEs and found that 
the highest risk for dying of cardiovascular disease were for women in the highest 
quartiles of CML [31]. From these reports, it appears that high concentrations of AGEs 
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could be a risk factor for cardiovascular disease, but further evidence is needed to 
support this statement.  
 
2.3.2 Sarcopenia 
Loss of muscle mass and strength (sarcopenia) is a serious problem among older 
populations [32]. In accordance with recent studies, one third of women and half of men 
older than 60, have sarcopenia in the U.S. [33]. The pathogenesis of sarcopenia is 
multifactorial, and may include hormonal changes, increased oxidative stress and 
inflammation, changes in vasculature, and inactivity [34-36]. AGEs may also contribute 
to this condition by increasing oxidative stress and inflammation. Some studies have 
found a relation between AGEs and muscular function in older population. Haus et al. 
found that pentosidine concentrations were 200% higher in a group of older individuals 
with a mean age of 78 y (n=22) compared with their younger counterparts with a mean 
age of 25 y (n=20). The authors concluded that AGEs may contribute to the decline of 
muscular function observed in aging [37]. Dalal et al. conducted a study of older women 
to measure the AGEs concentration in blood and handgrip strength. Serum 
carboxymethyl-lysine (CML), the circulating soluble form of receptor for advanced 
glycation end products (sRAGE), endogenous secretory receptor for advanced glycation 
end product (esRAGE) and grip strength, were measured in 559 moderately-to-severely 
disabled women, age 65 and older, in the Women’s Health and Aging Study I in 
Baltimore. The authors found that women with higher concentrations of CML had less 
grip strength than women with lower CML concentrations. The authors concluded that 
women with higher AGEs have more muscle weakness [38]. These studies presented 
interesting results, but they are not conclusive of a causal relationship between AGEs 
and sarcopenia, and more studies will need to further address this health problem 
among older population.  
 
2.3.3 Renal Disease  
The relationship between renal disease and AGEs has largely been studied in patients 
with type 2 diabetes mellitus, and to a lesser extent in older populations. Semba et al. 
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[39] demonstrated that in an older population (n=1008), elevated circulating AGEs were 
an independent predictor of renal function. The study was carried out in men and 
women, age 64 and older, participating in the InCHIANTI study in Tuscany, Italy. The 
results of the study demonstrated an elevated plasma concentration of CML 
independently associated with chronic kidney disease and the estimated glomerular 
filtration rate (an index of kidney function) at baseline, after three and six years of follow-
up. These findings suggest that the potential adverse effects of AGEs on the kidney are 
applicable to the general population of older community-dwelling adults [39]. In another 
study of 548 women from the Women’s Health and Aging Study I in Baltimore, 51.6% of 
women had decreased glomerular filtration rate, which was associated with increased 
serum levels of CML and sRAGE. However, more follow-up studies on the elderly 
population are needed to establish if high levels of CML could predict decreased in renal 
function [40]. 
 
2.3.4 Alzheimer’s Disease 
Although a definitive etiology for Alzheimer’s disease is unknown, oxidative stress has 
been identified as a primary risk factor for the disease. Both aging itself and the 
presence of AGEs are thought to be risk factors through their role in chemical, pro-
oxidant, and inflammatory actions as previously described. A comparison of normal 
control and Alzheimer’s disease patients’ brain tissue found higher AGEs and RAGE 
expressions in age-matched controls [41]. In addition, there is evidence that RAGE 
mediates the blood-brain barrier transport of amyloid peptides in certain situations [42]. 
A recent review has described possible links between Alzheimer’s disease and 
diabetes, which include AGEs, advancing age, as well as oxidative stress and 
hypercholesterolemia, although exact mechanisms and relationships require additional 
research [43].  
 
2.3.5 Diabetes 
Hemoglobin A1c is the most widely recognized early glycation product, and is also used 
as an indicator of blood glucose management in those with diabetes. Hyperglycemia 
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increases the glycation process, and is especially apparent in insulin independent 
tissues such as red blood cells, peripheral nerve tissue cells, endothelial cells, eye lens 
cells, and kidney cells [44]. It is also hypothesized that glycation of proteolytic enzymes 
in diabetes reduces their efficiency, resulting in more build up of glycated end products 
[44]. Not surprisingly, AGEs have also been implicated in delayed wound healing 
associate with diabetes, presumably through vascular, neurological, or intermediary 
metabolic modifications [45]. 
 
2.4 Exogenous Sources of AGEs 
In addition to in vivo production, AGEs can also be found in cigarettes and in foods. The 
curing of tobacco leaves has been proposed as the source for compounds that can 
readily increase in vivo AGEs. Cerami et al. found that glycotoxins from cigarettes are 
inhaled into the alveoli, and then they are transported to blood stream or to lung cells 
where they can interact with other glycation products and contribute with AGEs 
formation [46].  
 
2.4.1 Dietary AGEs 
Heat has been used for treatment of foods to improve their safety, bioavailability and 
taste. In addition to these positive effects, overheating of foods can also provoke protein 
degradation and other deteriorative reactions [47]. Heat treatment in some foods results 
in promotion of the Maillard reaction, which adds desirable flavor, color and aroma. In 
the food industry, the Maillard reaction has been used for caramel production, coffee 
roasting, and bread baking among others. Some products of the Maillard reaction can be 
added to industrialized products such as sodas and juices among others [48]. There is 
growing evidence that the average Western diet is a plentiful source of exogenous 
AGEs. The AGEs content of a diet depends on the nutrient composition (foods rich in 
protein and fat have the highest content) and on the way food is processed [49,50]. 
AGEs formation can be rapidly accelerated by increasing the time and degree of 
exposure to heat and can be introduced into the body in heat-processed foods 
[47,49,50]. These findings were demonstrated using an AGE-specific, enzyme-linked 
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immunosorbent assay (ELISA), and it was estimated that ≈10% of ingested 
immunoreactive AGEs are transported into circulation, two-thirds of which remain in the 
body, and are incorporated covalently in tissues. Only one third is excreted via the 
kidneys [51]. 
 
However, it has been controversial whether dietary AGEs are harmful to human health. 
One of the reasons for this controversy is that, as well as those found in vivo, Maillard 
reaction products formed in foods are heterogeneous and only a few have been 
characterized. Some of the products formed during this intricate reaction are furfurals, 
pyrralines and dicarbonyl compounds such as methylglyoxal. The products formed in 
the last reaction of this process are known as melanoidins in food science [52]. As 
mentioned before, regardless of the diversity of AGEs, CML has been reported as one 
of the most abundant in vivo and it was one of the first to be characterized in foods (milk 
and milk products). For this reason in most studies CML is chosen as a marker of AGEs 
in foods and in vivo [53]. 
 
Studies on the effects of AGEs from foods not only are limited to CML, but also to the 
melanoidins found in bread crust, bakery products and coffee. Some positive and 
negative effects of melanoidins have been studied. Ames et al. found that melanoidins 
increased the number of anaerobes, clostridia, and bifidobacteria in a culture of human 
fecal bacteria [54]. These results indicate that a mixture of melanoidins can stimulate 
growth of health-beneficial bacteria in the gut. Borrelli et al. found similar results 
showing that melanoidins from bread crust can promote growth of some bifidobacterias 
strains, indicating a possible potential prebiotic effect of bread crust melanoidins. 
Somoza et al. carried out a study in rats fed with malt and bread crust to measure the 
activity of chemopreventive enzymes such as glutathione-S-transferase (GST) and UDP 
glucuronyl-transferase (UDP-GT) [55]. The activity of GST in kidney increased by 18% 
on the group fed with bread crust, while UDP-GT in liver increased by 27%. The authors 
concluded that diet malt and dietary bread crust increased chemopreventive enzymes in 
rats.  
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On the other hand, several studies, mostly with CML and MG, have shown that the 
intake of dietary AGEs modifies circulating AGEs levels in human subjects and animals 
with or without diabetes or renal disease. In a study with 90 healthy subjects, Uribarri et 
al. estimated the amount of AGEs from three days food records using a database with 
the AGEs content of certain foods. They found a significant correlation between the 
ingested AGEs and the plasma levels. A subgroup was exposed to a dietary restriction 
of AGEs and their plasma levels decreased as well. These results are similar to 
previous reports on patients with diabetes and renal failure patients [56]. Those findings 
support the view that the intake of dietary AGEs is an important contributor to the body 
AGEs pool [56-60]. Besides the endogenously formed AGEs, dietary AGEs have also 
been shown to act as RAGE ligands and activate major signal transduction pathways in 
vitro [11,61,62]. Dietary AGEs, together with those made endogenously, could promote 
a systemic glycoxidant burden, oxidant stress and cell activation, which increases 
vulnerability of target tissues to injury [63,64]. 
 
2.4.2 Dietary AGEs Metabolism  
Several studies have focused on understanding the absorption, metabolism and 
excretion of dietary AGEs. Forster et al. carried out a study to try and understand the 
bioavailability and the kinetics of elimination of some Maillard products found on 
custard, pretzels and brewed coffee. They found that pretzel sticks are a rich source of 
pentosidine and pyrraline. The study was carried out with 18 healthy subjects who 
received specific amounts of these foods on a single day. Urinary excretion of pyrraline 
and pentosidine was measured by chromatographic methods for the following three 
days. The urinary excretion of both Maillard products increased after ingestion and the 
rate of recovery in urine was around 50% for pyrraline and around 60% for pentosidine. 
However, the metabolic fate of the pyrraline and pentosidine is unknown [65]. 
The mechanisms of intestinal absorption of AGEs are not yet well understood. A recent 
study trying to answer this question found that pyrraline is absorbed by the peptide 
transporter hPEPT1. This study is the first one addressing this question and studies on 
the absorption mechanism for more AGEs are needed [66]. 
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A few studies about intestinal absorption of different AGEs have been conducted. 
However, the complete extent of absorption of each individual AGE is not well known. 
As mentioned before, the most studied dietary AGEs are CML, pyrraline and 
pentosidine. Several studies have shown different rates of absorption of each of them. 
However, their metabolic pathways have not been elucidated. More studies on this area 
are needed to understand the impact of dietary AGEs on health and aging. 
 
2.5 AGEs in the Elderly 
The serum levels of AGEs are dependant of endogenous production, exogenous intake 
and renal and enzymatic clearance, which together produce transient increases and 
decreases in serum AGEs levels. Several enzymes (glyoxalase I, II and carbonyl 
reductase) and a receptor (AGER1) have been shown to be part of a detoxification and 
counterregulation system against the prooxidant effects of glycation [67,68]. In addition, 
renal excretion eliminates excess of AGEs production under physiological conditions. 
Some authors have proposed that with aging as well as in some pathological conditions 
there is imbalance in this steady-state. This imbalance can be due to an increased 
endogenous production, or an increased exogenous intake that, in combination with 
lower renal AGEs clearance, leads to the accumulation of AGEs observed in older 
population [68,69].  
 
Uribarri et al. investigated whether AGEs intake correlated with glycotoxin levels, 
markers of inflammation and oxidative stress (OS) comparing older versus younger 
healthy adults. They studied 172 healthy volunteers in two groups (18–45 years) and 
(60–80 years). The CML and MG derivatives were higher in the older group. The 
concentration of AGEs in serum correlated with levels of inflammation markers and OS. 
Additionally, the level of dietary glycotoxins correlated independently with CML and MG 
derivatives, as well as hsCRP. The association found between sCML and the 
homeostasis model assessment (HOMA an instrument to measure insulin sensitivity) 
levels of normal persons could be linked to metabolic processes, which may precede 
insulin resistance, diabetes mellitus, or vascular dysfunction at any age [70]. Vlassara et 
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al. found similar results in a study with 325 healthy participants and 66 participants with 
kidney disease (CKD). Serum CML and MG were higher in the group of older 
participants, and serum CML correlated negatively with eGFR and positively with 
age [67]. 
 
The accumulation of AGEs in tissues may contribute to increased OS, and as a final 
result, impair organ function [16]. Indeed, within the complex the association between 
OS and aging ovarian follicles, AGEs may have an important role as they accumulate 
over the lifespan [71]. More recent work suggests a mechanism for this in that 
detoxification of an AGEs precursor is significantly diminished in older mice, allowing 
AGEs to increase [72]. Additionally, slowly diminishing renal function with age [73] could 
affect the ability to excrete AGEs. Uribarri et al. suggest this as a possible explanation 
as to why they found high AGE levels in the older group, even though the intake of 
dietary AGEs by the older age group was reduced [70]. More evidence is needed, but 
these results suggest the important role of dietary and circulating AGEs in chronic 
degenerative diseases, which are more prevalent in the elderly. 
 
2.6. Strategies for AGEs Reduction  
Some of the strategies studied to lower the extra load of AGEs are reducing dietary 
AGEs, pharmacological treatment and, more recently, exercise.  
 
2.6.1 Dietary Restriction of AGEs 
Findings in several intervention studies, both human subjects and animals, indicate that 
the high intake of dietary AGEs contributes to tissue damage that can be prevented by 
dietary AGEs restriction. These intervention studies reduced dietary AGEs by 
decreasing the heat during the preparation of foods [74-79]. Sebekova et al. found that 
long-term consumption of AGEs in rats leads to a dose-dependent increase in 
proteinuria that overtime could induce renal damage [80]. In addition, the high long term 
consumption of AGEs has also been associated to higher levels of fasting glucose, 
insulin and serum AGEs, as well as increased AGEs localization and RAGE staining in 
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ovarian tissue of rats [81]. In studies of mice, reduced dietary AGEs have been found to 
attenuate insulin resistance, increase the prevention of diabetes and, in diabetic mice, 
reduce diabetic vascular and renal complications, and improve impaired wound healing 
[74-76].  
 
Whereas in human studies, Uribarri et al. demonstrated that intake of dietary AGEs by 
people with type 1 and 2 diabetes promotes the formation of pro-inflammatory 
mediators, leading to tissue injury [82]. Patients with uremia, with and without diabetes, 
in whom the intake of AGEs was reduced, showed reduced levels of inflammatory 
molecules such as TNF-α and high sensitivity C-reactive protein (hsCRP) [79]. In 
another study in patients with type 2 diabetes mellitus, decreasing the intake of AGEs 
for six weeks contributed to decreased levels of circulating AGEs and inflammatory 
markers [60]. The effects of reducing dietary AGEs have also been studied in 
nondiabetic peritoneal dialysis patients, a group that has very high AGE levels, and the 
results showed significant reduction in the levels of AGEs and C-reactive protein [79]. 
 
2.6.2 Role of Restriction of Dietary AGEs in Lifespan 
It has been demonstrated that caloric restriction increases lifespan in C. elegans and 
mice. Several centenarian populations have been studied, and they have one thing in 
common: a lower caloric intake [83,84]. It has been postulated that positive outcomes of 
caloric restriction (CR) in mice could be explained in part by a decrease in the intake of 
AGEs and concomitant decrease of OS [85]. 
 
To investigate whether a reduction in CR would decrease the AGE intake, and whether 
this decrease could explain the benefits of CR, investigators studied three groups of 
mice assigned to one of three diets (n=22 per group): CR diet, regular diet; or CR diet 
high in AGEs [86]. A longer lifespan in CR mice versus Reg or CR-high mice (median 
and maximal survival 13.2% and 6%, respectively) was reported. Additionally, survival in 
CR-high mice was shorter than in Reg mice. There was a significant increase of OS in 
the CR-high group and accelerated aging-related cardiovascular and renal disease and 
  20 
a shorter lifespan. In these studies, the high levels of AGEs in the CR-high diet compete 
with the benefits of CR, but the mechanism remained uncertain [86].  
 
2.6.3 Exercise and AGEs 
Published reports of research linking exercise and AGEs are sparse. One of the first 
studies in this subject suggested a decrease in levels of AGEs in exercise-trained 
diabetic rats as compared with sedentary diabetic rats. A possible explanation for the 
decrease is that adaptation to systemic physical exercise in diabetic animals affects not 
only enzyme-regulated metabolism but also non-enzymatic processes involving protein 
glycation. This study was published in Russian, so access was only to the abstract. 
Another study explored whether exercise prevented the age-associated changes in 
non-enzymatic cross-linking of myocardial collagen, and thus may improve cardiac 
performance in an animal model. In this study long-term exercise training appeared to 
attenuate age-related deteriorations in cardiac contractility and myocardial stiffness and 
was related to decreases in myocardial pathologic collagen cross-linking (AGEs cross-
linked collagen) in old rats (n=7) when compared with controls (n=7) [87]. Boor et al. 
carried out a study in Zucker rats where one group (n = 8) had a training program for 
five weeks and the other group (n=8) did not perform any exercise. It was found that the 
group with the training protocol had lower levels of CML in plasma, renal cortex and in 
glomeruli, in comparison with the sedentary group [88].  
 
Few studies have explored the effects of exercise on AGEs on the human model. One 
of them showed the effect of Tai Chi in a healthy Malaysian population older than 45 
years. The subjects were randomized either to practice Tai Chi two times per week or to 
a control group. Measures were taken at 0, 6, and 12 months. The subjects in the Tai 
Chi group had a decrease in concentration of AGEs and malondialdehyde MDA (a 
lipoxidation marker) after 12 months of intervention [89]. In another study, researchers 
reported the acute effect of exercise in subjects with coronary artery disease, finding no 
difference between the levels of RAGE before and after the training session [90]. 
Recently, Yoshikawa recruited seventeen healthy women (30–60 y) who participated in 
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a lifestyle modification protocol for three months to measure changes in AGEs. The 
protocol aimed to increase physical activity among the intervention group, which was 
measured by a pedometer. An education session was given at the beginning of the 
study and participants attended supervised sessions once per week. Levels of CML 
decreased in the treatment group compared to the control group (n=12) and CML 
decrease was negatively correlated with the number of daily steps [91].  
 
2.6.4 Pharmacological Interventions 
Several pharmacological agents have been studied as blockers of AGEs crosslinking or 
as blockers of their actions using cellular, animal and human models: benfotiamine (a 
B1-like vitamin with higher bioavailability), metformin, aminoguanidine, aspirin, and 
inhibitors of the renin-angiotensin system for example. Saha et al. showed that 
Candersatan, an angiotensin receptor blocker, administered for 12 weeks reduced 
levels of CML in the urine of patients with diabetic kidney disease [92]. Aminoguanidine, 
a scavenger of α-dicarbonyl, showed in some studies promising results as an inhibitor 
of AGEs formation. However, a clinical trial carried out in diabetic patients was stopped 
due to safety concerns and lack of efficacy. Patients presented secondary effects that 
included gastrointestinal disturbance, abnormal tests for liver function, and flu-like 
symptoms [93]. Additionally, metformin has shown to decrease circulating AGEs in 
patients with diabetes, as well as decreasing the activity of NFκB [94]. In a study of 22 
women with polycystic ovary disease (PCOS), metformin therapy for six months 
resulted in a reduction of serum AGEs [95]. In a similar intervention with 21 women with 
PCOS, Orlistat, a lipase inhibitor, reduced serum AGEs after a high AGEs meal as 
compared to 15 women without PCOS by decreasing AGEs absorption [96]. A six 
month study evaluating the effect of calorie restriction and Orlistat found serum AGEs 
reduction in both the PCOS and obese groups, independent of body mass index 
changes [97]. Some of these agents are in preclinical or clinical phase trials, and it could 
be a long time before any of these treatments emerge as effective and safe therapeutic 
agents to inhibit and counteract AGEs effects. 
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2.7 Limitations of Dietary AGEs Studies 
Formation of AGEs in foods is a complex process involving several reactions and many 
end products. Only a few of them have been characterized and measured in foods. 
Some of these products have fluorescence properties. By taking advantage of this 
property, some studies have measured AGEs using chromatography methods while 
other studies have measured AGEs by immunohistochemical techniques [53,98]. There 
is as yet no agreement among the different groups studying dietary AGEs as to which is 
the best. Recently Uribarri et al. published a food database with approximately 500 food 
items with CML content using ELISA [49]. This database represents a great tool to 
asses CML content of the diet of larger populations. However, more extensive research 
with other methodology is needed to validate CML content of this database.  
 
Intervention studies on the implications of reducing dietary AGEs have been performed 
mainly in patients with renal disease or diabetes. A few studies exploring the short term 
effects (2–4 weeks) of reducing dietary AGEs in healthy subjects have been performed 
mainly in young population [99,100]. Long-term clinical studies with older individuals are 
needed to determine the health effects of dietary AGEs on this population, but the 
methodological design of long-term studies represents a great challenge. One of the 
difficulties is achieving diets with different dietary AGEs content, but with similar content 
in other nutrients, such as heat-sensitive vitamins. Pouillart et al. demonstrated that 
diets with different dietary AGEs content but similar thiamine, vitamin E and other heat-
sensitive vitamins content, are challenging but possible [101]. Future intervention 
studies addressing the impact of dietary AGEs will need to include diets with varying 
AGEs content, adequate content of all nutrients, as well as be attractive and tasteful to 
achieve high compliance during these long-term interventions.  
 
2.8 Conclusions  
Although the data are not conclusive, the convergence of data from diverse 
experimental studies suggests an important role of AGEs in healthy aging, as well as 
chronic disease morbidity. Certainly the data are supportive that endogenous AGEs are 
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associated with declining organ functioning. It appears that dietary AGEs may also be 
related. There are no conclusive results about the damaging effect of Maillard products 
from foods, but it appears from several studies that Maillard products coming from foods 
rich in protein and fat are more damaging than Maillard products from bread crust, and 
roasted coffee. Foods rich in protein and fat seem to have a higher content of CML and 
Methylglyoxal; in contrast, bread crust has lower content of these two AGEs. However, 
characterization of AGEs in food and biomarkers of these AGEs require additional 
research before reaching a conclusion.  
 
Although many promising pharmacologic anti-AGE therapies exist, their efficacy and 
safety are still under study. Research in this area is in the earliest phase, and a long 
time could pass before the U.S. Food and Drug Administration could approve a drug 
targeting AGE formation or modification. 
 
As of today, restriction of dietary intake of AGEs and exercise has been shown to safely 
reduce circulating AGEs, with further reduction in oxidative stress and inflammatory 
markers. More research is needed to support these findings and to incorporate these 
into recommendations for the elderly population. 
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Figure 2.1 Formation of AGEs. 
 
 
 
Figure 2.2 Mechanism of AGEs action at the cell level. 
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Chapter 3 
Role of Dietary Advanced Glycation End Products in Diabetes Mellitus2 
 
 
Abstract: Dietary AGEs can be formed via the Maillard reaction and several alternative 
pathways. AGEs exert their deleterious effects by damaging protein structure and 
function, as well as through activation of cellular mechanisms. At the cellular level, the 
damaging effects of AGEs have been attributed to several AGE-binding proteins. 
Increased levels of AGEs have been implicated in several chronic diseases, including 
diabetes-related complications such as renal diseases, retinopathy, neuropathy, and 
cardiovascular diseases, as well as delayed wound healing. To investigate the role of 
AGEs thoroughly, a reliable assessment of dietary AGEs is needed. Varying 
methodology, diverse food preparation, and quantification of a variety of dietary AGEs 
makes this a complex goal. In addition, some antiglycation food products may balance 
or offset the negative impact of dietary AGEs. 
Keywords: AGEs (advanced glycation end products), dietary AGEs (dietary advanced 
glycation end products), carboxymethyl-lysine, diabetes mellitus. 
 
 
 
 
 
 
 
 
 
2This chapter appeared in its entirety in the Journal of Evidence-Based Complementary & Alternative 
Medicine and it is referred as to Luevano-Contreras C, Garay-Sevilla ME, Chapman-Novakofski K. Role 
of Dietary Advanced Glycation End Products in Diabetes Mellitus. Journal Evid Based Complementary 
Altern Med. 2013, 18, 50-66.  This article is © 2013 by the authors. The original article can be found at 
http://chp.sagepub.com/content/18/1/50 with DOI: 10.177/2156587212460054. 
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3.1 Introduction  
According to the latest report from the International Diabetes Federation, 366 million 
people have diabetes mellitus worldwide with almost 80% of them living in low-to-middle 
income countries. The International Diabetes Federation also reports that 11% of the 
healthcare expenditures are due to diabetes mellitus [1]. In the United States the 
prevalence of diabetes is 8.3%, and it is the 7th leading cause of death according to the 
2011 report by the Centers of Disease Control and Prevention (CDC) [2]. According to 
the 2011 National Diabetes Fact Sheet by the CDC, diabetes complications represent a 
health care burden with diabetes being the leading cause of new blindness and the 
leading cause of renal failure and heart diseases [2].  
 
A causal relationship between chronic exposure to hyperglycemia and microvascular 
and macrovascular diseases found in diabetes mellitus has been well established [3]. 
There are at least three theories about how high levels of blood glucose could lead to 
the development of complications in diabetes mellitus: oxidative stress, protein kinase C 
activation, and the accumulation of a heterogeneous, complex group of compounds 
called advanced glycation end products (AGEs) that are formed mainly via the Maillard 
reaction [4]. The activation of the protein kinase C system in insulin independent cells 
has been identified as one of the mechanisms responsible for the metabolic 
consequences of hyperglycemia. Dihydroxyacetone phosphate and glyceraldehyde-3-
phosphate, glycolytic intermediates, promote the formation of diacylglycerol, which is a 
co-factor for protein kinase C activation. The activation of protein kinase C triggers the 
transcription of several growth factors including the transforming growth factor-β, which 
has been involved in the thickening of capillary basement membrane (an abnormality 
seen in tissues in diabetes) [5]. Hyperglycemia also could increase intracellular 
production of reactive oxygen species (ROS) by three mechanisms: the mitochondrial 
electron transport chain, the autoxidation of glucose, and the production of AGEs. 
Oxidant stress appears to be involved in the activation of the protein kinase C system 
as well as in AGEs formation [4,6].  
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The Maillard reaction occurs when a reducing sugar reacts in a non-enzymatic way with 
amino acids in proteins, some lipids or DNA to produce AGEs. This reaction has been 
studied for years in the food industry because its products add a desirable color and 
taste to foods. However, the study of the products of this reaction in vivo has received 
increasing attention in recent years due to the association of AGEs with certain chronic 
diseases, such as diabetes mellitus, cardiovascular diseases, and Alzheimer’s disease, 
as well as during the aging process [7]. 
 
In addition to those AGEs formed in vivo, the role of dietary AGEs (dietary AGEs) on 
health and on diabetes-related complications has been studied. Clinical studies have 
measured the effects of high dietary AGEs in terms of levels of blood AGEs and levels 
of inflammation and oxidation markers. In these studies, dietary AGEs intake has been 
assessed with 3-day food records. However, there is not a standardized assessment 
method for AGEs quantification in the diet, and the association between dietary AGEs 
consumption and diabetic complications has not been studied due to the longitudinal 
data needed for both AGEs intake and complications development. In order to 
appreciate the complexity of AGEs and complications related to diabetes, this article will 
review AGEs formation, metabolism and excretion, as well as the current literature 
related dietary AGEs to diabetes complication. In addition, some challenges to 
researchers will be reviewed, including diverse analytical measurement of dietary AGEs 
and how to measure AGEs in the diet to generate data on usual intake and establish a 
safe intake. Finally, dietary strategies to lower AGEs damage will be discussed.  
 
3.2 Formation of Advanced Glycation End Products 
 
3.2.1 Formation in vivo 
Several AGEs have been described and complex pathways for their formation have 
been elucidated. Their detailed description is outside the scope of this review, but a brief 
description on the Maillard reaction and alternative pathways is described.  
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Maillard reaction 
The Maillard reaction consists of three well-described phases. First, the carbonyl group 
of a reducing sugar interacts in a non-enzymatic way with an amino acid to form an 
unstable compound called Schiff base. Lysine and arginine are the amino acids most 
often described as taking part in this reaction, but hydroxylysine and glycine have also 
been described. During the second phase, the Schiff base has two fates; it could 
undergo hydrolyzation and generate the original sugar and amino acid, or it could 
undergo cyclization and further Amadori rearrangements to form more stable 
compounds called Amadori products. Despite their stability and similarity to the first 
phase, under physiological and non-oxidative conditions 90% of Amadori products could 
sustain a reversible reaction to the initial sugar and amino acid [8]. In the last phase 
Amadori products can generate AGEs by two different ways, either oxidative or non-
oxidative cleavage. The oxidative cleavage of Amadori compounds will yield two 
intermediates that after autoxidation and further rearrangements will produce AGEs. 
The principal AGEs produced in this form is carboxymethyl-lysine (CML), one of the first 
AGEs characterized in vivo and the major AGEs’ biomarker in human tissues [9]. In 
contrast, the non-oxidative cleavage of Amadori products will produce the α-dicarbonyl 
derivative 3-deoxyglucosane. This derivative can react with an amino acid and also form 
carboxymethyl-lysine or other AGEs cross-links as pyrraline, pentosidine or imidazolone 
(Figure 3.1) [8-11]. A study of the kinetics of AGEs formation measured the 
fluorescence of final AGEs and it showed that ribose is the most reactive sugar, 
followed by fructose and lastly glucose. However, ribose and fructose concentration in 
tissues is significantly lower that the concentration of glucose. In addition, when glucose 
remains for a long time it will produce the same amount of fluorescence [12], which 
makes glucose the principal contributor for the Maillard reaction [11]. 
 
Alternative pathways, formation of α-dicarbonyl: methylglyoxal, glyoxal 
and 3-deoxyglucosane 
Other pathways generate AGEs by producing short chain carbonyl compounds known 
as α-dicarbonyl or α-oxaldehydes as glyoxal, methylglyoxal and 3-deoxyglucosane. The 
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α-dicarbonyl compounds are very reactive, participating in the formation of intra- or 
inter-protein cross-links. In addition, α-dicarbonyls also have the ability to form AGEs 
either by directly reacting with an amino acid or by starting the Maillard reaction instead 
of a reducing sugar. For this reason, α-dicarbonyls have been suggested as the main 
precursors for AGEs formation, particularly methylglyoxal [13]. Among the pathways that 
produce α-dicarbonyls, the Namiki and the Wolff pathways are the more important. The 
Namiki pathway occurs when a Schiff base degrades and forms glyoxal, while the Wolff 
pathway involves the autoxidation of monosacharides. For instance, the autoxidation of 
glucose at physiological conditions produces α-dicarbonyls. In addition, other metabolic 
intermediates have been implicated in α-dicarbonyl production with subsequent 
generation of AGEs. For example, glycolytic intermediates (glucose-6-phosphate, 
glyceraldehyde 3 phosphate and dihydroxyacetone phosphate), a polyol pathway 
intermediate (fructose-6 phosphate), an intermediate from ketone body and threonine 
metabolism (acetol), and lipid peroxidation also generate methylglyoxal (Figure 3.1) [13-
15]. 
 
3.2.2 Formation of dietary AGEs 
Since its first description in 1912 by Louis Camille Maillard, the Maillard reaction has 
been extensively studied in food science to explain the nonenzymatic darkening of 
fruits, the modification of skim milk during storage, and the production of off-flavor and 
pleasant aromas of some foods. It has also been used for caramel production, coffee 
roasting and bread baking [16,17]. In the food industry, proteins are used for 
emulsifying, foaming, gelling and solubilizing foods, and protein glycation increases 
emulsifying activity, improves foaming properties, increases protein solubility, promotes 
the formation of compounds with antioxidant activity (extending shelf life on food via 
delaying lipid oxidation), and improves food texture [18].  
 
As well as in in vivo formation, AGEs production in foods (dietary AGEs) involves the 
Maillard reaction. An amino acid from a protein, amine or phospholipids reacts in a non-
enzymatic fashion with carbonyl groups from reducing sugars as well as with 
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degradation products of carbohydrates, lipids, and ascorbic acid, and the resulting 
products often are referred to in the food science literature as Maillard reaction 
products. The reaction occurs in three well-identified stages previously described. There 
are low molecular Maillard products such as aldehydes, ketones, acryl amides, and 
AGEs, as well as high molecular products as melanoidins [17,19]. Other products 
formed during this intricate reaction are furfurals, pyrralines and α-dicarbonyl 
compounds such as methylglyoxal. The last products formed in the Maillard reaction, 
very well studied in food science, are the melanoidins, which are brown pigments [10]. 
Some other dietary AGEs studied in foods are furosine, which is a degradation product 
of Amadori compounds, as well as carboxymethyl-lysine and pentosidine formed in the 
last stage of the Maillard reaction [20]. 
 
Another source of dietary AGEs could be autoxidation of fatty acids and amino acids 
[21]. Chao et al proposed that heat could cause oxidation of unsaturated fatty acids from 
soybean oils and some fishes such as salmon and cod. The oxidative products could 
participated in the rearrangement of Amadori adducts to form irreversible crosslinks like 
pentosidine or carboxymethyl-lysine [20].  
 
Regardless of the diversity of AGEs, carboxymethyl-lysine has been reported as one of 
the most abundant in vivo and it was one of the first to be characterized in foods (milk 
and milk products). For this reason, in most studies carboxymethyl-lysine is chosen as a 
marker of AGEs in foods and in vivo [22]. 
 
3.3 Metabolism of AGEs 
Increased levels of AGEs have been implicated in several chronic diseases, including 
diabetes-related cardiovascular complications and renal disease, as well as aging 
[23,24]. AGEs exert their deleterious effects by damaging protein structure and function, 
and also are implicated in activation of cellular mechanisms. Besides endogenous 
AGEs, dietary AGEs also have been shown to be a major source of the body’s pool of 
AGEs, and it is believed that they are also involved in tissue damage. An important point 
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to review is how dietary AGEs are absorbed and if they can exert damage similar to that 
of endogenous AGEs.  
 
From the quantitative point of view, the contribution of dietary AGEs to the total pool of 
AGEs in the body is considered more important than the contribution from endogenous 
AGEs by abnormal glucose metabolism or lipid peroxidation. Henle estimated that 10-50 
times more dietary AGEs are supplied by a conventional diet that those found in plasma 
or tissues of subjects with uremia [25]. Evidence from human studies shows the 
contribution of dietary AGEs as carboxymethyl-lysine and methylglyoxal to the levels of 
circulating AGEs. Cross-sectional and randomized studies have demonstrated a 
correlation between dietary AGEs and circulating AGEs [26-30]. A cross-sectional study 
with 90 healthy subjects showed significant correlation between carboxymethyl-lysine 
estimated from 3 days food records and plasma levels of AGEs. When a subgroup 
decreased their intake of carboxymethyl-lysine their plasma levels also decreased [26]. 
A similar study of healthy volunteers compared older (60–80 years, n=56) versus 
younger (18–45 years, n=116) healthy adults. The plasma levels of carboxymethyl-
lysine and methylglyoxal were higher in the older group and correlated with levels of 
inflammation markers and oxidative stress. Additionally, the level of dietary glycotoxins 
(measured by three days of dietary records) correlated independently with serum 
carboxymethyl-lysine (r=0.46, p < .001) and methylglyoxal (r=0.37, p=0.001), as well as 
with C reactive protein (r=0.200, p=0.042) [27]. Vlassara et al found similar results in a 
study with 325 healthy participants and 66 participants with kidney disease. Serum 
carboxymethyl-lysine and methylglyoxal were higher in the group of older participants, 
and serum carboxymethyl-lysine correlated positively with age and with dietary AGEs 
[28]. These findings support the view that the intake of dietary AGEs is an important 
contributor to the body’s AGEs pool [26,27,29,30]. 
 
In contrast, a recent study by Semba et al found that urinary carboxymethyl-lysine was 
positively correlated with intake of starchy vegetables, whole grains, sweets, nuts/seeds 
and chicken, and negatively correlated with intake of fast foods. Intake of AGE-rich 
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foods such as fried chicken, French fries, bacon, sausage and crispy snacks were not 
significantly correlated with serum or urinary carboxymethyl-lysine.  In contrast to other 
researchers, these researchers concluded that the high consumption of foods 
considered high in carboxymethyl-lysine was not a major determinant of either serum or 
urinary carboxymethyl-lysine [31]. 
 
Several authors have studied the metabolism and absorption of some dietary AGEs and 
their precursors. For instance, a study by Erbersdobler and Faist on Amadori products  
(dietary AGEs precursors) found that their intestinal absorption is by diffusion [32]. They 
used 14C-labelled fructose amino acids in rats and humans and found that urinary 
excretion of Amadori products after the ingestion of test meals showed a rapid 
elimination of the absorbed part, while the fecal output, although low, persisted for 3 
days. Only 1-3 % of the ingested amounts of protein-bound Amadori products were 
recovered in the urine, leaving around 90% of Amadori products unaccounted [32]. A 
review regarding metabolism of premelanoidins and melanoidins showed data 
suggesting that on average 16 to 30% of absorbed premelanoidins were excreted in the 
urine and 1 to 5% for melanoidins. A possible explanation suggested for this low 
recovery of pre- and melanoidins was that digestive microbial enzymes degraded pre- 
and melanoidins during intestinal transit [33]. For instance, Wiame et al showed that 
bacteria that reside normally in the large intestine degrades around 80% of dietary 
Amadori products [34]. It also has been proposed that the rest of premelanoidins are 
metabolized and retained by different tissues [33]. 
Koschinsky et al conducted a study with 43 subjects with diabetes mellitus and 5 
healthy subjects. The AGEs were measured using an AGE-specific enzyme-linked 
immunosorbent assay (ELISA) in urine and serum 24 hours before and 48 hours after a 
rich AGEs meal. It was demonstrated that ingested AGEs are absorbed, and it was 
estimated that ≈10% of ingested immunoreactive AGEs were transported into 
circulation, two-thirds of which remained in the body, and were incorporated covalently 
in tissues. Only one third was excreted via the kidneys [35]. Foerster and Henle have 
studied the bioavailability and kinetics of elimination of pyrraline and pentosidine. In a 
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first study, seven healthy subjects were asked to ingest a normal diet on days 1 and 5, 
and on days 2, 3 and 4 a diet virtually free of Maillard compounds. Urinary excretion of 
free pyrraline was directly affected by composition of the diet, decreasing from 
4.8mg/day on day 1 to 0.3 mg/day on day 2, 3 and 4. The analysis of the 24-hour urine 
sample established that most of dietary pyrraline was absorbed and then rapidly 
excreted via the kidney within 48 hours [36]. Another study with 18 healthy volunteers 
who received specific amounts of custard, pretzels and brewed coffee on a single day 
found the rate of recovery in urine to be close to 50% for pyrraline and 60% for 
pentosidine. However, the metabolic fate of the pyrraline and pentosidine is unknown 
[37]. This study raises the question of how pyrraline or other dietary AGEs can cross the 
intestinal epithelial barrier. An in vitro study trying to answer this question concluded 
that, in general, free or protein-bound dietary AGEs could cross the intestinal epithelium 
by simple diffusion, by endocytotic processes or mediated by transport proteins. It was 
found that pyrraline is absorbed by the peptide transporter hPEPT1 in HeLa cells [38]. 
 
AGEs clearance 
It has been proposed that levels of serum AGEs depend on the endogenous production, 
the intake of dietary AGEs, and on the clearance system. This clearance system 
consists of several enzymes (glyoxalase I, II and carbonyl reductase) and a receptor 
(AGER1), and they have been proposed to have a role in AGEs detoxification [28,39]. In 
addition, renal clearance is the predominant means of excretion of AGEs, mainly the 
low-molecular weight fraction (glycation-free adducts) [40]. The predominant plasma 
AGEs (imidazolones, carboxymethyl-lysine and carboxyethyl-lysine) have a high renal 
clearance [41] and their levels are inversely correlated with renal function [42]. The 
AGEs adducts and peptides are filtered through the glomeruli and a small proportion 
may be reabsorbed and degraded by proximal tubular cells [43]. It has been reported 
that the presence of near normal renal function is critical to maintain the body load of 
AGEs and possibly other oxidants at nontoxic levels [44]. However, the AGEs clearance 
system is altered in diabetes mellitus and aging, and although the kidney is key in the 
oxidative stress defense system, it is also a target for AGE-induced injury [45]. Serum 
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AGEs correlate directly with the levels of inflammatory markers and oxidative stress, 
and inversely with creatinine clearance and urinary AGE clearance also correlates 
directly with creatinine clearance [42]. Hence, persons with diabetes mellitus and renal 
disease display elevated serum AGEs levels and reduced urinary AGEs excretion [46]. 
Limited information concerning absorption, biodistribution and elimination of AGEs is 
available. Therefore, studies in this area would help us understand the extent of the role 
of dietary AGEs on disease. 
 
3.4 Receptors of Advanced Glycation End Products 
At the cellular level, the damaging effects of AGEs have been attributed to several AGE-
binding proteins, such as RAGE (receptor for AGEs), AGEs receptor (AGER) 1, R2, R3, 
and scavenger receptors such as CD-36 [47] and SCR-II [48]. These receptors are 
present on vascular, renal, hemopoietic, and neuronal/glial cells, and they serve in the 
regulation of AGEs uptake and removal. The AGEs receptors also modulate cell 
activation, growth-related mediators, and cell proliferation, consequently influencing 
organ structure and function. Furthermore, these receptors have been shown to play 
distinct functional roles in AGEs toxicity or detoxification [49]. 
 
The most notable receptor is RAGE, and it triggers oxidative stress and inflammation in 
both acute and chronic diseases, including diabetes mellitus [50]. This receptor is a 
member of the immunoglobulin superfamily of cell surface molecules, [51] and 
increased serum and tissue levels of AGEs activate RAGE. The interaction of AGEs and 
RAGE promotes the activation of the mitogen-activated protein kinases (MAPKs), the 
phosphatidylinositol-3 kinase (PI3-K) and the nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH, a complex of enzymes which produces superoxide) and 
when this complex is upregulated, it increases intracellular oxidative stress (Figure 3.2). 
The activation of these pathways will lead to the activation of the transcription factor NF-
κB (nuclear factor kappa B) which activates the transcription of genes for 
proinflammatory cytokines, growth factors and adhesive molecules, such as tumor 
necrosis factor α (TNF-α), interleukin 6 (Il-6), well known inflammation promoters, and 
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vascular cell adhesion molecule 1 (VCAM1) [52-55]. Induction of these proinflammatory 
molecules could contribute to cellular dysfunction and damage target to organs, and 
ultimately lead to complications as atherosclerosis, cardiovascular disease, and 
nephropathy [56-58]. 
 
Besides the endogenously formed AGEs, dietary AGEs have also been shown to act as 
RAGE ligands and activate major signal transduction pathways in vitro [59,60]. Dietary 
AGEs, together with those made endogenously, could promote a systemic glycoxidant 
burden, oxidant stress and cell activation, which increases vulnerability of target tissues 
to injury [61,62]. 
 
In contrast, AGER1 suppresses AGEs and their related oxidative stress and 
inflammation (Figure 3.2). This receptor is encoded by the gene DDOST, and it is a type 
1 transmembrane protein of ~50kDa [63]. Overexpression of AGER1 inhibits the 
epithelial growth factor receptor, suppresses RAGE proinflammatory signaling 
pathways, and contributes to maintain AGEs homeostasis [63-65].  Likewise, AGE-R3 
(a 32-kDa protein and member of the β-galactoside-binding lectin family) exhibits high 
binding affinity for AGEs, thus protecting against AGEs-induced proinflammatory 
response [66]. Hence, AGER1 and AGER3 are largely responsible for AGEs-recognition 
and high-affinity binding [67,68]. Lastly, AGER2 is implicated in several biological 
functions, including cell growth, proliferation, differentiation, and apoptosis [69]. It may 
undergo AGEs-induced phosphorylation and could play a role in signal transduction and 
cell activation associated with-receptor binding [70]. The AGE-receptor systems may be 
regulated by factors related to diabetes such as glucose, insulin, AGEs, and reactive 
oxygen species (ROS) [71]. 
 
Some data suggests that AGER1 may be suppressed or saturated in the presence of 
high-AGEs induced oxidant stress.  For instance, low expression of AGER1 in the 
kidney of non-obese diabetic mice was associated with high tissue AGEs levels and 
kidney disease [72]. Furthermore, human circulating mononuclear cells from diabetic 
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subjects with severe diabetes complications showed low expression of AGER1 and high 
serum AGEs [73]. Although, the cause of AGER1 down regulation in diabetes mellitus is 
not yet known, this effect is reversible by consumption of AGE-restricted diet in both 
humans and mice [28,74-76]. Indeed, a study with young and old mice fed high or low 
AGEs found that old mice maintained on high AGEs diets developed insulin resistance, 
decreased AGER1, increased RAGE, fibrosis in the heart and kidney, a depleted 
glutathione/oxidized glutathione ratio, and increased serum 8-isoprostane. In contrast, 
mice kept with low dietary AGEs had an enhanced antioxidant reserve, had no insulin 
resistance, had higher tissue AGER1 levels and had a reduction on systemic AGEs 
accumulation [75].  
 
In addition, increased AGER1 expression also has been associated with extended 
lifespan in mice [75,76]. Similarly, a study with type 2 diabetic patients showed that the 
suppressed expression and function of AGER1 in diabetic peripheral blood 
mononuclear cells were nearly normalized by dietary AGEs restriction [74]. Another 
study showed that a moderate (30-50%) reduction of dietary AGEs by healthy 
participants substantially reduced the normal baseline levels of serum AGEs, oxidative 
stress and inflammation as well as AGER1 [28]. The defense mechanism exerted by 
AGER1 was lost in patients with diabetes mellitus and its efficiency decreased with 
aging [63]. It has been shown in animal studies that a way to restore this balance is by 
reducing dietary AGEs [75]. Therefore, efforts should be made to corroborate these 
results with human studies in those with and without diabetes. 
 
3.5 Diabetes and Related Complications  
Formation of AGEs in vivo depends of specific intra and extracellular conditions. Some 
of the studied factors involved in AGEs production are the rate of turnover of the 
proteins, oxidant stress in the intra or extracellular environment, and the degree of 
hyperglycemia [77]. It has been reported that intracellular AGEs formation significantly 
increases in endothelial cells after 1 week of hyperglycemia. Additionally, the type of 
reducing sugar also affects the rate of AGEs formation with intracellular proteins, with 
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the slowest reaction in the presence of glucose when compared with fructose, 
glyceraldehyde-3-phosphate, and glucose-6-phosphate [77]. Accumulation of AGEs in 
blood and in tissues has been found in healthy aging persons, and this accumulation is 
higher during high blood glucose concentrations. In addition, AGEs have been reported 
to be elevated in human tissues, plasma and urine in cases of metabolic and vascular 
disorders like diabetes mellitus, atherosclerosis, and renal disease [46,78-80]. 
Therefore, increased levels of AGEs in physiological matrices often serve as biomarkers 
for those diseases. 
 
One of the main biomarkers of diabetes mellitus is hemoglobin A1c, an Amadori product 
that results from the reaction of glucose with the valine terminal of hemoglobin A [81], 
and it is used as an indicator of the average glucose levels in diabetes mellitus. As 
mentioned before, high levels of glucose increases glycation of the extracellular matrix, 
but this also occurs with intracellular proteins, especially in insulin-independent cells 
such as red blood cells, peripheral nerve tissue cells, endothelial cells, eye lens cells, 
and kidney cells [9]. It is also hypothesized that glycation of proteolytic enzymes in 
diabetes reduces their efficiency, resulting in accumulation of additional glycated end 
products [9]. One of the first studies showing that glycemic status correlates with AGEs 
levels was carried out by Portero-Otin et al, and their results on the quantification of 
pyrraline (a non-oxidative glucose-derived Maillard reaction product) in urine showed 
higher levels for individuals with diabetes mellitus when compared with healthy 
individual 3.4 and 1.1 mg/day respectively [82]. In addition to higher renal excretion of 
AGEs, Kalousova et al also found a slight elevation of serum AGEs in patients with 
diabetes mellitus type 2 (n=24) when compared with healthy controls (n=34) [79]. 
Furthermore, subjects with type 2 diabetes mellitus (n=50) had levels of AGEs in serum, 
skin and saliva that increased with the progression of complications in diabetes mellitus 
[46]. How these diabetes mellitus complications relate to elevated AGEs levels is not 
completely known. However, microvascular damage characteristic of diabetes in the 
kidney, retina, and microvasculature of peripheral nerves could occur when endothelial 
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cells from microvascular beds are damaged with subsequent capillary occlusion, 
ischemia and organ damage [83].  
 
Retinopathy 
Changes seen in retinopathy such as capillary occlusion and retinal ischemia could be 
due to high levels of glucose that could provoke dysfunction of intraretinal blood 
vessels, increased permeability of capillaries and progressive loss of retinal pericytes 
and endothelial cells [83]. The level of AGEs from retinal blood vessels has been found 
to correlate to the degree of retinopathy in subjects with type 2 diabetes mellitus [72], 
and it is hypothesized that they could be involved in the damage seen in retinopathy. In 
a review study, Ahmed described studies in cell cultures that have shown the toxicity of 
AGEs for the pericytes, and also that AGEs increase the levels of RAGE mRNA in 
pericytes and endothelial cells. The interaction of AGE-RAGE in retinal cells could 
promote upregulation of vascular growth factors as the vascular endothelial growth 
factor (VEGF). The vascular endothelial growth factor is capable of increasing 
angiogenesis and neovascularization (characteristic of proliferative retinopathy). In 
addition, subjects with retinopathy were found to have increased levels of AGEs and 
interleukin-6 (IL-6) in the eye vitreous. Interleukin-6 could also promote angiogenesis by 
increasing expression of the vascular endothelial growth factor [23]. 
 
Renal disease 
The relationship between renal disease and AGEs has been studied in animal models. 
A recent study by Coughlan et al [84] described a study in which urinary carboxymethyl-
lysine excretion was increased four weeks after diabetes induction, which preceded the 
excretion of urinary albumin and continued to rise progressively after 32 weeks. They 
concluded that the most informative marker of progressive renal damage linked to the 
AGEs pathway in experimental diabetic nephropathy was urinary excretion of 
carboxymethyl-lysine.  
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Researchers have also investigated these outcomes in patients with type 2 diabetes 
mellitus, and to a lesser extent in older populations. Semba et al [85] demonstrated that 
in an older population (n=1008), elevated circulating AGEs were an independent 
predictor of renal function. The study was carried out with men and women, age 64 and 
older, participating in the InCHIANTI study in Tuscany, Italy. The results of the study 
included an elevated plasma concentration of carboxymethyl-lysine independently 
associated with chronic kidney disease and the estimated glomerular filtration rate (an 
index of kidney function) at baseline, after three and six years of follow-up. These 
findings suggest that the potential adverse effects of AGEs on the kidney are applicable 
to the general population of older community-dwelling adults [85]. In another study of 
548 women from the Women’s Health and Aging Study I in Baltimore, 51.6% of women 
had decreased glomerular filtration rates, which were associated with increased serum 
levels of carboxymethyl-lysine and sRAGE (the soluble form of RAGE) [86]. In normal 
renal function, circulating AGEs are cleared by the kidneys, but high levels of AGEs 
have been found in patients with uremia as well as in patients with diabetic 
nephropathy, probably because of inadequate renal clearance [87]. Levels of AGE were 
measured in a study with patients with diabetes mellitus and no renal damage (n=22), 
with end stage renal disease but no diabetes mellitus (n=8), with end stage renal 
damage and diabetes mellitus (n=12) and healthy controls (n=17). It was found that all 
groups had higher levels when compared with the healthy controls [88]. AGEs are 
associated with damage seen in renal disease such as glomerular basement membrane 
thickening, mesangial expansion, glomerulosclerosis, and tubulointerstitial fibrosis [89]. 
Some of these changes could be mediated by an increase in the transforming growth 
factor β (TGF-β) that increases synthesis of collagen matrix components responsible for 
the basement membrane thickening [23]. 
 
Neuropathy 
High levels of AGEs have also been found in the peripheral nerves of subjects with 
diabetes mellitus [89]. In a recent review, Ahmed found that in vitro studies have shown 
that there is increased glycation of myelin in diabetes. Nerve demyelination seen in 
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diabetic neuropathy could be explained by phagocytosis of the glycated myelin by 
macrophages. In animal studies, when AGEs are injected to peripheral nerves there is a 
reduction on sensory motor conduction velocities, nerve action potentials and blood flow 
[23]. However, the mechanism by which AGEs could be involved in diabetic neuropathy 
is not clear.  
 
Cardiovascular diseases 
As previously described, [90] the in vivo accumulation of AGEs over time contributes to 
changes in the structure and function of the cardiovascular system and presents as 
arterial stiffening, myocardial relaxation abnormalities, atherosclerotic plaque formation 
and endothelial dysfunction. Several authors have described some of the potential 
mechanisms for these changes. One of the proposed mechanisms involves additional 
cross-linking on collagen (whose normal structure already contains crosslinking) by 
glycation of its free amino acids. The collagen-AGEs cross-linking will produce stiffness 
of blood vessels. Sims et al completed a histological study on 27 samples of post-
mortem aortas from people with diabetes and controls and found a correlation between 
AGEs accumulation and aortic stiffness [91]. Another mechanism by which AGEs exert 
damage to the cardiovascular system is reduction of low-density lipoproteins (LDL) 
uptake by cell receptors. This occurs through glycation of the LDL particle on the 
apolipoprotein B and in the phospholipid components of LDL. The glycated LDL is more 
susceptible to cross-linking with collagen on the arterial wall than non-glycated LDL.  
Because of this, it is not taken up into the cell and accumulates in circulation. 
Macrophage uptake of these modified LDL lead to foam cell formation, and the 
development of atheroma [88,92,93]. Furthermore, decreasing nitric oxide activity is 
another mechanism by which AGEs can damage the cardiovascular system. Nitric oxide 
(a vasodilator) biosynthesis in the endothelium counteracts some of the mechanisms for 
atherosclerosis. Some authors proposed that AGEs reduce nitric oxide synthase half-life 
in the endothelium. For instance, Xu et al found a decrease in nitric oxide synthase 
activity after exposure to carboxymethyl-lysine-albumin both in vivo (rabbit femoral 
artery) and in vitro (rabbit aortic ring). They also found that after 30 minutes of exposure 
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to carboxymethyl-lysine-albumin, there was a reversible inhibition of endothelium and 
vascular response dependent on nitric oxide in vivo and in vitro [4,94]. Therefore, the 
accumulation of AGEs could explain some of the cardiovascular changes associated 
with the cardiovascular diseases seen in diabetes, such as vascular stiffening, diastolic 
dysfunction and endothelial dysfunction [95].  
 
Wound healing 
Not surprisingly, AGEs have also been implicated in the delayed wound healing 
associated with diabetes, presumably through vascular, neurological, or intermediary 
metabolic modifications [96]. Interaction of AGE-RAGE increases the production of 
inflammatory molecules such as tumor necrosis factor α (TNF-α) that could create a 
state of chronic inflammation in diabetes patients as well as production of destructive 
matrix metalloproteinases. These two events could prevent deposition of matrix 
components that are necessary for wound healing [23]. 
 
Even when some of the mechanisms responsible for the complications of diabetes are 
not well described, an association between the accumulation of endogenous AGEs and 
those complications is clear. In addition, several research groups [74,97,98] have 
addressed the role that exogenous AGEs could have on diabetes and its complications.  
 
3.6 Managing Dietary AGEs for Health 
 
3.6.1 Analytical measurement of AGEs in foods 
One of the challenges in studying dietary AGEs is knowing the amount of AGEs in 
foods. Formation of dietary AGEs is a complex process involving several reactions and 
many end products, and only a few of them have been characterized and measured. 
Some of the analytical techniques used for this purpose are capillary electrophoresis, 
autoimmune assays, mass spectrometry, high performance liquid chromatography or 
gas chromatography. Some AGEs have fluorescence properties. By taking advantage of 
this property, some studies have measured AGEs using fluorescence 
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spectrophotometry. However, according to Zhang et al, high performance liquid 
chromatography and gas chromatography coupled with fluorescence, flame ionization or 
with mass spectrometry are more specific and sensitive methods for AGEs 
quantification [10]. However, other authors have measured AGEs by 
immunohistochemical techniques [99]. There is as yet no agreement among the 
different groups studying dietary AGEs as to which is the best.  
 
Analytical measurement of AGEs in foods was for a long time focused on monitoring the 
quality of food products and for detecting indications of thermal damage in foods, mainly 
in milk and milk products. Furosine, pyridosine, pyrraline and carboxymethyl-lysine have 
been used for this purpose [100]. Since dietary AGEs have been associated with 
chronic diseases, some authors have measured dietary AGEs in foods more 
extensively.  
 
Delgado-Andrade et al studied in a clinical setting how two different diets (one rich in 
AGEs and one low in AGEs) affected protein digestibility in adolescents (n=18) in Spain. 
They prepared two 7-day diets and measured the total furosine, hydroxymethylfurfural 
and fluorescence by high performance liquid chromatography in both diets [101]. In 
another study in Spain, the levels of glyoxal and methylglyoxal were measured in a 
mixture of 26 commercial cookies. The mean level of glyoxal was 15 mg/kg and 29.9 
mg/kg for methylglyoxal [102]. Methylglyoxal was measured in 13 commercial 
carbonated beverages, 11 of which contained high fructose corn syrup as the sweetener 
and 2 of them contained an artificial sweetener. Levels of methylglyoxal were in the 
range of 23.5–139.5 μg/100 mL for the 11 beverages with high fructose corn syrup and 
less than 10 μg/100 mL for the beverages with artificial sweetener [103]. In another 
clinical study measuring risk factors for diabetes mellitus and cardiovascular disease in 
healthy individuals, the carboxymethyl-lysine content of a standard and a steam diet 
(foods were cooked with steam techniques) was measured by gas chromatography– 
mass spectrometry. Total carboxymethyl-lysine intake was 5.4±2.3 and 2.2±0.9 mg/d for 
subjects in the standard and steam diet, respectively. Individual analysis of foods 
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showed that bread, dough, cookies, meat and fish were the main contributors of 
carboxymethyl-lysine to the standard diet [97]. 
 
Chao et al measured pentosidine, carboxymethyl-lysine and furosine in some sauces 
used in Asian cuisine: soybean sauce, sour-sweet sauce, and barbecue sauce, as well 
as in sauce-treated chicken, pork, beef, salmon. They used three cooking methods: 
boiling, deep-frying and baking. Carboxymethyl-lysine, and pentosidine were measured 
by high performance liquid chromatography followed by fluorescence detection. The 
content was reported as µg per 100 mg of food. Cooking the food increased the amount 
of furosine, pentosidine and carboxymethyl-lysine in all the foods tested in comparison 
with the raw sample. They found that salmon and cod fried in soybean oil (temperature 
used 356ºF, 180ºC) had higher pentosidine and carboxymethyl-lysine than baked 
samples (temperature used 446ºF, 230ºC). The authors concluded that the amount of 
glycation products produced was affected by the interaction of the hot frying oil and 
food. The authors also noted that cooked salmon had higher levels of pentosidine, 
carboxymethyl-lysine and furosine than cooked cod, suggesting a role of 
polyunsaturated fatty acids, which are higher in salmon than cod, in the formation of 
dietary AGEs. The authors also concluded that when food was treated with the sauces 
tested, the sauce and heat could have a synergistic effect on dietary AGEs formation. 
Their hypothesis was that heat releases amino acids from the tested foods and led to 
the interaction with reducing sugars found in the sauces, thereby forming dietary AGEs 
[20].   
 
The first attempt to measure a considerable number of foods to create an AGEs food 
content database was made by Goldberg et al [99]. They selected 250 typical foods and 
measured carboxymethyl-lysine by enzyme-linked immunosorbent assay (ELISA) with 
an anti-carboxymethyl-lysine monoclonal antibody. The results were expressed as 
AGEs units per milligram of protein or lipid, and then the AGE value was multiplied by 
the amount of protein or lipid per gram of food. The cooking methods used were boiled 
in water (212ºF, 100°C), broiled (437ºF, 225°C), deep fried (356ºF, 180°C), oven fried 
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(446ºF, 230°C), and roasted (350ºF, 177°C). The food group with the higher mean 
values of carboxymethyl-lysine was the fat group. Butter, cream cheese, cream and 
mayonnaise had the highest values followed by oils and nuts with values ranging from 
1,300 to 450 kU of AGEs. Foods rich in protein and fat also had a high content of 
carboxymethyl-lysine that increased depending on the cooking method. Foods that were 
oven fried had higher amounts of carboxymethyl-lysine followed by deep frying, broiling, 
roasting and lastly boiling. The authors concluded that the presence of free radicals 
from lipoxidation reactions could increase formation of AGEs, and that glycoxidation and 
lipoxidation increased by heat could be responsible for the carboxymethyl-lysine content 
in foods rich in fat with lower protein content. The groups with lower levels of 
carboxymethyl-lysine were milk, fruits and vegetables; however infant formula had a 
100-fold higher content of carboxymethyl-lysine than cow’s milk, which was consistent 
with similar finding from Sebekova et al [104]. Even when cereals had a lower content of 
carboxymethyl-lysine, some products in this group had higher amounts depending on 
the processing. For instance, breakfast cereals with processing temperatures over 
446ºF (230º C) had higher amounts of carboxymethyl-lysine [99].  
 
Recently, Uribarri et al published a larger food database with approximately 500 food 
items, including those published by Goldberg et al, with the carboxymethyl-lysine 
content using the same enzyme-linked immunosorbent assay [105]. Additionally, they 
also measured methylglyoxal in some food items to validate their findings. They found 
the same pattern of carboxymethyl-lysine content in foods depending on their food 
composition and method of cooking. They attributed the higher amount of 
carboxymethyl-lysine in meats to the amount of intracellular components in muscle, 
such as amino-lipids and reducing sugars as fructose or glucose-6-phosphate, which in 
the presence of heat accelerates new AGEs formation. They also highlighted that higher 
amounts of carboxymethyl-lysine in some cheeses could be due to the curing or aging 
processes, and that the high content in fats could be due to the extraction and 
purification procedures involving heat and dry conditions. In addition to exposure to 
higher temperatures, they also noted that lower moisture increased the amount of 
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carboxymethyl-lysine for the same food. Therefore, frying, broiling, grilling, and roasting 
would produce higher carboxymethyl-lysine than boiling, poaching, stewing and 
steaming. A new observation in this study was that marinating meat in acidic solutions 
such as lemon juice or vinegar for at least 1 hour could reduce production of new 
carboxymethyl-lysine by half in comparison with foods not marinated [105]. This 
database represents a great tool to assess the carboxymethyl-lysine content of the 
diets. However, corroboration of the carboxymethyl-lysine values using different 
technology would help validate this AGEs database.  
 
3.6.2 Restriction of dietary AGEs 
Findings in several intervention studies, both human subjects and animals, indicate that 
the high intake of dietary AGEs contributes to tissue damage and increased levels of 
inflammatory markers that can be prevented by dietary AGEs restriction. Clinical trials 
on restriction of dietary AGEs in human subjects are presented on Table 3.1.  The 
effects of reducing dietary AGEs have been studied in non-diabetic peritoneal dialysis 
patients, a group that has very high AGE levels, and the results showed significant 
reduction in the levels of AGEs. For instance, Uribarri et al studied 18 non-diabetic 
patients with peritoneal dialysis, in whom the intake of AGEs was reduced for 4 weeks 
by exposing meat to different cooking methods by participants. Subjects with the low 
AGEs diet showed 34% reduction in serum carboxymethyl-lysine and 35% reduction in 
methylglyoxal when compared to baseline. Subjects with high AGE diet had elevation of 
serum carboxymethyl-lysine and methylglyoxal by 29% and 26% respectively [106]. In a 
similar study, a decreased in vascular adhesion molecule 1 (VCAM1) and tumor 
necrosis factor α (TNF-α) were also found in the low AGE diet compared with the high 
AGE diet [107]. Another study with overweight and obese volunteers randomized to a 
low- and high-AGE- diet during 2 weeks found that renal function and the inflammatory 
profile improved following the low-AGE diet [108]. 
 
Intervention studies with patients with diabetes mellitus have had similar results. In a 
study of 13 patients with type 2 diabetes mellitus, decreasing the intake of dietary AGEs 
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(meals were provided to participants) for six weeks contributed to decreased levels of 
circulating AGEs and inflammatory markers (vascular adhesion molecule 1 and tumor 
necrosis factor α) [30]. In another study, 24 patients with diabetes mellitus were 
randomized to one of two groups with different diets for 6 weeks (meals were provided), 
one with a high level of dietary AGEs and the other with low AGEs. It was found that the 
low-density lipoprotein (LDL) in the group with high dietary AGEs intake was more 
glycated than in the group with low AGEs intake [62]. In addition, the acute effect of a 
meal rich in dietary AGEs has also been measured in type 1 and type 2 diabetes 
mellitus. It was found that flow-mediated dilation of the brachial artery (used as a 
measure of endothelial function) decreased after a single challenge with dietary AGEs 
and inflammatory markers as vascular adhesion molecule 1 increased [109,110]. 
Finally, a recent study with type 2 diabetes mellitus patients (n=18) and healthy controls 
(n=18) found a lower homeostatic model assessment (HOMA) and lipoxidation markers 
in subjects with lower dietary AGEs intake. The participants were randomly assigned to 
a low dietary AGEs (instructions were given for lowering AGEs in foods) or left with their 
usual dietary AGEs intake (around 20 equivalent of AGEs, measured by 3 days of 
dietary records) during 4 months. Patients assigned to the low dietary AGEs diet had 
lower levels of serum carboxymethyl-lysine, methylglyoxal, 8-isoprostane (a lipoxidation 
marker) and insulin in serum, as well as a lower homeostatic model assessment when 
compared with the subjects with the regular dietary AGEs intake [74].  
 
These results suggest that dietary AGEs could exert similar effects as those studied 
from endogenous AGEs. However, it is important to note that the same research group 
has performed most of the intervention studies presented here, and more studies from 
different groups are needed to corroborate these results.  
 
3.6.3 Anti-glycative dietary factors 
There are a number of different pathways by which glycation of end products may be 
interrupted. These include cleaving AGEs cross-links; blocking of RAGE; blocking 
carbonyl groups on reducing sugars, Amadori products, and 3-deoxyglucosones; 
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deglycating Amadori products (Amadoriases); protecting against glycation-derived free 
radicals (antioxidants); and preventing autoxidation of glucose and Amadori products 
through chelators that remove transition metals. These last four processes are thought 
to occur through food or food components. The first two processes occur through 
pharmacological means [111].  
 
The most profuse process for antiglycation is through antioxidants, which scavenge free 
radicals. Antioxidants are abundant in foods containing large amounts of vitamins C and 
E, carotenoids, and selenium, as well as phenolic compounds such as anthocyanins, 
flavonoids, catechins, and lipoic acid. These nutrients and food components are present 
in fruits and vegetables (vitamin C, anthocyanins, flavonoids), green tea (catechins), 
nuts seeds and oils (vitamin E), wine and chocolate (flavonoids), and liver, spinach, 
broccoli, and potatoes (lipoic acid). Additional food components with antioxidative 
properties include curcumin, and aged garlic extract [111]. 
 
Aged garlic extract contains a higher concentration of antioxidants than whole garlic. 
During the aging and extraction over 10 months, the garlic can become odorless as the 
organosulfur compounds become water soluble [112]. The aged garlic extract contains 
many compounds that have been investigated for health benefits, including lectins, 
fructooligosaccharides, apigenin which is a flavonoid, fructosyl arginine which is a 
Maillard reaction product, and tetrahydrocarbolines [113]. Although aged garlic extract 
has primarily been investigated for cardiovascular [114,115], cancer [116-118] and 
immune system effects [119], it has also been used in in vitro experiments to determine 
its ability to inhibit AGEs products. Aged garlic extract inhibited the cross-linked 
glycation end products and an ingredient of garlic extract, S-allyl cysteine, also inhibited 
non-crosslinked AGEs [120]. An in vitro study also found that aged garlic extract 
scavenged superoxide radicals in at dose dependent manner over three dosages [112].  
Curcumin is a major component of turmeric, a popular ingredient in Asian foods. 
Curcumin has been reported to interact with a number of immunoregulatory enzymes 
and transcription factors, and therefore has been evaluated for its role in cancer 
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treatment and prevention [121,122], as well as inflammatory conditions [123], dementias 
[124], and obesity-related disorders [121]. However, intestinal metabolism of curcumin 
results in metabolites with short half-lives and limited cell permeability [125]. 
Nevertheless, numerous studies have reported anti-diabetic properties of curcumin 
[126]. In one animal study, diabetic rats fed curcumin with their diet for 16 weeks had 
lower fasting blood glucose and urinary glucose as compared to control animals. A 
variable effect of curcumin on lysosomal enzymes was found depending on which 
lysosomal enzyme and where in the body it was measured [127]. However, one animal 
study reported increased oxidative stress and AGEs formation with hyperglycemic 
animals fed curcumin, as evidenced by faster cataract formation. Non-diabetes rats 
showed beneficial effects at very low levels of curcumin [128]. Recently, in vitro work 
concluded that curcumin induced gene expression of AGE-receptor 1(AGER1), which 
facilitates the clearance of AGEs [129].  
 
Other antioxidants have also shown promising results in animal and in vitro studies. A 
number of fruits, vegetables and herbs were evaluated using in vitro techniques to 
assess their antiglycation ability. Ginger, cinnamon, and cumin have been reported to 
reduce AGEs formation in vitro by more than 50% at 1.0 mg/ml [130]. In one animal 
study, the phenolic acids caffeic and ellagic acid were added to mouse chow at 2.5 or 5 
g per 100 g diet and fed to diabetic mice for 12 weeks. Hemoglobin A1c, glycated 
albumin, and renal carboxymethyl-lysine levels were lower for animals fed the phenolic 
acids, with more significant effects seen with the higher intakes [131]. A study to 
investigate the effects of Pu-erh tea, which is a fermented tea, on AGEs accumulation 
associated with diabetic nephropathy found that Pu-erh tea prevented diabetes-induced 
accumulation of AGEs and led to decreased level of RAGE expression in glomeruli 
[132]. In another animal study, green tea extract was administered to rats for 4 weeks 
(300 mg per kg body weight per day). Fluorescence of AGEs, blood glucose and 
hemoglobin A1c was significantly reduced when compared to diabetic rats not receiving 
the extract (P < .05) [133]. However, in a study where green tea or vitamins C and E 
were added to the rats’ drinking water, there was no difference in glycemia when 
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compared to control animals, but did decrease lens fluorescence. Surprisingly, the 
group fed the additional vitamins C and E exhibited worsened collagen glycoxidation in 
certain tissues. Additionally, tendon breaking time in urea, which can be used as a 
marker for total cross-linking, increased with both vitamin C and E administration and 
with green tea, leading the authors to speculate that treatment of oxidative stress alone 
may not ameliorate complications of diabetes, but that other stresses as well as 
attention to intracellular and extracellular activities, could be important [134]. Indeed, in 
vitro experiments suggest some caution concerning flavonoids and AGEs. In general, 
lower concentrations were found to be inhibitory while higher concentrations were more 
often enhancing of carboxymethyl-lysine production, presumably through increased 
hydrogen peroxide production [135]. 
 
Few studies have evaluated these foods or ingredients in human studies. However, 
Klein et al evaluated mate tea’s impact on blood glucose and lipid values in diabetes 
and pre-diabetes. Each group was divided into receiving the mate tea, an educational 
intervention, or both the tea and education. Those instructed to drink the tea were to 
make it from 6.6 g of yerba mate leaves and 330 mL of boiling water, drinking the 330 
mL three times per day for 60 days. No differences were found in the pre-diabetes 
group across treatments. In the diabetes group, those drinking mate tea demonstrated 
significant decrease in blood glucose and hemoglobin A1c [136].  
 
Of course, drugs have been developed for their antiglycation properties, particularly 
alagebrium, which has been shown to have positive effects in animal models [108,137]. 
 
3.7 Summary, Implications for Research 
The health impact of dietary AGEs has increasingly been studied since recognition of 
their potential deleterious effects. Some of these effects can be attributed to changes in 
the nutritional composition of the foods from which the dietary AGEs are derived. The 
nutritional consequences of the Maillard reaction in foods include the loss of some 
amino acids, such as lysine, arginine, tryptophan and histidine. Good indicators of loss 
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of lysine in foods are furosine, pyrraline and carboxymethyl-lysine [100]. There is also 
some evidence that AGEs could affect mineral metabolism. Studies in rats have shown 
increased urinary excretion of calcium, magnesium, sodium zinc, and copper compared 
with animals fed a control diet [17]. Similar studies in adolescents have shown impaired 
iron bioavailability [138].  
 
Secondly, dietary AGEs can have an impact on health through a variety of systematic 
mechanisms. Studies focusing on the effects of dietary AGEs have been shown to 
increase circulating AGEs, to accumulate in tissues, to affect endothelial function, to 
increase pro-inflammatory cytokine and oxidation markers and to act as a ligand for the 
advanced glycation end products receptor (RAGE). Furthermore, data from our group 
shows that AGEs intake was higher in participants with presence of cardiovascular 
disease complications when compared with those without complications [139]. 
 
Although a role for AGEs in diabetes-related complications seems well supported by the 
literature, in other areas the role of AGEs in general and dietary AGEs in particular is 
less clear. For instance, there is no consensus among the researchers investigating 
dietary AGEs about their health impact, probably because of the diversity in AGEs, their 
effects, and dose-response issues. Indeed, some studies have found some beneficial or 
no effects from dietary melanoidins (late products of Maillard reaction in foods) or other 
AGEs such as pentosidine. For instance, Ames et al. found that melanoidins from bread 
crust increased the number of anaerobes, Clostridia, and Bifidobacteria in a culture of 
human fecal bacteria [140], indicating a possible potential prebiotic effect of bread crust 
melanoidins [141]. In addition, other study showed an increase in the activity of 
chemopreventive enzymes as glutathione-S-transferase [142].  
 
Moreover, AGEs heterogeneity has made measuring them in foods and comparing data 
from different research groups difficult. Also, only short term effects have been 
measured and information about long term effects have not been studied yet. The 
methodological design of long-term studies represents a great challenge. One of the 
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difficulties is achieving diets with different dietary AGEs content, but with similar content 
in other nutrients, such as heat-sensitive vitamins. Pouillart et al. demonstrated that 
diets with different dietary AGEs content but similar thiamine, vitamin E and other heat-
sensitive vitamins content, are challenging but possible [143].  
 
Future studies on the role of dietary AGEs on diabetes mellitus and their related 
complications also should address the methodological problem for their measurement in 
the diet. Most studies of dietary AGEs have used 3 days food records for their 
quantification in the diet. However, 7 days food records are better for measuring 
proteins and fat [144]. While the database for dietary AGEs has grown, consensus 
about how dietary AGEs should be measured has not been reached. Finally, human 
studies including antiglycation food products need to be conducted to elucidate any 
valid role these foods and food components may have in health. 
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Figure 3.1 Different pathways for advanced glycation end products formation in vivo 
 
A) Non-oxidative Amadori product cleavage  B) Namiki pathway C) Wolff pathway, glucose autoxidation 
D) Glycolytic pathway E) Polyol pathway F) Ketone body and threonine metabolism G) Lipid peroxidation 
 
 
Figure 3.2 Interaction of AGEs with their receptors 
 
AGE = Advanced glycation end product; RAGE = receptor for AGE; MAPK = mitogen-activated protein 
kinases; AGER1 = AGEs Receptor 1; PI-3k = phosphatidylinositol-3 kinase; NAD(P)H oxidase = enzymes 
complex which produces superoxide; TNF-α = tumor necrosis factor α; IL-6 = Interleukin 6; VCAM-1 =  
vascular adhesion molecule 1. 
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Table 3.1 Clinical studies with dietary AGEs restriction in human subjects 
AGER1=AGEs Receptor 1; CML=carboxymethyl-lysine; CML-LDL=carboxymethyl-lysine-low density lipoprotein; CRP=C reactive 
protein; HDL=high-density lipoproteins; HOMA=homeostatic model assessment; ICAM-1= intracellular adhesion molecule 1; 
MAPK=mitogen-activated protein kinases; MG=methylglyoxal; p66 Shc=Shc adaptor protein; RAGE =receptor for AGE; 
TBARS=thiobarbituric acid-reactive substance; TNFα =tumor necrosis factor α; VCAM-1= vascular adhesion molecule 1. 
 Study 
population 
Design Diets Results  
Vlassara 
2002[30] 
11 subjects 
with diabetes 
(DM) 
2 weeks crossover; 
meals were 
provided to 
participants with 
different AGEs 
content 
Low AGEs: 
 3.67±1.2 x 106 AGEs units 
Serum AGEs ⇓ 30% 
VCAM-1 ⇓ 50%  
High AGEs: 16.3±3.7 x 106 
AGEs units 
Serum AGES ⇑ 64% 
13 subjects 
with DM  
6 weeks study; 
meals were 
provided with 
different AGEs 
content 
Low AGEs: 
 3.67±1.2 x 106 AGEs units 
CML ⇓ 40%, CRP ⇓ 20%, 
VCAM-1 ⇓ 20% 
High AGEs: 16.3±3.7 x 106 
AGEs units 
CML ⇑ 28%, CRP ⇑ 35%,  
TNF- α ⇑ 86% 
Uribarri 
2003[106] 
26 subjects 
with 
peritoneal 
dialysis (non-
DM)  
4 weeks study; 
participants ate 
meat cooked with 
different methods. 
Low AGEs, Basal: 13.8±3 
 Final: 17±3 x106 AGEs units 
Serum CML ⇓ 34% MG ⇓ 
35% and CML-LDL ⇓ 28% 
High AGES Basal: 12.4±1.5 
Final: 5.5±0.9 x106 AGEs units 
Serum CML ⇑29%, MG ⇑ 
26% and CML-LDL ⇑ 50%  
Cai 
2004[62] 
24 subjects 
with DM 
6 weeks study; 
meals with different 
AGEs content 
Low AGEs: 
 3.67±1.2 x 106 AGEs units 
LDL was 50% less glycated 
and 80% less oxidized  
High AGEs: 16.3±3.7 x 106 
AGEs units 
⇑ MAPK phosphorylation, NF-
κB activity, and VCAM-1 
production on endothelial cells 
Negrean 
2007[109] 
20 subjects 
with DM 
 
6 days study; acute 
effect of 2 different 
AGEs diets on days 
4 and 6; single meal 
was provided 
 
Low AGEs meal:  2750 KU  CML and MG  ⇓  
High AGEs meal: 15100 kU   
 
 
 
CML and MG  ⇑ after 4 h. 
Impaired macrovascular 
function: Flow mediated 
dilation ⇓ 36.2%. Markers of 
endothelial dysfunction:  E-
selectin ⇑ 51%, ⇑I-CAM and 
⇑VCAM. Marker of oxidative 
stress, TBARS ⇑ 21% 
Stirban 
2008[145] 
20 subjects 
with DM 
 
6 days study; acute 
effect of 2 different 
AGEs diets on days 
4 and 6; single meal 
was provided 
Low AGEs meal: 2750 KU    
High AGEs meal: 15100 kU  Leptin and adiponectin ⇓ 
Vlassara 
2009[28] 
40 healthy 
subjects 
 
4 months study; 
instructions to 
change cooking 
methods 
> 13 AGE 106 
AGEs units 
Low AGEs 
Reduction on CML, MG and 
AGER1, RAGE, and p66Shc, 
8-isoprostane, VCAM-1 and 
TNFα  9 CKD-3 
subjects 
4 weeks study; 
instructions to 
change cooking 
methods 
Birlouez-
Aragon 
2010[97] 
62 healthy 
subjects  
4 weeks study; 
meals were 
provided with 
different cooking 
preparations 
Low AGEs 
2.2±0.9 mg 
⇓ Total cholesterol, HDL and 
triglycerides 
High AGEs: 
5.4±2.3 mg 
⇑ CML, fasting insulinemia, 
HOMA  
Uribarri  
2011[74] 
18 healthy 
and 18 
subjects with 
DM 
4 months study; 
instructions to 
change cooking 
methods  
High AGEs: 
20000 KU AGEs 
Low AGEs  
Lower levels of CML, MG, 8-
isoprostane (a lipoxidation 
marker) and insulin in serum, 
as well as a lower HOMA 
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Chapter 4 
The Relationship Between Dietary Advanced Glycation End Products And 
Indicators Of Diabetes Severity In Mexicans And Non-Hispanic Whites: A Pilot 
Study3,4 
 
Abstract: Diet is an important source of exogenous advanced glycation end products 
(AGEs). Dietary AGEs content depends on nutrient composition and on the way food is 
processed/cooked. The objective of our study was to compare AGEs intake of 2 
different ethnic groups (Mexicans and non-Hispanic whites) with type 2 diabetes mellitus 
(DM) and to study the relationship between dietary AGEs and diabetes-related 
complications. Complications were self-reported by subjects (n=65) and categorized 
according to a published DM disease severity index as low risk or moderate-high risk. 
Dietary records for 10 days were used to estimate dietary AGEs from a published food 
table. Non-Hispanic whites had higher intake of dietary AGEs (natural logarithm was 
used, LogAGEs) when compared with Mexicans, which was consistent with their higher 
intake of saturated fat. Additionally, for each unit increase in the LogAGEs, a participant 
was 3.7 more likely to have moderate-high risk for cardiovascular disease.  
Key words: Dietary AGEs, cardiovascular complications, carboxymethyl-lysine (CML). 
 
 
 
 
 
 
 
3This chapter appeared in its entirety in the International Journal of Food Science and Nutrition and it is 
referred as to Luevano-Contreras C, Preciado-Puga M, Garay-Sevilla ME, Chapman-Novakofski K. The 
relationship between dietary advanced glycation end products and indicators of diabetes  severity      
in Mexicans and non-Hispanic whites: a pilot study. Int Journal of Food Sci and Nutrition, 2013, 64,16-20. 
This article is © 2013 by Informa Healthcare, and is reprinted with the permission of the publisher. It is 
available at http://www.informahealthcare.com using DOI: 10.3109/09637486.2012.704905 
 
4Additional analysis and tables not included on the published manuscript are included on Appendix A, and 
questionnaires used for this study are included on Appendix B.  
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4.1 Introduction 
The prevalence of diabetes mellitus (DM) is dramatically increasing worldwide, 
especially for some ethnic and racial groups. For instance, Mexican-Americans have 
higher prevalence, as well as higher risk and prevalence of diabetes-related 
complications when compared to non-Hispanic whites [1]. Several mechanisms have 
been proposed for the development of diabetes-related complications. A research area 
gaining interest in recent years is the accumulation of a group of compounds called 
advanced glycation end products (AGEs). AGEs can be formed in the body 
(endogenous) and contribute to vascular damage in diabetes. In addition, exogenous 
sources of AGEs can be found in some foods rich in protein and fat, with high cooking 
temperatures increasing AGEs formation. Several AGEs have been characterized, and 
one of the most widely used as a marker of AGEs in foods and in vivo is carboxymethyl-
lysine (CML) [2].  
 
The effects of dietary AGEs have been measured in clinical research studies in terms of 
levels of blood AGES and inflammatory and oxidation markers. Patients in the groups 
with higher AGEs intake had higher levels of inflammatory and oxidation markers such 
as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and C-reactive protein (CRP) 
than patients in the lower AGEs intake group. In these studies, AGEs intake has been 
assessed with 3-day food records. However, while some authors have found that 3 days 
of food records are good for providing a reasonable estimate of the quality of the diet, 
they are not very accurate in estimating individual nutrients, and at least 7 to 10 
nonconsecutive days are necessary to represent usual intake of energy and 
macronutrients [3,4]. The length of time needed to adequately represent AGEs intake 
has not been studied, but AGEs intake is highly dependent on the macronutrients fat 
and protein [5].  
 
Because Mexican-Americans are one of the minorities with higher prevalence of DM, 
one of the objectives of this study was to compare the diets of Mexicans (living in 
Mexico or in USA) and non-Hispanic whites with diabetes. In addition, we wanted to 
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study the relationship between dietary AGEs and diabetes parameters, as well as to 
recognize tertiles of AGEs intake in these groups using 10 days of food records. Our 
hypothesis was that subjects with higher intake of AGEs could have higher risk for self-
report diabetes complications.  
 
4.2 Methods 
A convenience sample of Mexican-Americans (n=15) and non-Hispanic white (n=15) 
adults in USA and Mexican adults (n=35) in Mexico with type 2 DM were recruited 
directly by investigators, through key informants, or email bulletins. All participants were 
over 18 years of age and had type 2 DM by self-report. Pregnant or breastfeeding 
women were not included, nor vegan (strict vegetarian), vegetarians, nor participants 
with a protein restricted diet. Participants must have had a recent (past 3 months) 
glycosylated hemoglobin A1c (HbA1c) test (self-report). The Institutional Review Boards 
in both countries approved the protocol. 
 
In a first meeting, participants had a brief training (10-15 minutes) about how to 
complete the 10-day food records after they had read and signed the informed consent 
(Spanish or English, by preference). For the training, food models and measuring cups 
were used to increase the accuracy of the reported food amounts. Reporting cooking 
methods and food brands was emphasized. After patients reported the first day, they 
were interviewed again to increase the likelihood that all foods were included, cooking 
methods reported, portions were as accurate as possible, and to answer any questions 
the participants may have had. A final meeting clarified any inconsistencies or 
omissions.  
 
In addition, they completed background questionnaires: a history of diabetes mellitus 
questionnaire which included type of medication, history of complications, health-related 
visits, history of smoking and alcohol intake, self-reported HbA1c, blood glucose levels, 
weight, and height; and a vitamins and supplements intake questionnaire [6,7]. The 
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body mass index (BMI) was calculated with self-reported weight and height according to 
the formula weight (kg)/[height (m)]2.  
 
4.2.1 Dietary assessment  
For the quantification of micro- and macronutrients, Food Processor software (Salem, 
Oregon, 2008) was used for the analysis of US dietary records, with foods added 
according to label nutrient content when needed. For the Mexican dietary records, the 
software Nutrikal (2007) was used. A registered dietitian reviewed all the analyses.  
 
To develop a classification of AGEs intake, we reviewed six previous clinical studies that 
assessed low and high AGEs intake in humans [8-13]. The average intake for the low 
AGEs groups was 3900 KU (2700-5500 KU), and the average intake for the high AGEs 
was 15000 KU (12200-16300 KU). Therefore, for the present study, consumption higher 
than 15000 KU was considered high, between 4000 and 15000 KU was considered 
moderate and less than 4000 KU was considered low. The AGEs content of food was 
taken from a published database with around 500 foods with the amount of CML 
expressed as AGE Kilounits (KU) [14]. In addition, because higher caloric intake may 
influence the intake of AGEs, dietary AGEs were divided by caloric intake to derive 
AGEs density. 
 
4.2.2 Complications 
The Michigan Diabetes history form was used for background medical history data [6]. 
Participants answered the questionnaire at home and were advised to contact their 
primary physician with questions regarding their medical history. Three categories of 
complications were used: cardiovascular disease, eye disease, and peripheral disease. 
For cardiovascular disease, questions included those pertaining to the presence of 
hypertension, high levels of cholesterol, angina, heart attack, heart failure, artery bypass 
surgery, angioplasty, and heart catheterization. For eye disease complications, 
questions ranged from presence of cataracts, detached retina, blurred vision, 
retinopathy, blindness, macular degeneration, macular edema, and laser treatment or 
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cataract surgery. For peripheral disease questions, presence of peripheral vascular 
disease, intermittent claudication, peripheral neuropathy, foot ulcers, gangrene, 
amputation of the toe, foot or leg were asked. To categorize the self-reported 
information about complications, we used a published disease severity index for DM, 
but we used only two risk levels (low or moderate-high) instead of the original four [15]. 
Participants were classified as low risk if they answered ”no” to all the questions 
regarding a specific complication category or as moderate-high risk if they answer “yes” 
to any of the questions regarding that complication. Another section of the diabetes 
history questionnaire was regarding health care. The questions included those related to 
the last visit to the ophthalmologist, diabetes educator and dietitian, as well as how 
many visits they had with a health care provider in the last 12 months.  
 
4.2.3 Statistical Analysis 
Normality was assessed by the Shapiro-Wilk test. Skewed data is presented as median 
and interquartile range, and dietary AGEs were transformed using the natural logarithm 
(LogAGEs). One-way analysis of variance (ANOVA) was used for testing differences 
among groups with a Bonferroni correction test for post-hoc analysis, and Tamhane test 
when homogeneity of variance was not assumed. For non-normally distributed data and 
non-continuous variables the test Kruskal-Wallis was used. Stepwise linear regression 
was used to evaluate the relationship between dietary variables, and dietary AGEs 
(LogAGEs) as dependent variable. An influential outlier was eliminated in our final 
model. In addition, logistic regression was used to evaluate the relationship between 
each complication category and other independent variables as health care variables, 
smoking, metformin use, BMI, LogAGEs, and AGEs density. All statistical analyses 
were performed in SPSS (version 17.0, 2008 Chicago IL).  
 
4.3 Results  
We analyzed data for 65 participants, 35 in Mexico, 15 non-Hispanic white Americans 
and 15 Mexican-Americans in USA. Sixty-nine participants started the study, but 4 of 
them did not complete it (2 Mexicans, 1 non-Hispanic White and 1 Mexican-American). 
  75 
For the Mexican group, 74% of the participants were females and 26% males. For the 
non-Hispanic white and Mexican-American groups, both included 47% females and 
53% males. The HbA1c was similar for Mexicans and Mexican-Americans (8.2±1.8% 
and 8.1±2%) and lower for non-Hispanic whites (7.1±1.2%), but not statistically different. 
Mexicans had the lowest BMI (29.0±4.9 kg/m2) followed by Mexican-Americans (32.3±7 
kg/m2) and non-Hispanic white (36.2±8.8 kg/m2), but only Mexicans and non-Hispanic 
whites were statistically different (p<0.01).  
 
Results from the dietary analysis are shown in Table 4.1. There was a trend of lower 
intake of energy, fat and saturated fat for Mexicans followed by Mexican-Americans. 
Regarding dietary AGEs (LogAGEs), there was a significant difference among groups; 
Mexicans had the lower intake followed by Mexican-Americans, and the highest 
consumption was for non-Hispanic whites. These results remained consisted after 
accounting for differences in weight (AGEs/kg) and differences in energy intake (AGEs 
density). After using stepwise linear regression, dietary AGEs (LogAGEs) were 
associated with protein and saturated fat. The association remained significant after 
adjusting for group (F=55.12, p<0.0001, R2=0.78)(Table 4.2). 
 
4.3.1 Severity Index for Diabetes-related Complications 
Participants were classified into two risk levels (low or moderate-high) for each 
complication category. For cardiovascular complications, all of non-Hispanic whites 
were classified as moderate-high risk level (100%) followed by Mexican-Americans 
(80%) and Mexicans (69%); non-Hispanic whites and Mexicans were statistically 
different. Regarding peripheral disease complications, Mexicans had the highest 
frequency of moderate-high risk level (57%), followed by Mexican-Americans (40%), 
and lastly non-Hispanic whites (20%); Mexicans and non-Hispanic-whites were 
statistically different. For eye disease complications, the frequencies were very similar 
among groups.  
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Regarding health care variables, the only significant difference was for ophthalmologic 
visits 80% of non-Hispanics whites participants had visited the ophthalmologist in the last 
12 months, but only 37% of Mexicans participants had visited the ophthalmologist in the 
last 12 months.  
 
4.3.2 Relationship between Complications and dietary AGEs 
Logistic regression was used to find a relation between each category of complication 
and dietary AGEs. Only cardiovascular complications were associated with dietary 
AGEs (LogAGEs) when adjusting for HbA1c, metformin intake and smoking habits. It was 
found that the odds ratio for LogAGEs was 3.7 (Table 4.3). Therefore, we find that one 
unit increase in the LogAGEs is associated with a 270% increase in the predicted odds 
for being at the moderate-high risk level for cardiovascular disease. The association was 
still significant after adjusting for energy intake (AGEs density), but the odds ratio for 
AGEs density was 1.5 (Table 4.3). It is important to note that no association was found 
for saturated fat (results not shown). Participants in the moderate-high risk level for 
cardiovascular disease had a significant higher intake of AGEs (11,921±8,671 KU) 
when compared with those in the low risk level (7,414±4,168 KU)(p<0.01).  
 
4.4 Discussion 
One of the most interesting findings of our study was the association between dietary 
AGEs (LogAGEs) and the risk level for cardiovascular disease. There are no similar 
studies comparing intake of AGEs between subjects with diabetes-related complications 
and without complications. However, clinical studies have found that DM subjects 
assigned to a high intake of dietary AGEs had more glycated low-density lipoproteins 
(LDL) than subjects with the low AGEs intake [12]. In addition, the acute effect of a meal 
rich in AGEs has also been measured in type 1 and type 2 DM. It was found that after a 
single challenge with dietary AGEs flow-mediated dilation of the brachial artery (used as 
a measure of endothelial function) decreased, and inflammatory markers as VCAM-1 
increased [10,11]. Furthermore, Chao et al. studied subjects with type 2 DM and found a 
positive correlation between high dietary AGEs intake and levels of inflammatory 
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cytokines (IL-1α, and TNF-α), levels of the oxidation marker 8-isoprostane and levels of 
glycated LDL [16]. 
 
Dietary intake for energy, fat and saturated fat was significantly higher in non-Hispanic 
whites when compared to Mexicans, but there were no difference between non-Hispanic 
whites and Mexican-Americans. For Mexican-Americans and Mexicans, only saturated fat 
intake was significantly different; it was higher for Mexican-Americans. A study among 4 
adult female groups: Mexicans, Mexicans-Americans (MA) born in Mexico, MA born in 
USA and non-Hispanic whites found statistical differences in energy, fat and saturated fat 
intakes between Mexicans and MA born in Mexico, as well between MA born in Mexico 
and non-Hispanic whites. The authors concluded that an increase exposure to US 
environment among Mexicans shifted the diet toward an increase in energy, fat, saturated 
fat and sugar intake. [17]. Although, we did not find a significant difference between 
Mexicans-Americans and non-Hispanic whites there was a trend of lower intakes for 
Mexican-Americans.  
 
The intake of AGEs was different among groups; Mexicans had the lower intake followed 
by Mexican-Americans and non-Hispanic whites which is consistent with their intake of 
saturated fat. However, it is important to have in mind that the database used was created 
considering usual intake of an urban population in USA, and is lacking usual Mexican 
foods. In a study in subjects with end-stage renal disease where 43% of them had 
diabetes, the mean AGE intake in those with diabetes was 14±7 KU X 106 [18] which is 
below the intake of AGEs in non-Hispanic whites. Similar to our results, a study in healthy 
subjects found that the intake of AGEs ranged from 20 KU X 106  to 14 KU X 106  [19]. 
Regarding the association of AGEs with other dietary variables, findings by Uribarri et 
al. showed a significant correlation of AGEs with the intake of protein, fat and saturated 
fat, and the multiple regression model showed that dietary AGEs was associated with 
dietary fat but not with protein or saturated fat (r=0.69; p=0.01)[18]. Likewise, we found 
a relation between protein and saturated fat intake and dietary AGEs. 
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Similar to our results, a study comparing diabetes-related complications among 
Hispanics and non-Hispanic whites from NHANES 2006 found that there was an 
increased risk for peripheral vascular disease among Hispanics [20].  
This study had some limitations. First, years with DM were not measured and it should be 
considered for future studies. There were no non-Hispanic whites without cardiovascular 
disease and so we could not test for any effect of ethnicity. Body weight, height and 
complications were self-reported. In addition, we did not measure AGEs levels in blood, 
however findings from several studies support the view that the intake of dietary AGEs is 
an important contributor to the body’s AGEs pool [16,21,22]. One of the strengths of this 
study was the comprehensive analysis of AGEs content in the diet; we used 10 days of 
food records and a recent published database with 500 foods with AGEs contents.  
 
4.5 Conclusions  
Non-Hispanic whites had higher intake of dietary AGEs when compared with Mexicans, 
which is consistent with their higher intake of saturated fat. For each unit increase in the 
LogAGEs, participants were 3.7 more likely to have moderate-high risk for cardiovascular 
disease. Despite its limitations this study shows a significant association between dietary 
AGEs intake and the risk level for diabetes-related cardiovascular complications, which 
should be explore in future research [23] 
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Table 4.1. Dietary Characteristics by Group. 
 Mexicans 
(n=35) 
Mexicans-Americans  
(n=15) 
Non-Hispanic Whites 
(n=15) 
Dietary AGEs  (KU) 6303 ± 2842 * 11600 (7508, 15996) † 19798 ± 8707 † 
Log Dietary AGEs¶  8.6 ± 0.5 * 9.3 ± 0.5 † 9.8 ± 0.4 ‡  
AGEs density  3.9 ± 1.5* 6.9 ± 2.1 † 9.9 ± 2.6 ‡ 
Dietary AGEs by  
body weight (Kg)  
92.7 ± 38.9 * 154.8 ± 84.9 † 198.7 ± 83.9 † 
Energy intake (Kcal) 1575 ± 330 * 1603 (1307, 1900) * 1984 ± 582 † 
                         (Kj) 6594 ± 1381* 6711 (5472, 7954)* 8306 ± 2436 † 
Carbohydrates     (g) 217.5 ± 53.1* 196.1 (159.8, 216.5)* 226.2 ± 67.4* 
Protein                 (g) 72.4 ± 22.2* 69.7 (60.2, 90.1)* 85.9 ± 21.1* 
Fat                       (g) 54.1 ± 15.1 * 60.2 (50.6, 75.1) * 83.2 ± 31.2 † 
Saturated fat        (g) 13.5 ± 4.2 * 18.7 (14.1, 22.7) † 27.7 ± 11.2 † 
AGEs Intake  (n) (n) (n) 
Low <4000 KU  9 0 0 
Moderate 4-15000 KU  24 11 4 
High >15000 KU  2 4 11 
Results are presented as mean±SD or median and interquartile range. ¶Natural logarithm transformation 
used because skewed data. One-way Anova used for differences among groups. Different symbols show 
differences between groups (p<0.05). 
  
 
 
 
 
 
Table 4.2. Multiple Linear Regression for Dietary AGEs with Independent Dietary 
Variables Adjusted by Group.   
 
 
Independent 
variables 
Mexicans 
   (n=35) 
 β (SE) 
Mexicans-
Americans  
(n=15) 
 β (SE) 
Non-Hispanic Whites  
 (n=15) 
 β (SE) 
Constant 7.5 (0.1)* 7.9 (0.1)* 8.2 (0.1)* 
Protein 0.010 (0.002)* 0.010 (0.002)* 0.010 (0.002)* 
Saturated Fat 0.025 (0.006)* 0.025 (0.006)* 0.025 (0.006)* 
Coefficients (β) and their standard error (SE) are presented. F=55.1, p<0.0001, R2=0.79. 
*p-value<0.001 for individual coefficients. 
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Table 4.3. Logistic Regressions for Cardiovascular Disease Complications  
Model 1 β (SE) Odds Ratio 95% Confidence intervals 
Constant -10.7 (5.7)   
LogAGEs 1.3 (0.6)* 3.7 (1.2, 11.9) 
Metformin intake -1.5 (0.9) 0.2 (0.04, 1.52) 
Number cigarettes  -0.2 (0.1) 0.8 (0.58, 1.04) 
HbA1c 0.2 (0.2) 1.2 (0.81, 1.87) 
Model 2 
AGEs density 
 
0.4 (0.2)* 
 
1.5 
 
(1.1, 2.1) 
Model 1: Chi-square=11.75, p=0.019, R2=0.26. Model 2: Chi-square=12.8, p=0.012, R2=0.3. The 
coefficient for the constant was -1.5, for Metformin intake, Number cigarettes and HbA1c were similar to 
the first model (±0.1). *p-value<0.05. 
 
 
 
 
 
 
 !
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Chapter 5 
Development, Relative Validity, and Reliability of a Food Frequency 
Questionnaire for a Case-Control Study on Dietary Advanced Glycation End 
Products and Diabetes Complications5, 6 
 
 
Abstract: Dietary advanced glycation end products (dAGEs) could be involved on 
diabetes complications, yet their quantification is not standardized. The objective of this 
study was to design a food frequency questionnaire (FFQ) for dAGEs, and to assess its 
reliability and validity. For the design, data from 30 subjects was used. The final 
instrument had 90 food items. To measure reliability and validity, 20 participants with 
type 2 diabetes filled out twice the FFQ (FFQ-T1, FFQ-T2) and 7-day food records (7-
dFR). The Shrout-Fleiss coefficient was 0.98 showing good reliability. For validation, the 
results for the weighted kappa were 0.55 (moderate agreement) for FFQ -T1 and 0.64 
(good agreement) for FFQ-T2, and 75% and 80% of subjects respectively were correctly 
classified into tertiles; Bland-Altman graphics showed no systematic bias. This FFQ is 
comparable to 7-dFR for measuring dAGEs. To our knowledge this is the first 
questionnaire designed to measure specifically dAGEs. 
 
 
Keywords: diabetes mellitus type 2, dietary intake, survey validation, dietary advanced 
glycation end products. 
 
 
 
 
 
5This chapter has been submitted for publication to the International Journal of Food Science and 
Nutrition and it is referred to as Luevano-Contreras C, Durkin T, Pauls M, Chapman-Novakofski K. 
Development, Relative Validity, and Reliability of a Food Frequency Questionnaire for a Case-Control 
Study on Dietary Advanced Glycation End Products and Diabetes Complications, 2013.  
 
6Note: Questionnaires used for this study are included on Appendix C. 
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5.1 Introduction 
Diabetes complications are the 7th leading cause of death in the US, and it is estimated 
that 20% of health care dollars are spent on people diagnosed with diabetes [1]. The 
accumulation of endogenous compounds called advanced glycation end products 
(AGEs) could be involved in the development of these complications [2]. In addition, 
results from studies in animals and humans suggest a role of dietary AGEs (dAGEs) on 
diabetes. Dietary AGEs could accumulate in tissues and exert the same damage 
attributed to endogenous AGEs. Clinical studies have shown that high dAGEs intake 
increased circulating AGEs levels, pro-inflammatory cytokines, oxidation markers, and 
affected endothelial function [3-5]. However, the long-term effects of dAGEs have not 
been studied, mainly because of the methodological challenges for their measurement 
in the diet.   
 
Among the different instruments for measuring dietary intake, the 7-day food record with 
weighing, measuring or estimation of portion size provides a reasonably accurate 
method of actual intake, but it is time consuming and it demands a high degree of 
cooperation from participants [6]. A good alternative to food records (FR) is the food 
frequency questionnaire (FFQ), because it decreases the participant’s burden of filling 
out several days of food records [7]. Among the advantages of this questionnaire is that 
it is inexpensive to administer and less time consuming for analysis. However, the foods 
selected for the FFQ are very important, as well as the correct choice of portion size [8]. 
The FFQ should have defined food categories [9]. Food frequency questionnaires and 
diet history methods are the best methods for assessing past diet and are therefore the 
only good choices when designing case-control studies [10].  
 
Food frequency questionnaires are also useful when the focus is on measuring a 
specific nutrient intake [11,12]. The list of foods used in this case should include foods 
with higher amounts of the nutrient of interest or with moderate levels, but consumed in 
larger amounts by the population of interest. For this reason, using previous dietary 
survey information collected from the population is highly recommended [7]. In 
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semiquantitative FFQs, the frequency of the food eaten is multiplied by the nutrient 
content of the food. In this fashion, nutrient intake can be classified in tertiles for low, 
medium and high intakes [13]. When a new FFQ is designed, a validation study is 
necessary in a sub-sample of the main study population, and weighed records or 
several days of FR are among the best reference methods [7].  
 
At this time, there is no standardized methodology for the quantification of AGEs in the 
diet. Having a reliable and valid FFQ specific for AGEs will increase the accuracy of 
associations between diabetes and dAGEs; decrease participant burden during studies; 
and decrease analysis time of food eaten. Thus, a FFQ could help to assess dAGEs in 
a time and cost saving manner. For this reason, the aim of this study was to design a 
FFQ using information on usually consumed foods from participants from a previous 
study [14]. In addition, we assessed the reliability and validity of a food frequency 
questionnaire for assessing dAGEs when compared with the results of 7 days of FR.  
 
5.2 Methods  
5.2.1 Development of the FFQ Specifically for dAGEs  
For the development of the FFQ, the dietary data from 30 subjects from a previously 
published research study were used [14]. These subjects had type 2 diabetes mellitus 
(DM) and they completed 10 days of FR. We calculated the dAGEs from the 10 days of 
FR using a database with the AGEs content in food [15]. The mean intake of dAGEs for 
these subjects was 16372±8898 KU AGEs. In order to identify which foods or 
beverages were the main contributors of dAGEs and to decide which foods would be 
included in the FFQ, steps suggested by Block were followed (Figure 5.1) [16].  
 
First, all foods and beverages reported on the 10-day FR along with their amount (g or 
mL) were entered into Excel (Microsoft, 2011). The objective was to create a 
comprehensive list of foods consumed by this population as suggested by Block [16]. If 
a subject reported eating the same food several days or several times per day that food 
was entered only once, but the total amount (g or mL) for the 10 days were recorded. 
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After entering all foods in Excel as reported by all subjects, a list of 335 foods along with 
their amount was compiled.  
 
Second, dAGEs (measured as AGE KU) were quantified using Uribarri’s database for 
content of AGEs in foods [15]. Only 271 food items (out of 335) were quantified for 
dAGEs, and the remaining 64 foods items were not quantified because no similar food 
was found in the database or no disaggregation was considered pertinent. The food 
items that could not be quantified were assigned a value of zero AGE KU. Of these 64 
food items, 32 were fruits or vegetables, 8 were different types of sauces (sweet and 
sour sauce, green sauce), 4 of them were complete dishes and 20 were miscellaneous 
foods.  
 
Third, similar foods were grouped into food item categories [17]. The objective was to 
reduce the food list to include in the FFQ. After grouping into categories, the list was 
reduced to 130 food items. For example, Italian salad dressing and ranch salad 
dressing were grouped into the food item category “salad dressing”, and for cookies all 
different types were grouped into the food item category “cookies”. In addition, if a food 
had different preparation methods it was also grouped into the same food category, for 
example “grilled chicken” and “steamed chicken” were grouped into the food category 
“chicken”. 
 
Fourth, the relative contribution for each food item was calculated [16]. For this purpose, 
the total amount of dAGEs consumed by all subjects was calculated by summing the 
amount of dAGEs in all servings of all foods reported. The relative contribution for a 
specific food item was calculated by the following formula, [(total AGEs KU by a specific 
food/total AGEs KU in all foods)*100] [16].  
 
Finally, food items were ranked by their relative contribution and the cumulative 
frequency calculated. According to Block, a FFQ should contain 80 or 90 percent of the 
original food list [16]. For this FFQ it was decided to include foods representing 95% of 
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the cumulative frequency because we were interested in capturing most of the dAGEs 
intake of our population. Figure 5.2 shows the 8 foods with higher relative contribution to 
the amount of dAGEs. 
 
The final FFQ for dAGEs had 90 food items (out of 335), some of them asking for 
specific cooking methods (meats group). These were divided into 7 groups: cereals, 
pastries/cookies, snacks, fats, meats, cheese, and combination foods. The frequencies 
used were similar to those used in the National Health and Nutrition Examination Survey 
(NHANES) FFQ [18]: never, 1 to 6 times per year, 7 to 11 times per year, once a month, 
2 to 3 times per month, once a week, 5 to 6 times per week, 2 to 4 times per week, once 
per day, 2 or more per day. The questionnaire measured the consumption of food over 
the last year, and was interviewer-administered.  
 
Regarding portion size, participants were allowed to choose their portion size for each 
food. For this purpose, Nasco three dimensional food models (Nasco Lifeform®), 
measuring cups and a portion size booklet were used [19]. The food frequency 
questionnaire was evaluated for completeness and for ease of use and 
understandability by an expert panel. 
 
5.2.2 Food Record Questionnaire 
The food record questionnaire asked for place, time and amount of food and beverages 
consumed. In addition, it included prompts to record cooking method and brand of food, 
when possible.  Although our past study of the FR [14] asked participants to record 10 
days, analysis of variance supported a shorter time frame of 7 days for the current 
study. Briefly, the average intake of energy and dAGEs for 10 days was compared with 
the average intake of the first 7 days and the first 3 days. There was no significant 
difference when comparing 10 days versus 7 days or when comparing 10 days versus 3 
days. However, for the 3 days of FR, 21.5% of subjects were classified in a different 
tertile category. In contrast, for the 7 days of FR only 3.1% of subjects were 
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misclassified (SPSS, version 17.0, 2008, Chicago, IL, USA). Therefore, we decided to 
use 7 days of FR (7-dFR) for the validity of the FFQ.  
 
5.2.3 Reliability and Relative Validity 
Reliability was evaluated by repeated completion of the FFQ in a test-retest manner, to 
determine if the instrument was stable over time.  Validity of the FFQ was evaluated 
with comparison to the 7-dFR, both for total AGEs content and types and amounts of 
food eaten.  
  
5.2.4 Subjects  
This was a convenience sample (n=20), and both men and women with type 2 DM were 
recruited. They were not included if they were following a protein-restricted, vegan or 
vegetarian diet. Participants from a previous study [14] were contacted by mail and 7 of 
them consented to participate in the present study. Additionally, 15 participants were 
recruited through email bulletins and flyers. Two participants that reported major 
changes in their diet during the study were excluded. The final sample size was 20 
participants. In addition to dietary questionnaires, participants were asked to report their 
age, years with diabetes, weight and height. Body mass index (BMI) was calculated with 
the formula weight (kg)/ [height (m)]2 [20]. All procedures were approved by the 
Institutional Review Board at the University of Illinois at Urbana-Champaign. 
 
5.2.5 Study Procedures 
During a first meeting (T1) and after consent, brief instructions and examples were 
given on how to complete the FFQ. The FFQ was interviewer-administered and a 
trained researcher carried out all the interviews. The FFQ did not include portion size, 
hence the subjects were asked to estimate their usual portion size with aid of food 
models, measuring cups and a portion size booklet [19]. These data are referred to as 
FFQ-T1. 
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During a second appointment (arranged two weeks after the first one), participants 
answered the interviewer-administered FFQ for a second time (T2) for reliability testing, 
following the same procedures used during the first interview. At the end of the second 
appointment, a closed package containing 7 days of FR (7-dFR) was given to the 
participants. A brief training was given about how to fill out the 7-dFR, such as how to 
estimate food serving sizes, and to include brand names, if possible, as well as cooking 
method and cooking time/temperature. The participants were asked to begin completing 
the 7-dFR one week after their second appointment, to minimize any influence from the 
food frequency completion. They received an email or phone call (their preferred 
contact) one day before they were to begin. After participants completed the first day’s 
FR, it was reviewed to assess completeness, by e-mail, or by telephone. During a last 
appointment, completeness was reviewed for all FR, and subjects were asked to 
complete any missing items, amount, or preparation method. 
 
5.2.5 Analysis of Questionnaires  
Data from the 7-dFR were analyzed using Food Processor software (ESHA Research, 
2011) for calories, carbohydrate, fat and protein content. Disaggregation of dishes into 
single ingredients was done before entering the data on Food Processor. Recipes 
websites (allrecipes.com, foodnetwork.com) were used to determine ingredients and 
amount based on what was reported. Nine new foods or recipes were added to Food 
Processor because initially they were not in the software database. The food 
composition was obtained either from food package labels on actual packages or on the 
internet, or adding the recipes by its component ingredients. In addition, in some 
instances the reported amount was not found in Food Processor and the website What's 
In The Foods You Eat Search Tool [21] was used to decide the amount to be entered in 
the software. 
 
The compilation of the food composition database was completed using an indirect 
method [22]. We used the data obtained by Uribarri et al. for AGEs content in foods [15]. 
Data from the 7-dFR and the FFQ for AGEs (completed twice) were entered in the 
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AGEs food content Excel database (Microsoft, 2011) for quantification of total AGEs 
intake from the two sources. The following frequency codes were used for the FFQ [18]; 
0 for never, 0.01 for 1 to 6 times per year, 0.028 for 7 to 11 times per year, 0.033 for 
once a month, 0.08 for 2 to 3 times per month, 0.14 for once a week, 0.29 for twice per 
week, 0.5 for 3 to 4 times per week, 0.79 for 5 to 6 times per week, 1 for once per day, 
and 2 for 2 or more per day. The amount of dAGEs was calculated by multiplying the 
frequency code and the gram or milliliters of food consumed by the AGEs (KU) amount 
in 100 g of food. Total dAGEs was determined by summing the intakes from each food. 
The actual database contains around 500 foods, therefore some foods were not found 
in the database. These foods were calculated with averages from similar foods available 
in the database. For example, there was no AGEs KU amount for pecans, therefore we 
used data for walnuts to quantify AGES KU; there was only deli ham, therefore 
turkey/chicken lunch-meat was entered there; when a meat did not have similar cooking 
method, a similar meat with the same cooking method was used. All decisions were 
made by at least 2 researchers and all final analyses were reviewed for any possible 
mistakes by a registered dietitian.  
 
5.2.6 Statistical Analysis 
Normality was assessed by the Shapiro–Wilk test. Skewed data are presented as 
median and interquartile range. Data on dAGEs from the FFQ-T1 and FFQ-T2 were 
analyzed and compared for reliability and Shrout-Fleiss intraclass correlation coefficient 
was used. A high value of this coefficient indicates low within person variation [23]. Data 
from 7-dFR were analyzed and compared to FFQ-T1 and FFQ-T2 for relative validity by 
parametric or nonparametric analysis, as appropriate. Spearman correlation coefficient 
was used because dAGEs data were non-normally distributed. For measuring 
agreement between questionnaires, the Bland-Altman method was used. Data of 
dAGEs were log transformed because data were skewed and limit of agreement was 
calculated as suggested by Bland et al. [24]. Because log transformed data were used, 
to determine the limit of agreement data were back transformed and reported as ratios. 
In addition, to measure how well the FFQ classified subjects in tertiles of AGEs 
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consumption compared to the 7-dFR, the percentage of subjects classified in the same 
tertile and the percentage of subjects classified in opposite tertiles by the different 
methods were calculated. The cut-off points for the tertiles were 4000 KU and 15000 
KU, thus consumption higher than 15,000 KU was considered high, between 4000 and 
15,000 KU was considered moderate and less than 4000 KU was considered low [14]. 
The weighted kappa statistic was calculated, and Masson et al. criteria were used as a 
measure of agreement [25]. Subjects classified into the same tertile were assigned a 
weight of 1, 0.5 for adjacent tertiles and 0 for opposite tertiles. Values of kappa > 0.80 
indicate very good agreement, between 0.61 and 0.80 good agreement, 0.41 to 0.60 
moderate agreement, 0.21 to 0.40 fair agreement and < 0.20 poor agreement [25]. All 
statistical analyses were carried out in SPSS (version 17.0, Chicago, IL, USA, 2008). 
The performance of the FFQ was considered adequate when a correlation coefficient 
was above 0.5, and 50% of subjects would be classified correctly into the same tertile 
and less than 10% grossly misclassified into opposites tertile, or weighted kappa values 
of at least 0.4 were found [25].  
 
5.3 Results 
The mean age of the 20 subjects (13 women; 7 men) was 56.6±10.2, years with 
diabetes were 6.9±4.8, and body mass index (BMI) was 37.4±7.7m2/kg. Energy and 
macronutrients intake from 7-dFRs are described in Table 5.1. Data on dAGEs 
assessed by each questionnaire and the categories of dAGEs by each questionnaire 
are shown in Table 5.2.  
 
5.3.1 Reliabil ity and Relative Validity  
For reliability, the Spearman’s correlation coefficient between FFQ-T1 and FFQ-T2 was 
0.89 (p<0.01), and the intraclass correlation coefficient was 0.98 with 95% CI (0.95, 
0.99). These values showed good reliability of the FFQ. For validity, data from 7-dFR 
were compared to both FFQ-T1 and FFQ-T2 (Table 5.3). The Spearman’s correlation 
coefficient showed good correlation for both FFQs. The weighted kappa showed 
moderate agreement for FFQ-T1 (0.55) and good agreement for FFQ-T2 (0.64). Both 
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FFQs had adequate percentages of subjects correctly classified in the same tertile, 75% 
for FFQ-T1 and 80% for FFQ-T2, and there was no misclassification into opposite 
tertiles for either of the FFQs. The FFQ-T1 overestimated dAGES by 93.6 KU in 
comparison to 7-dFR, but there was not a systematic bias as the average and the 
difference between both methods showed no correlation (R=-0.41, p=0.07). Figure 5.1 
shows the Bland-Altman data for FFQ-T1 with 1.96±SD limits of agreement. Values 
after back transformation were 2 for the upper limit and 0.55 for the lower limit. In 
contrast, the FFQ-T2 underestimated dAGEs by 464.6 KU in comparison to 7-dFR, but 
there was not a systematic bias as the average and the difference between both 
methods showed no correlation (R=-0.16, p=0.5). Figure 5.2 shows the Bland-Altman 
data for FFQ-T2 with 1.96±SD limits of agreement which values after back 
transformation were 1.67 for the upper limit and 0.55 for the lower limit. Visual 
inspection of Bland-Altman data showed that for lower intakes, FFQs at each time 
measurement overestimated dAGEs. The data can also be interpreted, conversely, that 
at lower intakes, 7-dFR underestimated intake. 
 
5.4 Discussion 
The main aim of the present study was the development of a FFQ to measure the 
amount of AGEs in the diet of subjects with diabetes. In addition, we were interested in 
testing the reliability and the relative validity of this instrument. To our knowledge this is 
the first specific questionnaire design to measure dAGEs. Although researchers may 
use slightly different methodology in developing and evaluating a new FFQ, identifying 
the foods to be included and the amounts that will differentiate intake is useful for 
determining usual intake of a nutrient [13]. 
 
The present study found that the FFQ is comparable to 7 days of FR to measure 
dAGEs. Other studies have used only 3 days of FR. However, according to Block [6], 7 
days of FR are better to measure macronutrients, and several studies showed that 
dAGEs are predicted better by amounts of protein and fat.  
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This FFQ has 90 food items. It was decided not to design a comprehensive FFQ to 
diminish burden in study participants, and only food items representing 95% of 
cumulative frequency were included. Our FFQ was shorter than other questionnaires 
measuring specific nutrients from the diet [12,22,26], although longer than others [11]. 
Some authors established that lengthy questionnaires impaired the accuracy of the 
answers and that when the purpose of the FFQ is very specific a short list of food is 
recommended [7,27]. 
 
Ten frequency categories were used, similar to the NHANES FFQ. This FFQ was 
developed to be applied in a case-control study of diabetes-related complications and 
for this reason, measuring past intake was important. An arguable issue on the 
development of a new FFQ is if to include portion size. For this FFQ, participants 
described their portion size with visual aids (food models, portion size booklet and 
measuring cups). A trained interviewer did both interviews for the FFQs, assuring 
completeness of the questionnaires. A challenge of including a portion size is when 
participants do not consume the amount of the food as indicated by choices for 
servings. This represents a problem because subjects have to calculate how often they 
consume the specified portion size. A review by Cade, et al. [28] showed that correlation 
coefficients between FFQ and references methods when subjects are allowed to 
describe their portion size is higher (0.5-0.6) than when a portion size is specified (0.4-
0.5). Similarly, correlation coefficients for this study between FR and FFQ-T1 was 0.68 
and with FFQ-T2 was 0.8. Our analysis showed that the questionnaire is reliable over 
time. The correlation coefficient 0.89 and the intraclass correlation coefficient 0.98 
showed good reliability and it was higher when compared with other studies [29,30].  
 
Regarding the validation of the FFQ, the dAGEs FFQ showed moderate to good 
agreement when compared with 7-dFR. The performance of the FFQ was considered 
adequate according to the criteria of Mason et al. [25], with a correlation coefficient 
above 0.5, 50% of subjects classified correctly into the same tertile, and weighted kappa 
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values of at least 0.4. All of these requirements were met on both applications of the 
FFQ, with the FFQ-T2 having sligtly better scores than FFQ-T1.  
 
There was no agreement concerning which statistical test should be used to measure 
validation, but using several methods increases the probability that a conclusion is true 
[25]. The analysis by the Bland-Altman method did not show systematic bias, but the 
limits of agreement were wide. However, Mason et al. [25] argued that for a FFQ 
expected to be used in epidemiologcal studies, it is more important that the instrument 
can classify subjects according to a category of intakes. Our results of cross-
classification indicated that our FFQ correctly classified more than 70% of subjects 
correctly.  
 
The database for this FFQ was compiled from published data, and as research in the 
field advances, additional food items with AGEs content will be added. At such time, this 
FFQ may need to be evaluated again as well. However, both the FFQ and the FR were 
analyzed with the same database which make any error similar on both methods. Other 
authors have faced similar challenges when attempting to validate a FFQ for 
compounds in foods not widely studied [22]. Currently, there is only one database with 
the amount of AGEs in foods, and the foods tested in the FFQ were the most commonly 
consumed within our population. 
 
A limitation of this study was the sample size. We only included 20 participants. 
However, it is important to point out that this is the first attempt to develop a FFQ 
measuring dAGEs, and further validation and review should follow. When biomarkers 
have been developed to reasonably reflect dAGEs, this also will add to determination of 
dAGEs role in health and disease. Additionally, this FFQ was designed and validated in 
a group of subjects with diabetes and mean age of 56.6 years. Before it can be used in 
another population it will need further validation.  
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The study of dAGEs in relation to health impacts faces several challenges. One of these 
is the large number and heterogeneity of AGEs [31], which has made measuring AGEs 
in foods and comparing data from different research groups difficult. Also, only short-
term effects have been measured and long-term effects have not been studied yet. The 
methodological design of long-term studies represents a great challenge. However, we 
hope that this FFQ could be used to generate the epidemiological data necessary to 
anwers the question about dAGEs and diabetes-related complications.  
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Figure 5.1. Development of the Food Frequency for dAGEs. 
 
 
 
Figure 5.2. Relative Contribution. 
 
Foods representing 95% of cumulative frequency were included on the FFQ. 
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Table 5.1. Energy and Macronutrients from 7-d FR (n=20) 
 Mean±SD 
Energy (Kcal) 
             (KJ) 
1948±504 
8156±2114 
Carbohydrates (g) 215±71 
Protein (g) 90±36 
Fat (g) 81±29 
Saturated Fat (g) 28 ± 13 
Results are presented as mean±SD.  
 
 
 
 
 
Table 5.2. dAGEs from 7-d FR and FFQ  
 Mean±SD Median, IR 
dAGEs 7-d FR (KU) 16884±9364 14766 (10671, 18668) 
dAGEs FFQ-T1 (KU) 16978±9085 13629 (11848, 13629) 
dAGEs FFQ-T2 (KU) 16419±9942 12766 (10456, 20673) 
 
Categories of dAGEs intake Low  Moderate High 
7-d FR (n) 1 9 10 
FFQ-T1 (n) 0 12 8 
FFQ-T2 (n) 0 13 7 
Results are presented as mean±SD and median and interquartile range.  
 
 
 
 
Table 5.3. Reliability for the FFQ. 
 FFQ-T1 vs FFQ-T2 
Spearman’s correlation 0.89*  
intraclass correlation coefficient 0.98**  
*(p<0.01), **CI (0.95, 0.99) 
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Table 5.3. Agreement between FFQs and 7-dFR 
 FFQ-T1 vs 7-d 
FR 
FFQ-T2 vs 7-d 
FR 
Spearman’s correlation 0.68* 0.80* 
Weight Kappa ± SE 
(95% CI) 
0.55±0.17 
(0.23, 0.860) 
0.64±0.15 
(0.35,  0.92) 
Cross-classification  
% classified into same tertile 75 80 
% classified into next tertile 25 20 
% misclassified 0 0 
*P<0.01 
 
 
 
 
 
 
 
Figure 5.3. Agreement between 7-d FR and FFQ-T1 for dAGEs 
 
 
 
 
 
 
  101 
Figure 5.4. Agreement between 7-d FR and FFQ-T2 for dAGEs 
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Chapter 6 
A Case-Control Study of Complications from Diabetes and Intake of Advanced 
Glycated End Products 
 
6.1 Introduction 
Diabetes-related complications classified as microvascular and macrovascular 
complications represent a health care burden. According to the 2011 National Diabetes 
Fact Sheet by the Center for Disease Control and Prevention (CDC), in 2004 heart 
diseases were noted on 68% of deaths and stroke among 16% of diabetes-related 
deaths. In 2005-2008, 67% of adults with self-reported diabetes had hypertension, and 
28.5% had retinopathy. In addition, diabetes is the leading cause of new blindness and 
the leading cause of renal failure. Regarding nervous system diseases, 60-70% had 
mild to severe forms of nervous system damage, almost 30% had impair sensation in 
the feet, and more than 60% of lower limb amputation are due to diabetes [1].  
 
Neuropathy (nervous system damage), nephropathy (renal system damage) and 
retinopathy (eye damage) can be classified as microvascular complications. On the 
other hand, cardiovascular disease (heart attack, chest pain, coronary heart disease, 
congestive heart failure), stroke, and peripheral vascular disease (leading to injuries, 
gangrene and amputation) can be classified as macrovascular complications [2]. Risk 
factors for microvascular and macrovascular are chronic exposure to hyperglycemia, 
age, years with diabetes, smoking, elevated triglycerides, and high BMI [2-4]. 
 
Hyperglycemia in diabetes leads to damage of vascular cells by non-enzymatic 
glycation (AGEs formation) and oxidative stress. High levels of glucose and subsequent 
autooxidation increase production of the AGEs precursors α-dicarbonyls (methylglyoxal, 
3-deoxyglucosone, and glyoxal). These α-dicarbonyls are very reactive and they form 
AGEs independently of HbA1c formation. In people prone to diabetes-related 
complications, dicarbonyl and oxidative stress are selectively activated, increasing 
glycated proteins and lipids byproducts, but not hemoglobin A1c (HbA1c) changes [5].  
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Some studies have shown elevation of serum AGEs in patients with diabetes-related 
complications [6]. For instance, serum AGEs were found to be significantly elevated in 
diabetic patients with coronary heart disease (CHD), (8.1 U/mL) vs diabetic patients 
without CHD (7.1 U/mL) [7]. Furthermore, AGEs levels increased with the progression of 
complications in subjects with diabetes mellitus (DM) [8]. 
 
In addition to endogenous AGEs, several studies have pointed also to dietary AGEs as 
a modulator of vascular damage [9-11]. In addition, data from several intervention 
studies indicate that the high intake of dietary AGEs contributes to tissue damage and 
increased levels of inflammatory markers that can be prevented by dietary AGEs 
restriction [12-15]. These results suggest that dietary AGEs could exert similar effects 
as those studied from endogenous AGEs at least through accumulation in the body in 
chronic degenerative diseases, particularly in diabetes and renal diseases. Furthermore, 
results from our research group pointed out that subjects with a moderate-high risk for 
cardiovascular disease (presence of cardiovascular disease, hypertension and 
hyperlipidemia) had a higher intake of dAGEs than those without risk for cardiovascular 
disease [16]. For this reason, the objective of this research was to investigate whether 
there was an association between different categories of AGEs intake and 
cardiovascular complications in patients with DM.  
 
6.2 Methods 
This was an observational study; in particular a case-control study to compare patients 
with DM that have diabetes-related complications (cases) to those with no complications 
(control). Our primary outcome was cardiovascular disease complications, but as 
secondary outcomes other complications were recorded.  
 
6.2.1 Sample Size  
A power analysis was conducted with data from a previous work on mean AGEs intake 
between participants with presence of cardiovascular disease complications and without 
it, and it was found that in order to achieve 80% power, alpha 0.05, a sample size of 42 
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participants was needed, 21 with diabetes complications and 21 without complications. 
This allowed for 2 participants to drop out, which is below the drop-out rate in the 
previous study (2 out of 30). 
 
6.2.2 Subject Characteristics 
Subjects with DM were recruited (n=42) through a primary care clinic, an endocrinology 
clinic, through key informants, and through a general email flyer to University faculty and 
staff. Non-Hispanic whites subjects older than 18 years were included. They had to 
have had type 2 DM within 2 to 20 years since diagnosis. For the cases group, subjects 
needed to have a diagnosis of any of the following cardiovascular complications: 
myocardial infarction, angina, coronary angioplasty, heart failure, cardiovascular 
bypass, stroke, transient ischemic attack, claudication, peripheral vascular disease. For 
the control group, they needed to have no cardiovascular complications. They were 
excluded if they were smokers (another source of exogenous AGEs), if they were 
pregnant or breastfeeding women (dietary changes due to condition), if they were vegan 
(strict vegetarian) or participants with a protein-restricted diet (would affect dietary 
AGEs), or if they were blind (self-report), cannot read (self-report), or not oriented to 
time and place as assessed by three questions. Also, they were excluded if they did not 
complete the seven days food record or if they failed to complete the second interview. 
 
6.2.3 Study Variables 
Dependent Variables 
Our main outcome variable was cardiovascular complications: myocardial infarction, 
angina, coronary angioplasty, heart failure, cardiovascular bypass, stroke, transient 
ischemic attack, claudication, and peripheral vascular disease. The subject’s primary 
care physician evaluated the subject for the presence of these complications. After the 
subject’s consent, the subject’s clinical history was obtained from the health care 
provider as well as results of a complete lipid profile (total cholesterol, low density 
lipoproteins [LDL-cholesterol], and triglycerides).  
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As a secondary outcome, other complications such as eye disease and renal disease 
were recorded. The subject’s primary physician also evaluated the subject for the 
presence of these complications. In addition, urine albumin and proteins lab results 
were requested, if available, to assess for renal disease complications. 
 
Independent Variable 
The exposure variable was the intake of dAGEs. We measured actual AGEs intake by 
seven days of dietary record and past intake by a food frequency questionnaire (FFQ). 
 
The AGEs intake was categorized in tertiles of consumption: low, moderate or high 
intake. For the AGE intake categories, we reviewed six previous clinical studies as 
described previously [16] evaluating the effects of high and low dAGEs with the purpose 
of developing a classification of AGEs intake. Consumption higher than 15000 KU was 
considered high, between 4000 and 15000 KU was considered moderate and less than 
4000 KU was considered low.  
 
For the analysis of dAGEs, a published database was used with approximately 500 
foods with their AGEs content [33]. Foods from food records were grouped into food 
categories, then, matched with specific foods from database with AGEs content. Foods 
with no specific match were estimated from similar foods from mean values. For the 
quantification of micro and macronutrients we used a commercial software Food 
Processor (ESHA Research, 2011). 
 
In our previous pilot study [16], 10 days of food records were used. However, after 
statistical analysis, we found that recording 7 days is sufficient for classifying the 
different AGEs categories. A FFQ validated for AGEs intake was used to measure past 
intake of AGEs. Additionally, subjects were asked if they had had significant changes in 
their diets in the last six months, last year or since diagnosis of diabetes. 
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6.2.4 Research Procedures  
Health care providers at Carle Foundation Hospital (Urbana, IL) gave an invitation letter 
(Appendix D, Figure D.1) to appropriate potential candidates. If potential participants 
were interested, they contacted the investigators through email or phone. In addition, 
participants were recruited through flyers at diabetes support groups and online bulletin 
(eweek). The inclusion/exclusion criteria were reviewed through email or phone before 
scheduling an appointment with potential participants (Appendix D, Figure D.2). 
 
If they met the criteria and were interested, a first appointment was scheduled for the 
person to meet with the researcher to review and sign the consent. This first 
appointment took around one hour. Potential participants read the consent, and it was 
explained to them that if they agreed to participate they needed to confirm a release for 
some information from their medical records. This information was related to 
cardiovascular complications: myocardial infarction, angina, coronary angioplasty, heart 
failure, cardiovascular bypass, stroke, transient ischemic attack, claudication, and 
peripheral vascular disease. Participants recruited through eweek or diabetes support 
groups were asked to obtain this information from their online medical records when 
available.  
 
After signing the consent, participants received instructions about how to answer a food 
frequency questionnaire (Appendix C, Figure C.4). Participants filled out the FFQ (45 
minutes). Then, participants received training about how to fill out the food records. For 
the training, food models, a food portion booklet and measuring cups were used to 
increase the accuracy of the amounts of food that they reported. The importance of 
reporting cooking methods and brand of foods when possible was emphasized. They 
were given written instructions, a food portion booklet and food records forms for 7 days 
(Appendix C, Figure C.5 and C.6). They also received two additional surveys to fill out at 
home (Appendix B, Figure B.8, and Figure B.10). 
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Staff at Carle was notified when the referral was interested and was requested to fill out 
the Diabetes Complications Data. They reviewed the medical record for information 
about the cardiovascular complications related to DM, as well as a list of diabetes-
related medications, including those related to cardiovascular, renal, eye, or peripheral 
conditions and as well as results of a complete lipid profile (total cholesterol, LDL-
cholesterol, VLDL- cholesterol and triglycerides), and urine albumin and proteins lab 
results were requested, if available, to assess for renal disease complications. 
(Appendix D, Figure D.4).  When participants did not receive their health care at Carle, 
they were asked to access their online medical records to provide their information 
regarding clinical data or to confirm with their physicians for the requested information. 
During recruitment, controls were matched to cases based on similar years since DM 
diagnosis.  
 
After subjects wrote down the first day’s food record, the investigator reviewed it for 
completeness, and to increase the likelihood that all foods were included, cooking 
methods, and portions, and to answer any questions the participants may have. This 
was done by phone or by e-mail.  
 
A last appointment was scheduled after subjects finished recording their 7 days of food 
records and the other surveys. In this last meeting, the investigator reviewed every food 
record and asked participants for specific details when needed, and for any clarification 
of cooking method or portion size or brand name. Participants received remuneration 
($50) upon completion of all questionnaires.  
Statistical Analysis 
Descriptive and categorical analysis of data, as well as logistic regression were used to 
find the odds of cardiovascular complications presence with high intake of dietary AGEs 
as the independent variable (SPSS). In addition, the weighted odds ratio will be 
calculated with the Mantel Haenszel method.  
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Smoking, years since diagnosis, HbA1c levels, some medications (metformin, lipid 
lowering medications) and antioxidants could be confounders for this study. Smoking 
was controlled at the design level by restricting participants that smoke. Cases and 
controls were matched by years since diagnosis and age. Levels of HbA1c, medications 
and antioxidants will be adjusted at the analysis phase.  
 
In order to address selection bias both groups had similar access to health care 
services. The interviews to obtain the dietary information and the quantification of AGEs 
on the diet were carried out by the researcher following established methodologies to 
minimize bias.  
 
Strengths 
Some of the strengths of this study were that was efficient and less expensive in 
comparison to a cohort study. In addition, we can assess several risk factors along with 
dietary intake of AGEs. 
 
Limitations 
This is a retrospective study and we should have caution with inference of a temporal 
relationship. This is a small population sample and we could risk having no statistical 
significance for our results. The results of this study are not generalizable, because we 
are studying non-Hispanic whites. 
Preliminary Results  
To date, we have data for 27 subjects, 15 controls and 12 cases. For the control group, 
there are 10 female and 5 males and for the case group there are 8 females and 4 
males. The mean and standard deviation for demographic characteristics and 
biochemical parameters are shown in Table 6.1. Preliminary data on dietary AGEs and 
dietary variables are shown in Tables 6.2 and 6.3. A t-test of these variables showed no 
significant differences between the group of controls and the group of cases. However, 
dietary AGEs was slightly higher in the cases, and this could indicate the trend for the 
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total sample size. For this study, cases were classified according to their presence of 
any of the following cardiovascular diseases: myocardial infarction, angina, coronary 
angioplasty, heart failure, cardiovascular bypass, stroke, transient ischemic attack, 
claudication, and peripheral vascular disease. It was decided not to include 
hypertension or dyslipidemias for classification purposes, but rather registered their 
presence and if pertinent adjust at the final analysis. For the group of controls, 67% of 
them had hypertension; in contrast, 91% of the cases had hypertension.  
 
It was important to ask for past and recent changes in the diet and it was found that 
20% reported changes in the last year and 73% since diagnosis for the control group 
and 17% for last year and 67% since diagnosis for cases. Subjects were classified by 
AGEs intake as previously described [16] as having a high intake, moderate or low 
intake, and their distribution by group is shown in Table 6.4. None of the subjects were 
classified as having a low intake. Therefore preliminary calculation of the odds ratio was 
done for high and moderate intake of AGEs. It was found that the odds ratio was 4, and 
after adjusting for years since diagnosis was 7.3 with a p-value of 0.057. 
 
For our final analysis, in addition to the dietary variables shown on Table 6.2, simple 
sugars and antioxidants from food records will be reported and analyzed to explore 
potential detrimental or protective role on diabetes-related complications. Other 
information to include will be information related to lipid lowering medications.  
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Table 6.1 Characteristics by Group. 
 Control n=15 Case n=12 
 Mean Standard Deviation Mean 
Standard 
Deviation 
Year with DM 8.7 4.4 10.9 6.9 
Age 57.8 11.6 58.5 10.5 
BMI (kg/m2) 38.1 10.9 38.9 7.1 
HbA1c (%) 7.7 1.4 7.8 1.5 
Fasting Glucose (mg/dL) 154.5 48.7 156.5 63.7 
Triglycerides (mg/dL) 137.1 68.3 221.1 130.8 
Cholesterol (mg/dL) 176.0 47.3 162.9 57.8 
Creatinine (mg/dL) 0.93 0.44 1.0 0.5 
t-test showed no significant differences between groups. 
DM=diabetes mellitus; BMI=body mass index; HbA1c=hemoglobin a1c 
 
 
Table 6.2 Dietary Variables by Group. 
 Control n=15 Case n=12 
 Mean Standard Deviation Mean 
Standard 
Deviation 
Dietary AGEs (AGE KU) 15299 5183 21208 11346 
AGEs density  
                 (AGE KU/Kcal) 8.6 3.5 10.7 5.5 
Kilocalories (Kcal) 1947 633 2038 689 
Carbohydrates (g) 207 81 204 53 
Protein (g) 86 28 97 49 
Fat (g) 88 40 93 39 
Saturate fat (g) 30 17 33 17 
t-test showed no significant differences between groups. !
 
Table 6.3 Intake of dAGEs in Cases and Controls  
Dietary AGEs   
Control 
 
      Total Case 
High Intake 
Moderate Intake 
6 
6 
3 
12 
9 
18 
Total 12 15 27 
Odds ratio was 7.3 after adjusting for years since diagnosis (p=.057). !
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 Chapter 7 
Conclusions and Future Directions 
 
Longitudinal studies have shown that glycemic control is the best strategy to delay 
complications in diabetes [1]. However, recent large clinical trials [The Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study, the Action in Diabetes and Vascular 
Disease (ADVANCE) study, and the Veterans Affairs Diabetes Trial (VADT)] with 
aggressive treatment to normalize hyperglycemia (HbA1c lower 6.5%) have shown no 
significant decrease in incidence of cardiovascular events or in the rate of death from 
any cause [2]. The overall results from these clinical trials show that glycemia control 
decreases retinopathy risk better than cardiovascular disease risk. Targeting glycemia 
only lowers risk for cardiovascular disease in a modest way [3]. 
 
This evidence has prompted researchers to discuss the need for new biomarkers that 
could predict diabetes-related complications more accurately, for instance, the 
endogenous AGEs (CML). A review by Beisswenger discussed evidence from studies in 
subjects with diabetes-related complications showing that AGEs can be formed 
independently from HbA1c formation. The argument about how AGEs could be better 
markers for diabetes-related complications over time is also discussed [4].  
 
The strongest data supporting this argument comes from an epidemiological study, the 
Joslin 50-year medalist study on subjects with Type 1 diabetes with more than 50 years 
with diabetes. They assessed retinopathy, neuropathy, nephropathy and cardiovascular 
complications (clinical data only). A lack of correlation between current HbA1c or long-
term HbA1c (average of 20 measurements over a period of time) and complications was 
found. In contrast, they found that subjects with high levels (above the media) of plasma 
CEL (carboxyl-ethylysine) and pentosidine were 7.2 fold more likely to have any 
complication [5].  
 
Similar to these results, our first study did not show a relation between HbA1c and risk 
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of complications. Our results showed that HbA1c was slightly high but not statistically 
different for Mexicans (8.2±1.8%) than for non-Hispanic whites (7.1±1.2%). However, 
non-Hispanics whites had a higher rate of cardiovascular risk than Mexicans. In 
addition, risk for diabetes-related complication could not be explained by HbA1c in the 
regression analysis [6]. However, a limitation of the study was that we did not measure 
endogenous AGEs to see if they explained better the differences in the rate of 
complications than HbA1c. Future studies should explore if there is a correlation 
between the amount of dAGEs estimated from dietary questionnaires with AGEs 
measured in serum or other tissues. In addition, preliminary results from our case-
control study suggest no difference in values of HbA1c between cases and controls.  
 
How AGEs damage tissues is still not completely understood. However, it is proposed 
that microvascular damage in the kidney, retina, and microvasculature of peripheral 
nerves could occur when endothelial cells are damaged with subsequent capillary 
occlusion, ischemia and organ damage [7]. Regarding cardiovascular complication, the 
proposed mechanisms are additional cross-linking on collagen by glycation of its free 
amino acids (collagen-AGEs cross-linking will produce stiffness of blood vessels), 
reduction of low-density lipoproteins (LDL) uptake by cell receptors, and reduction of 
nitric oxide synthase half-life in the endothelium [8]. This could explain some of the 
cardiovascular changes associated with the cardiovascular diseases seen in diabetes, 
such as vascular stiffening, diastolic dysfunction and endothelial dysfunction.  
 
In addition to endogenous AGEs, the role of dietary components on diabetes-related 
complications should also be discussed. For instance, it is well established that high fat 
leads to a reduction in flow-mediated vasodilatation (FMD) of the brachial artery, a 
standard test for in vivo endothelial function in humans [9]. More recently Urribarri et al. 
and Negrean et al. demonstrated that dietary AGEs could also alter FMD. In these 
studies it was found that FMD of the brachial artery decreased after a single challenge 
with dietary AGEs and inflammatory markers, such as VCAM-1, increased [10,11]. 
Long-term effects of dietary AGEs on FMD have not been studied, but it is possible that 
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a prolonged exposure could provoke permanent damage of vascular tissue. Indeed, a 
clinical study carried out during 6 weeks found that LDL in the group with high AGEs 
intake was more glycated than the low AGEs intake [12]. Glycated LDL has been 
proposed as one of the mechanisms for developing atherosclerosis [13]. The longest 
intervention on the effects of dietary AGEs (4 months) showed that patients assigned to 
the low AGEs diet had lower levels of serum CML, methylglyoxal, 8-isoprostanes (a 
lipoxidation marker) and insulin in serum, as well as a lower homeostatic model 
assessment (HOMA) when compared with the subjects with the regular AGEs intake 
(around 20 equivalent of AGEs, measured by 3 days of dietary records) [14]. Our results 
from a pilot study showed that subjects with higher intake of AGEs have a higher risk 
level for cardiovascular disease. Dietary AGEs better explained a high level of risk for 
cardiovascular disease than other variables from the diet (saturated fat) or any other 
variable studied [6]. In addition, our preliminary results for the case-control study 
measuring dietary AGEs for the last year point to a higher intake of AGEs in the group 
of cases and an odds ratio that could be indicative of negative association between 
cardiovascular diseases and dietary AGEs.  
 
Although a role for dietary AGEs in diabetes-related complications seems supported by 
the literature, there is yet no agreement among researchers working with dietary AGEs 
about important aspects of this area of research. For instance, in vitro cellular studies 
could help elucidate if intracellular signaling of AGEs interferes with the insulin pathways 
as MAPK  and PI-3K. This could explain why some studies have found improvement in 
insulin resistance after a diet low in dAGEs [14]. In addition, at least three different 
areas also demand further research: 1) absorption, metabolism and accumulation of 
dietary AGEs; 2) additional analytical quantification of AGEs in foods; and, 3) 
measurement of dietary AGEs from food questionnaires. 
  
The first area of research, absorption, excretion and metabolism studies have been 
broadly described before [15]. However, it is important to discuss a recent study by 
Roncero-Ramos et al. addressing accumulation of dietary AGEs in an animal model. 
  116 
They fed rats with different fractions and amounts of CML for 88 days [16]. It was found 
that the heart and tail tendons of rats had higher concentration of CML in the group with 
the higher intake of CML. The correlation between CML intake and the concentration in 
the heart was 0.41 (p=0.02). Despite the use of an animal model, these results support 
that high intake of dietary AGEs could result in their accumulation in target tissues 
affected by diabetes-related complications in healthy individuals. Further research 
supporting this evidence needs to be done in a diabetes mellitus animal model and also 
the length of this accumulation should be addressed.  
 
The second area of research, the analytical quantification of AGEs in foods is one of the 
most highly discussed among research groups. The heterogeneity of AGEs has made 
measuring them in foods and comparing data from different research groups difficult. 
Uribarri et al. used an immunohistochemical technique to quantify AGEs using arbitrary 
units (AGEs KU) for CML amount in foods. However, according to Zhang et al, high 
performance liquid chromatography and gas chromatography coupled with 
fluorescence, flame ionization or with mass spectrometry are more specific and 
sensitive methods for AGEs quantification [17]. For our study, we used the database 
published by Uribarri et al. [18]. Despite the use of arbitrary units and that comparison 
could not be made with other foods, this database have the larger amount of foods with 
content of AGEs. Food scientists need to standardize the methodologies for analytical 
quantification of dietary AGEs. Until then, Uribarri et al. database [18] represents a 
useful tool for estimating AGEs.  
 
The last area of research needing further attention is the estimation of dietary AGEs 
from food questionnaires. Measuring dietary variables has always been an approximate 
task since bias from the subject reporting the diet and bias from the observer exists. 
Measuring dietary AGEs adds difficulty to the task since dietary AGEs highly depend on 
cooking methods. The work from this dissertation contributed most to this issue. 
Previous studies failed to describe how the evaluation of AGEs from food records was 
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analyzed. Our study of the food frequency questionnaire explains in detail how this was 
done, and our proposed food frequency questionnaire could help to facilitate this task.  
 
It is true that long-term clinical studies are needed to corroborate the role of dietary 
AGEs on diabetes-related complications, however long-term dietary interventions 
always face compliance issues. For this reason, epidemiological observational studies 
could offer a good alternative for assessing the health impact of dietary AGEs especially 
in subjects with diabetes. Case-control studies addressing dietary exposures are always 
difficult to carry out because of a high possibility of recall bias. However, with outcomes 
having long latent periods, cohort studies are difficult to carry out and case-control are a 
good alternative to explore diet and disease interactions. For this reason, a case-control 
study was suggested for this work. One of the limitations of this study is its retrospective 
nature. Additionally, since diet is a cornerstone of diabetes subject’s treatment, people 
with diabetes may have changed their diets after diagnosis or after a complication is 
diagnosed. We were aware of this potential limitation and we asked about diet changes 
in the last year and since diagnosis of diabetes. Preliminary data showed no great 
difference between groups, however changes in diet for cases could hinder a relation 
between dAGEs and complications in this study. It seems from our preliminary results 
that controls have a lower intake of AGEs and the preliminary analysis indicates an 
odds ratio of 7.4 with a p value of 0.057. Despite its limitations, this study could support 
a proposal for a larger scale epidemiological study to corroborate these results. The 
best study design for doing this could be a cohort study at different stages of diabetes, 
but with subjects without complications, and as endpoint any diabetes-related 
complication. This could allow studying the influence of dAGEs before and after the 
onset of diabetes. 
 
In summary, this work found increased intake of dietary AGEs by subjects with diabetes 
with higher risk for cardiovascular disease and a possible negative association between 
dietary AGEs and diabetes-related cardiovascular complications. In addition, the 
development of the FFQ for dAGEs could help standardize data reported by other 
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researchers when measuring dAGEs in the diet. Recommendations regarding dAGEs 
still cannot be made because more research is needed. However, the health impact of 
dAGEs should not be ignored, especially in susceptible populations (subjects with 
diabetes and kidney disease).  
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Appendix A 
Additional Results for Chapter 4 
 
 
This appendix includes data that were not part of the published manuscript, however it 
is important to report these results. Previously, it was shown that body mass index 
(BMI) was statistically different between Mexicans and non-Hispanic whites. An analysis 
by gender was also carried out to analyze if the differences in BMI were due to gender 
only (Table A.1). It was found that BMI in males is similar among groups, while BMI in 
females was different only between Mexicans and non-Hispanic whites.  
 
Metformin intake and smoking could be confounders for this study; hence a brief 
description of its distribution among all participants is shown in Table A.2. 
 
Participants in the moderate-high risk level for cardiovascular disease had slight lower 
levels of HbA1c (7.9±1.8%) when compared with those in the low risk level (8±1.9%), 
but not statistically significant. 
Regarding the relationship of complications and dietary AGEs, only cardiovascular 
complications were associated with dietary AGEs (LogAGEs). The odds ratio found was 
3.01 with the following confidence intervals (1.1, 8.4) (X2=10.9, p=0.027 R2=0.24).  
Several variables have been reported as risk factors for cardiovascular disease, 
including smoking, BMI, hemoglobin a1c (HbA1c), and gender. In addition, metformin 
intake could have a role in decreasing levels of AGEs. For this reason, logistic 
regression was used to explore an independent relation for each of these variables with 
cardiovascular complications, but no associations were found.   
Finally, the effect of gender was also of interested and for this reason logistic regression 
was used to look for an association between dAGEs after controlling for gender. Results 
are shown on Table A.3. 
Additional results for dietary variables (Table A.4), health care variables (Table A.5) and 
the percentage of moderate-high risk cardiovascular disease, eye disease and 
peripheral disease (Figure A.1) are also shown. 
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Table A.1. BMI Results by Gender. 
 Mexicans Mexicans-Americans  Non-Hispanic Whites  
Males   
BMI (kg/m2) 
n=9 
29.1 ± 7.1 
n=8 
31.6 ± 4.4 
n=8 
35.7 ± 11.8 
Females 
BMI (kg/m2) 
n=26 
29 ± 4.1* 
n=7 
33.2 ± 9.6 
n=7 
36.8 ± 4.4* 
Results are presented as mean±SD. One-way ANOVA used for differences among groups. Same symbols show 
differences between groups (p<0.05). 
 
 
Table A.2. Metformin and Smoking Percentages.  
 Frequency 
Metformin 72% 
Current or past smokers 34% 
Current smokers:  
Less than 10 cigarettes per day 
More than 10 cigarettes per day 
12.3% 
9.2% 
3.1% 
 
 
Table A.3. Logistic Regressions for Cardiovascular Disease Complications.  
 β (SE) Odds Ratio 95% Confidence intervals 
Constant -8.352 (4.8)   
LogAGEs 1.07 (0.6)* 2.9 (1.01, 8.5) 
Gender 0.12(0.7) 1.1 (0.3, 4.5) 
X2=5.2, p=0.07 R2=0.11 
 
 
Table A.4. Dietary Variables. 
 Mexicans 
(n=35) 
Mexicans-Americans 
(n=15) 
Non-Hispanic Whites 
(n=15) 
Dietary AGEs  (KU) 6303 ± 2842 * 12947 ± 7940 † 19798 ± 8707 † 
Log Dietary AGEs¶  8.6 ± 0.5 * 9.3 ± 0.5 † 9.8 ± 0.4 ‡ 
Energy intake (Kcal) 1575 ± 330 * 1821 800 * 1984 ± 582 † 
Carbohydrates     (g) 217.5 ± 53.1* 214 ± 80 * 226.2 ± 67.4* 
Protein                 (g) 72.4 ± 22.2* 84 ± 41* 85.9 ± 21.1* 
Fat                       (g) 54.1 ± 15.1 * 71 ± 40 * 83.2 ± 31.2 † 
Saturated fat        (g) 13.5 ± 4.2 * 22 ± 12 † 27.7 ± 11.2 † 
Results are presented as mean±SD. ¶Natural logarithm transformation used because skewed data. One-
way anova used for differences among groups. Different symbols show differences between groups 
(p<0.05). 
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Table A.5. Health Care Variables. 
 Mexicans 
(n=35) 
Non-Hispanic 
Whites  (n=15) 
Mexicans in 
Illinois (n=15) 
Ophthalmologic visits     
Within the last 12 months (%) 37.1* 80* 60 
More than 1 year (%) 31.4 13.3 20 
Never (%) 31.4 6.7 20 
Diabetes Educator visits    
Within the last 12 months (%) 68.6 33.3 26.7 
More than 1 year (%) 5.7 60 33.3 
Never (%) 25.7 6.7 40 
Dietitian Visits    
Within the last 12 months (%) 65.7 33.3 33.3 
More than 1 year (%) 8.6 53.3 40 
Never (%) 25.7 13.3 26.7 
 
 
 
Figure A.1. Percentage of Moderate-High Risk Cardiovascular Disease, Eye Disease 
and Peripheral Disease. !
!!!!!!
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Appendix B 
Questionnaires for Chapter 4 
!
This appendix includes questionnaires in English and in Spanish used for the study “The 
Relationship Between Dietary Advanced Glycation end products and Indicators of 
Diabetes Severity in Mexicans and non-Hispanic Whites: A Pilot Study” presented on 
chapter 4. The material in this appendix includes Recruitment Material, Screening Tool, 
Inform Consent, Diabetes History Questionnaire, Vitamins and Supplement Intake and 
Food Records.  
!
Recruitment material!
 
Figure B.1. Recruitment Post on Eweek. 
 
 
 
 
 
 
 
 
Figure B.2. Recruitment Flyer. 
 
 
 
 
 
 
 
 
 
 
Diabetes, food-record study seeks participants 
------------------------------------------------------------------------ 
If you have diabetes, are 18 or older, and are willing to keep food 
records for 10 days, you could partipate in our study and receive 
$100. Especially seeking Hispanic adults from Mexico. Contact Claudia 
Luevano Contreras at luevano1@illinois.edu or 244-6281. 
We need participants for our study on diabetes mellitus complications 
and diet 
We invite you to participate: 
• If you have Diabetes Mellitus type 2 
• If you are 18 years or older, 
• If you are non-Hispanic white or Mexican American or Mexican,  
             AND 
• If you are willing to write down what you eat for 10 days  
You will get a compensation of 100 dollars if you write down for 10 
days what you eat. 
If you are interested, please contact Claudia Luevano: luevano1@illinois.edu, 217-721-2757, 
217-244-6281 
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Figure B.3. Recruitment Flyer in Spanish.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Necesitamos participantes para nuestro estudio de complicaciones 
en diabetes mellitus y el tipo de alimentación 
Te invitamos a participar si: 
• Tienes diabetes mellitus tipo 2 
• Eres mayor de 18 años 
• Si eres Mexicano o Mexico-Americano 
 
El estudio consiste en que registres tu consumo de alimentos por 10 días. 
Recibirás 100 dólares como compensación por tu participación. 
 Si estas interesado contacta a Claudia Luevano:   217-721-2757  o  217-244-6281 ,  
Luevano1@illinois.edu 
  126 
Screening Tools 
 
Figure B.4. Screening Tool.  
Are you 18 or older? 
____ yes [continue] ____No [thank but cannot continue] 
Are you either non-Hispanic white or Mexican American or Mexican? 
____ yes [continue] ____No [thank but cannot continue] 
Do you have type 2 diabetes? 
____ yes [continue] ____No [thank but cannot continue] 
Have you had your blood glucose or hemoglobin A1c measured in the past 3 months? 
____ yes [continue] ____No [thank but cannot continue] 
Do you know what that number was, and will you share that number with us? 
____ yes [continue] ____No [thank but cannot continue] 
Are you a vegan? 
____ yes [thank but cannot continue]____No [continue]  
Are you following a protein restricted diet for any reason? 
____ yes [thank but cannot continue]____No [continue]  
Are you pregnant or breastfeeding? 
____ yes [thank but cannot continue]____No [continue]  
Are you willing to write down what you eat for a 10 day timespan? 
____ yes [continue] ____No [thank but cannot continue] 
Do you have a phone, can you meet with one of the investigators, or can you email your first 
day's record so we can review any problems with the completeness of the record? 
____ yes [continue] ____No [thank but cannot continue] 
Where can we send your information packet, or when can we meet to review?  The information 
packet includes all the surveys and 2 copies of the informed consent. One copy is for you to keep. 
One copy needs to be mailed back to us or delivered to one of the investigators.  
 
Figure B.5. Screening Tool in Spanish.  
¿Eres mayor de 18 años?  
Si___   No___ ( gracias pero no puedes continuar) 
¿Eres Mexicano o Mexico-Americano?  
Si___   No___ ( gracias pero no puedes continuar) 
¿Tienes diabetes mellitus tipo 2? 
Si___   No___ ( gracias pero no puedes continuar) 
¿Te han medido tu  glucosa en ayunas o hemoglobina A1c en los últimos tres meses? 
Si___   No___ ( gracias pero no puedes continuar) 
 ¿Sabes los resultados y los compartirías con nosotros? 
Si___   No___ ( gracias pero no puedes continuar) 
¿Eres vegetariano? 
Si___   No___ ( gracias pero no puedes continuar) 
¿Estás embarazada o amamantando? 
Si___   No___ ( gracias pero no puedes continuar) 
¿Estás dispuesto a escribir todos los alimentos que consumas por un período de 10 días? 
Si___   No___ ( gracias pero no puedes continuar) 
¿Tienes teléfono o un correo electrónico para que los investigadores puedan revisar el 
registro de alimentos del primer día para ver que este completo? 
Si___   No___ ( gracias pero no puedes continuar) 
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Inform Consents 
 
Figure B.6. Inform Consent. 
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Figure B.6 (cont.) 
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Figure B.7. Inform Consent in Spanish. 
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Figure B.7 (cont.) 
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Diabetes History Questionnaires  
Figure B.8. Diabetes History Questionnaire. 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
 
 
 
 
  134 
Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
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Figure B.8 (cont.) 
 
Adapted from Michigan Diabetes 
Research and Training Center DH2.0 
© 1998 The University of Michigan 
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Figure B.9. Diabetes History Questionnaire in Spanish. 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Figure B.9 (cont.) 
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Code U ~ Vitamin and Supplement Sunray
Datl2! SP'tJb9
1. How often, if at all, do you take any vitamin or mineral supplemcnl in pill or
liquid fonn?
More thill, one supplement per day
Every day or almost everyday
Every so often
Not at all
11 {\\ \
\l.V) ) _
(1.1 )----- --
(1.2) ----
(1.3) /
If you checked 1.0, 1.1 or 1.2, please continue to 2.
2. Which types of supplements do you usuaiiy take (check all that apply)?
Muitivitamin
Multivitamin with iron or other minerals
Antioxidants
Single vitamins/minerals
(2.1)
(2.2)
(2.3) /'/
(2.4) //
If you know the name of the supplement, please list
3. Which of these single vitamins and minerals do you usually take? rfyou know the
milligrams of each, or the brand name, please provide that infonnation.
Vitamin A (3.1)
iVitamin BIB complex
2;,Vitamin C 3)
/!,Vitamin D 3.4i.IVitamin E 5
/
Calcium
6/
I
IFolacin 7
I
I
Fluoride
8/
Iron
9I
/
Zinc
(3.1OJ1Selenium
(3. 11)
Chromium
3. 2 /
Vitamins and Supplement Intake Questionnaires 
Figure B.10. Vitamins and Supplement Intake Questionnaire. 
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Something else (please specify) (3.13) _
4. How often, if at all, do you take a fish oil or omega three fatty acid supplement?
Every day or almost everyday (4.1 )
Number of capsules per day?Every so often
2)
Not at all
3
5.
How often, if at al , do you take a fiber supplement?
Every day or almost everyday
5
Every so often
.
U
V
6. How often, if at all, do you take a nutrition supplement, (such as Ensure,
Glucema, Slimfast) in either liquid or solid form?
Every day or almost everyday
Every so often
Not at all
(6.1)
(6.2) _
(6.3) _
If you checked 6.1 or 6.2, p~easespecify: ~ \
}/ A1 R.. 5W p~ (ft&V rei Lot)7. How often, if at all, do you take herbal remedies or supplements (example.
Echinacea, 81. Johns wort, Gingko bi10ba)?
Every day or almost everyday
Every so often
Not at all
(7.1) _
(7.2) _
(7.3) V
If you checked 7.1 or 7.2, please specify: _
8. Any other vitamins or supplements that you take?
~/
Figure B.10 (cont.) 
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Figure B.11. Vitamins and Supplement Intake Questionnaire in Spanish.  
 
 
 
Código______         Encuesta de vitaminas y suplementos  
Fecha _______ 
 
1. ¿Con qué frecuencia, tomar cualquier vitamina o suplemento mineral 
en forma de píldoras o líquido? 
Mas de un suplemento por día   (1.0) )________________ 
Todos los días ó casi todos los días  (1.1)________________ 
Muy frecuente      (1.2)________________ 
No en todos las anteriores     (1.3)________________ 
 
Si marcó 1.0, 1.1 o 1.2, por favor, siga 2 
. 
2. ¿Que tipo de suplemento usted usualmente toma ? (marque todo los que apliquen)  
Multivitaminas      (2.1)________________ 
Multivitaminas con hierro u otro mineral  (2.2)________________ 
Antioxidantes     (2.3)________________ 
Vitaminas y minerales solos   (2.4)________________ 
Si usted conoce el nombre del suplemento, por favor, márquelo 
 
3.  ¿Cuál de estas vitaminas y minerales normalmente toman? Si conoce 
los miligramos de cada uno, o la marca, sírvase proporcionar esa 
información. 
Vitamina A     (3.1)________________ 
Vitamina B/complejo B    (3.2)________________ 
Vitamina C     (3.3)________________ 
Vitamina D     (3.4)________________ 
Vitamina E     (3.5)________________ 
Calcio      (3.6)________________ 
Ácido fólico     (3.7)________________ 
Fluoruro      (3.8)________________ 
Hierro      (3.9)________________ 
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Figure B.11 (Cont.) 
 
 
Zinc      (3.10)_______________ 
Selenio      (3.11)_______________ 
Cromo      (3.12)_______________ 
Alguna otra cosa  (por favor especifique) (3.13)_______________ 
______________________________________________________________ 
1. ¿Con qué frecuencia, toma  aceite de pescado omega tres o suplemento de  ácidos 
grasos ¿ 
Todos los días o casi todos los días   (4.1)________________ 
Número de capsulas por día?            _______________ 
Muy frecuente       (4.2)________________ 
Ninguna       (4.3)________________ 
2. ¿ Con que frecuencia toma suplementos de fibra?  
Todos los días o casi todos los días  (5.1)________________ 
Muy frecuente      (5.2)________________ 
Ninguna       (5.3)________________ 
3. ¿ Con qué frecuencia, usted toma un suplemento nutricio, (tales como Ensure, 
Glucerna, Slimfast), ya sea en forma líquida o sólida? 
Todos los días o casi todos los días  (6.1)________________ 
Muy frecuente      (6.2)________________ 
Ninguna       (6.3)________________ 
Si usted marco 6.1 o 6.2, por favor especifique: ________________________ 
 
______________________________________________________________ 
 
4. ¿  Con qué frecuencia, usted toma remedios de hierbas o suplementos (ejemplos: 
Echinacea, mosto de St Johns, Gingko biloba)? 
Todos los días o casi todos los días  (7.1)________________ 
Muy frecuente      (7.2)________________ 
Ninguna       (7.3)________________ 
 
Si usted marco 7.1 o 7.2, por favor especifique: _________________________ 
 
 
8.  ¿Alguna otra vitamina o suplemento que usted tome ?  
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Food Records  
 
Figure B.12. Food Records. 
Instructions for Recording the Food Record 
1. Record everything you ate or drank during the 24-hour time period indicated (12:01 a.m. 
midnight) 
2. To the best of you ability described combinations or mixed dishes that were eaten. For 
example, what ingredients were included on that piece of pizza?  Was it thick or thin 
crust? Include brand names if known. 
3. Describe the amounts consumed in terms appropriate to that item. For example: ounces 
(cup) of milk, tablespoon of French dressing, slices of bread, pieces of fruit, etc. If you 
had a piece of pizza, how big was it in inches or sections, etc.? 
4. Describe how the food was cooked and for how long, if known or can be estimated. For 
example, 1 egg, scrambled in margarine; 1 breakfast biscuit microwaved on high or 2 
minutes.  
5. Remember to include beverages, and anything you may add to them, such as milk or 
sweetener.  
6. Remember to include anything added to a food after it is prepared, such as margarine, 
salt, catsup, and the estimated amount.  
7. If you need additional space, use the back of the paper or attach additional sheets. 
8. Answer the question at the bottom of the day’s record. (Does this day’s record represent 
your usual food intake? Yes____  No___). If your answer is no, explain why it was not 
representative. Were you ill or are you on a special diet? Did you have unexpected guests 
and you took them out to dinner? 
 
 
 Breakfast  
Raisin bran 
2% Milk 
Orange 
Toast with butter and  
strawberry jelly 
Coffee 
 
1 ounce o 30 ml 
6 ounce o 180 ml 
½ naranja 
1 piece and 1 teaspoon 
2 tablespoons 
1 taza (8 onzas o 240 ml) 
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Figure B.12 (Cont.) 
Day of the Week Code 
Food or Beverage Item 
Consumed 
Amount Consumed 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does this day’s record represent your usual food intake? ___  Yes ___ No. If not, please 
explain. 
Day of the Week ____________       Code________ 
 
Food record follow-up survey 
Please scan the food intake and answer these questions: 
1) Do you know the specific brand names for the products consumed?  Yes____ No ___ 
 If yes, please include brands on the list 
2) Were any of the foods microwaved?       Yes ___     No ___ 
 If yes, please list foods and how long the food was microwaved (approximately) 
and if the microwave power was high, medium, or low. 
3) Were any of the meats broiled or grilled?     Yes ___          No ____ 
 If yes, please mark which foods. 
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Figure B.13. Food Records in Spanish. 
INSTRUCCIONES PARA EL RECORDATORIO DE 24 HORAS 
 
CODIGO_____________ 
1.-Recuerde  TODO lo que haya comido o bebido durante las 24 horas de tiempo indicado 
(12:01 a.m.-medianoche) 
2.-Describa la combinación o mezclas de platillos que haya consumido. Por ejemplo, ¿cuales 
ingredientes  se incluyeron en ese pedazo de pizza? ¿La pasta de la  pizza es gruesa o delgada? 
Incluya el nombre del pan si lo sabe. 
3.-Describa la   cantidad consumida en términos apropiados para este caso. Por ejemplo: 
onzas (tazas) de leche, cucharadas de aderezo, rebanadas de pan, piezas de frutas, etc. Si tiene 
un trozo de pizza que tan grande es en centímetros o rebanadas. Recuerde exactamente las 
cantidades, lo mejor que Ud. pueda. 
4.-Describa como se cocinó la comida y  por cuánto tiempo si puede calcularlo. Por ejemplo: 
1 huevo frito en margarina, 1 bisquet en el microondas a potencia alta por 2 minutos. 
5.-Recuerde las bebidas y cada cosa que agregó a ellas, como leche y  endulzante. 
6.-Recuerda incluir cualquier cosa que se agregue a la comida después de ser preparada, como 
margarina, sal, cátsup y la cantidad calculada.   
7.-Si necesita espacio adicional, utilice la parte posterior de la hoja o agregue otras  hojas 
adicionales. 
8.-Responda las preguntas en la parte inferior del cuestionario. 
¿Este recordatorio representa su alimentación usual?  Si ______No________ 
Si no es así, explique porque no es representativo. 
¿Está en una dieta especial?__________________________ 
¿Tuvo invitados inesperados y  salió a comer fuera?_________________ 
 
EJEMPLO DE DESAYUNO  
Cereal Raisin bran 
2% leche 
Naranja 
Pan integral tostado con mantequilla 
  Y con mermelada de fresa 
Café negro 
 
1 onza o 30 ml 
6 onzas o 180 ml 
½ naranja 
1 porción(de mantequilla) 
2 cucharadas cafeteras 
1 taza (8 onzas o 240 ml) 
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Figure B.13 (Cont.) 
DIA DE LA SEMANA CÓDIGO 
COMIDA O BEBIDA CONSUMIDA CANTIDAD CONSUMIDA 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
¿Este  día de recordatorio representa su comida  usual? Si_____  No______ 
Si es no explique porque_______________________ 
Por  favor  revisa los alimentos consumidos  y contesta las siguientes preguntas 
1.- ¿Sabes lo nombres específicos de las marcas  incluidas en los productos consumidos? 
Si_______________   No_______________ 
Si es si incluya el listado 
 ¿Alguna de las comidas fue horneada en microondas? 
 Si es si, que poder tuvo: alto, medio o bajo y tiempo (aproximadamente). 
3.- ¿Algún alimento fue cocinado a la parrilla o asado? 
Si_______________ No___________________ 
Si es si  describa cual de los alimentos. 
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Appendix C 
Questionnaires for Chapter 5 
 
This appendix includes questionnaires used for the study “Development, Relative 
Validity, and Reliability of a Food Frequency Questionnaire for a Case-Control Study on 
Dietary Advanced Glycation End Products and Diabetes Complications” presented on 
chapter 5. The material in this appendix includes Recruitment Material, Screening Tool, 
Inform Consent, Food Frequency Questionnaire and Food Records.  
 
 
 
 Figure C.1. Recruitment Material. 
WE NEED PARTICIPANTS FOR TESTING A FOOD 
QUESTIONNAIRE. 
We invite you to participate: 
• If you have Diabetes Mellitus type 2, 
• If you are 18 years or older, 
AND 
• If you are willing to write down what you eat for 7 days 
and complete 2 food frequency surveys. 
You will get $50 dollars.  
If you are interested, please contact Claudia Luevano: luevano1@illinois.edu, 217-974-0710. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  167 
Figure C.2. Screening Tool 
Screening Tool 
 
Name:  __________________________________  Date: _____________________ 
 
 
Cognitive Evaluation: 
 
1. What is the day of the week? 
2. Do you know where you are?  
3. What is your name?  
 
If person does not know the answer to any of the questions, thank them 
for their time and tell them they are not eligible. 
 
Inclusion criteria: 
 
1. Are you 18 years old and older? 
2. Do you have type 2 diabetes? 
3. Can you read?  
 
 
If person responds no to any questions above, thank them for their time 
and tell them they are not eligible. 
 
Exclusion criteria: 
 
1. Are you blind? 
2. Are you a vegan? 
3. Are you following a protein restricted diet for any reason? 
4. Are you willing to write down what you eat for a 7 day timespan? 
5. Do you have a phone, can you meet with one of the investigators, or can 
you email your first day's record so we can review any problems with the 
completeness of the record? 
 
If person responds yes to any questions above, thank them for their time 
and tell them they are not eligible. 
 
 Patient is eligible to participate in study 
 Patient is ineligible to participate in study 
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Figure C.3. Inform Consent 
Title!of!Project:!Relative!validity!of!a!food!frequency!questionnaire!for!assessing!dietary!advanced!glycation!end!products.  !
Responsible!Principal!Investigator:!Dr.!Karen!Chapman<Novakofski,!University!of!Illinois!at!Urbana<Champaign!! 1. Purpose!of!the!study:!This!is!a!research!study!looking!at!some!food!components!found!in!foods!rich!in!protein!or!fat!that!when!are!fried,!broiled!or!grilled!could!be!associated!to!diabetes!complications.!We!need!a!good!questionnaire!to!measure!these!components!in!the!diet!of!individuals.!For!this!reason!this!research!is!looking!to!validate!a!food!frequency!questionnaire.!! 2. Procedures!to!be!followed:!After!you!have!been!screened!for!eligibility!in!this!project!(able!to!read!and!write!and!answer!a!couple!basic!questions),!you!will!be!briefly!trained!on!how!to!complete!a!food!frequency!questionnaire!(10!minutes).!This!training!can!be!completed!at!the!investigator’s!office!or!at!your!place!of!convenience.!We!will!read!with!you!the!instructions!for!completing!the!food!frequency!questionnaire.!In!addition,!we!will!provide!you!with!food!models!or!pictures!of!foods’!portion!size!that!could!help!you!to!answer!the!questionnaire.!You!will!fill!out!the!food!frequency!questionnaire!in!this!first!meeting!(approximate!time!is!40!minutes).!At!the!end!of!this!first!meeting!we!will!set!an!appointment!to!see!you!again!in!two!weeks.!The!total!time!for!the!first!meeting!is!around!1!hour.!At!this!second!meeting!you!will!again!fill!out!the!food!frequency!questionnaire.!We!will!read!with!you!the!instructions!and!we!will!provide!you!with!food!models!and!pictures!of!foods’!portion!size!again.!At!the!end!of!this!meeting!we!will!give!you!a!closed!package!with!food!records!that!you!fill!out!for!7!days.!We!will!give!you!a!brief!training!on!how!to!fill!out!these!food!records.!The!total!time!for!the!second!meeting!is!also!around!1!hour.!We!will!ask!you!to!start!filling!out!the!food!records!two!weeks!after!our!second!meeting.!We!will!send!you!a!reminder!email!or!leave!a!phone!message.!After!you!fill!out!the!first!food!record,!one!of!the!investigators!will!review!it!with!you!to!make!sure!you!understand!all!the!information!about!the!food!we!need.!This!can!be!by!e<mail,!by!fax!or!by!telephone.!All!seven!days!must!be!recorded,!but!they!do!not!need!to!be!consecutive!in!case!a!special!occasion!arises.!Each!food!record!will!take!around!15!minutes!to!fill!out.!!At!the!end!of!the!study!you!need!to!meet!again!with!the!investigator!by!phone!or!in!person,!to!review!the!completeness!of!the!food!records.!This!last!meeting!will!take!around!10!to!15!minutes.!!!Therefore,!for!this!research!your!total!time!commitment!will!be!around!4!hours.!! 3. Discomfort!and!Risks!and!Costs:!If!you!choose!to!visit!the!investigator!in!person,!you!may!have!transportation!costs.!If!you!use!your!telephone!or!internet!service!to!send!food!records,!you!could!have!a!charge!to!participate.!There!are!not!risks!outside!of!those!you!may!encounter!in!everyday!life.!!!!
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Figure C.3 (Cont.)!4. Benefits:!There!are!not!personal!benefits!to!you!for!participating!in!this!study.!However,!your!participation!may!help!us!to!find!a!good!questionnaire!to!asses!some!components!in!foods!that!could!be!linked!to!diabetes!complications.!! 5. Statement!of!confidentiality:!All!the!questionnaires!and!food!records!will!be!coded.!A!key!with!your!code!and!your!name!will!be!kept!in!a!locked!cabinet!at!the!investigators!office!until!all!the!questionnaires!are!completed.!The!identifying!key!will!then!be!shredded.!We!will!use!screening!forms!for!evaluating!eligibility!for!this!study.!Your!consent!form!and!the!screening!form!will!also!be!kept!locked!in!the!investigator’s!office.!At!the!end!of!the!study!the!screening!form!will!also!be!shredded.!The!results!of!this!research!could!be!published!in!professional!meeting!or!journals,!but!no!personal!information!will!be!shared.!!! 6. Whom!to!contact:!Please!contact!Dr.!Karen!Chapman<Novakofski!(217<244<2852,!kmc@illinois.edu)!or!Claudia!Luevano<Contreras!(217<974<0710,!luevano1@illinois.edu)!if!you!have!any!question!or!concerns.!You!may!also!contact!us!if!you!feel!you!have!been!injured!or!harmed!by!this!research.!If!you!have!any!question!about!your!rights!as!a!participant!in!this!study,!please!contact!the!University!of!Illinois!Institutional!Review!Board!at!217<333<2670!or!via!email!at!irb@illinois.edu.!!! 7. Compensation:!If!you!complete!the!food!frequency!questionnaires!and!the!food!records!you!will!receive!$50.!If!you!complete!only!the!food!frequency,!you!will!receive!$10.!For!completing!both!food!frequencies!and!not!completing!the!7!days!of!food!records,!you!will!receive!$20.!! 8. Voluntariness:!Your!participation!is!voluntary.!You!may!discontinue!at!anytime.!The!decision!to!participate,!decline,!or!withdrawn!from!participation!will!have!no!effect!on!future!relations!with!the!University!of!Illinois.!!!!
• I!am!18!years!of!age!or!older!
• I!have!read!and!understand!the!above!consent!form!and!voluntarily!agree!to!participate!in!this!study.!
• You!will!be!given!a!copy!of!this!consent!form!for!your!records.!!!!!!!_______________________!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!______________________!Participant!signature!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Date!!!!
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Figure C.4. Food frequency questionnaire. 
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Figure C.4 (Cont.) 
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Figure C.4 (Cont.) 
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Figure C.4 (Cont.) 
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Figure C.4 (Cont.) 
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Figure C.5. Food record.
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Figure C.5 (Cont.) 
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Figure C.5 (Cont.) 
Food or Beverage consumed / Place / Time 
Please remember to include brands of foods and cooking type. 
Amount  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Does this day’s record represent your usual food intake? ___  Yes ___ 
No.  
If not, please explain. 
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Figure C.6. Food Portion Booklet 
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Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
 
 
 
 
  184 
Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
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Figure C.6 (Cont.) 
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Appendix D 
Questionnaires for Chapter 6 
 
This appendix includes questionnaires used for the study “A Case-Control Study of 
Complications from Diabetes and Intake of Advanced Glycated End Products” 
presented on chapter 6. The material in this appendix includes Invitation Letter, 
Screening Tool, Inform Consent, and Diabetes Complications Data. 
 
Figure D.1. Invitation Letter 
Dear Patient,  
 
We want to invite you to participate in a research project that is a joint 
project between the University of Illinois and Carle.  The research study is 
called A Case-Control Study of Complications from Diabetes and Intake of 
Advanced Glycated End Products. 
 
Advanced Glycation End Products are found in some foods rich in proteins 
and fat and that are fried, broiled or grilled. We want to see if eating very 
high or very low levels of these foods is associated with complications of 
diabetes. 
 
To be in the study you must be over 18 years old, have diabetes, to not be a 
smoker, and be willing to keep a food intake record for 7 days. The expected 
duration of the study will be ten days in which you have to record your 
entire food intake. 
 
You will receive $50 as compensation for keeping the food records and for 
allowing indicators of your health to be released to the investigators. Those 
indicators include your hemoglobin A1c, your blood pressure, if you have 
albumin in your urine, your blood lipid levels, whether you have indications 
of eye, kidney or nervous tissue damage that may be caused by your 
diabetes.  
 
 
If you would like to participate or have questions about participating, please 
call or email Dr. Karen Chapman-Novakofski at 217-244-2852, 
kmc@illinois.edu or Claudia Contreras at luevano1@illinois.edu. 
 
Thank you 
 
[physician name] 
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Figure D.2. Screening Tool. 
Screening Tool 
 
Name:  __________________________________  Date: _____________________ 
 
Cognitive Evaluation: 
 
4. What is the day of the week? 
5. Do you know where you are?  
6. What is your name?  
 
If person does not know the answer to any of the questions, thank them 
for their time and tell them they are not eligible. 
 
Inclusion criteria: 
 
4. Are you 18 years old and older? 
5. Do you have type 2 diabetes? 
6. Have you had type 2 diabetes for 3 to 10 years?  
7. Are you willing to write down what you eat for a 7-day timespan? 
8. Do you have a phone, can you meet with one of the investigators, or 
can you email your first day's record so we can review any problems 
with the completeness of the record? 
9. Can you read?  
 
If person responds no to any questions above, thank them for their time 
and tell them they are not eligible. 
 
Exclusion criteria: 
1. Are you a vegan or vegetarian? 
2. Are you following a protein-restricted diet for any reason? 
3. Are you blind?  
4. Do you smoke? 
5. Are you pregnant? 
6. Are you breastfeeding? 
 
If person responds yes to any questions above, thank them for their time 
and tell them they are not eligible. 
 
 Patient is eligible to participate in study 
 Patient is ineligible to participate in study 
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Figure D.3. Inform Consent. 
Title! of! Project:!A!Case<Control!Study!of!Complications! from!Diabetes!and!Intake!of!Advanced!Glycated!End!Products.!
Responsible! Principal! Investigator:! Dr.! Karen! Chapman<Novakofski,! University! of!Illinois!at!Urbana<Champaign!! 1. Purpose!of!the!study:!This!is!a!research!study!looking!at!some!food!components!found!in!foods!rich!in!protein!or!fat!that!when!are!fried,!broiled!or!grilled!could!be!associated!to! diabetes! complications.! We! will! measure! these! components! on! foods! with! a! food!frequency! questionnaire! and! with! 7<days! of! food! records.! In! addition,! we! will! need!information! from! your! physician! regarding! diabetes! related! cardiovascular!complications,!as!well!as!a!list!of!diabetes<related!medications,!including!those!related!to!cardiovascular,!renal,!eye,!or!peripheral!conditions.!Specifically!we!will!need!information!regarding!presence!of!myocardial!infarction,!angina,!coronary!angioplasty,!heart!failure,!cardiovascular! bypass,! stroke,! transient! ischemic! attack,! claudication,! and! peripheral!vascular!disease.! In!addition,! results!of!a! complete! lipid!profile! (total! cholesterol,!LDL<cholesterol,! VLDL<! cholesterol! and! triglycerides),! and! urine! albumin! and! proteins! lab!results! will! be! requested,! if! available,! to! assess! for! renal! disease! complications.! The!purpose!is!to!find!if! there!is!an!association!between!the!diabetes<related!complications!and!the!food!components!that!we!are!measuring.!! 2. Procedures! to!be! followed:!After!you!have!been!screened!for!eligibility!in!this!project!(able! to! read! and! write! and! answer! a! couple! basic! questions)! and! you! consent! to!participate,! you! will! be! briefly! trained! on! how! to! complete! a! food! frequency!questionnaire!(5!minutes).!This!training!can!be!completed!at!the!investigator’s!office.!We!will!read!with!you!the!instructions!for!completing!the!food!frequency!questionnaire.!In!addition,!we!will! provide! you!with! food!models! or! pictures! of! foods’! portion! size! that!could! help! you! to! answer! the! questionnaire.! You! will! fill! out! the! food! frequency!questionnaire! in! this! first! meeting! (approximate! time! is! 35! minutes).! Then,! you! will!receive! training! about! how! to! fill! out! the! food! records! (5! minute).! You! will! be! given!written!instructions,!a!food!portion!booklet!and!food!records!forms!for!7!days.!You!also!will! receive! two! additional! surveys! to! fill! out! at! home! (Diabetes!History! and!Vitamins!Intake).!At!the!end!of! this! first!meeting!we!will!set!an!appointment!to!see!you!again! in!two!weeks.!The!total!time!for!the!first!meeting!is!around!50!minutes.!We!will!ask!you!to!start!filling!out!the!food!records!a!day!after!our!first!meeting.!After!you!fill!out!the!first!food! record,! one! of! the! investigators! will! review! it! with! you! to! make! sure! you!understand!all!the!information!about!the!food!we!need.!This!can!be!by!e<mail,!by!fax!or!by!telephone.!All!seven!days!must!be!recorded,!but!they!do!not!need!to!be!consecutive!in!case!a!special!occasion!arises.!Each!food!record!will! take!around!15!minutes!to!fill!out,!and! the! additional! surveys! (Diabetes!History! and!Vitamins! Intake)! around!10!minutes!each.!When!you! finish!your! food!records!and!surveys!you!need!to!meet!again!with! the!investigator!in!person,!to!review!the!completeness!of!the!food!records.!This!last!meeting!will! take!around!10!minutes.! !Therefore,! for! this!research!your! total! time!commitment!will!be!around!3!hours.!! 3. Discomfort!and!Risks!and!Costs:!If!you!choose!to!visit!the!investigator!in!person,!you!may!have!transportation!costs.!If!you!use!your!telephone!or!internet!service!to!send!food!records,!you!could!have!a!charge!to!participate.!There!are!not!risks!outside!of!those!you!may!encounter!in!everyday!life.!!
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Figure D.3 (Cont.) 4. Benefits:! There! are! not! personal! benefits! to! you! for! participating! in! this! study.!However,!your!participation!may!help!us!to!determine!if!the!food!components!that!we!are!studying!are!associated!with!increased!complications!secondary!to!diabetes.!!! 5. Statement!of!confidentiality:!All!the!questionnaires!and!food!records!will!be!coded.!A!key!with!your!code!and!your!name!will!be!kept!in!a!locked!cabinet!at!the!investigators!office! until! all! the! questionnaires! are! completed.! The! identifying! key! will! then! be!shredded.!We!will! use! screening! forms! for! evaluating! eligibility! for! this! study.! Your!consent! form! and! the! screening! form! will! also! be! kept! locked! in! the! investigator’s!office.!At!the!end!of!the!study!the!screening!form!will!also!be!shredded.!The!results!of!this!research!could!be!published!in!professional!meeting!or! journals,!but!no!personal!information!will!be!shared.!!! 6. Whom! to! contact:! Please! contact! Dr.! Karen! Chapman<Novakofski! (217<244<2852,!kmc@illinois.edu)! or! Claudia! Luevano! (217<974<0710,! luevano1@illinois.edu)! if! you!have! any! question! or! concerns.! You! may! also! contact! us! if! you! feel! you! have! been!injured! or! harmed!by! this! research.! If! you! have! any! question! about! your! rights! as! a!participant! in! this!study,!please!contact! the!University!of! Illinois! Institutional!Review!Board!at!217<333<2670!or!via!email!at!irb@illinois.edu.!! 7. Compensation:! If! you! complete! the! food! frequency,! the! food! records! and! the!additional!surveys!you!will! receive!$50.! If!you!complete!only! the! food! frequency and!additional!surveys!you!will!receive!$25,!and!at!the!last!meeting!after!you!turn!in!the!7<day!of!food!record,!you!will!received!another!$25.!!!8. Voluntariness:!Your!participation! is!voluntary.!You!may!discontinue!at!anytime.!The!decision!to!participate,!decline,!or!withdrawn!from!participation!will!have!no!effect!on!future!relations!with!the!University!of!Illinois.!!
• I!am!18!years!of!age!or!older.!
• I! have! read! and! understand! the! above! consent! form! and! voluntarily! agree! to!participate!in!this!study.!
• You!will!be!given!a!copy!of!this!consent!form!for!your!records.!!!_____I! will! initial! here! if! my! physician! can! share! information! regarding! diabetes<related! complication! with! the! investigators.! I! understand! that! they! will! not! have!direct!access!to!my!medical!records.!!!!_______________________!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!______________________!Participant!signature!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Date!
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Figure D.4. Diabetes complications data. 
CODE:_________________ 
 
 
            Values: 
HbA1c  
Glucose levels   
Triglycerides  
Cholesterol  
LDL, low-density lipoprotein cholesterol level  
Serum Creatinine  
Albumin  
Actual Medication  
Weight   
Height   
Arterial Pressure  
 Yes  No  
Cardiovascu lar  d i s ease     
Angina     
CABG, coronary artery bypass graft;     
CAD, coronary artery disease;     
CHF, congestive heart failure;     
CVA, cerebrovascular accident;     
CVD, cardiovascular disease;     
HTN, hypertension;     
LVH, left ventricular hypertrophy;     
MI, myocardial infarction;     
PVD/per iphera l  vascu lar  d i s eases     
Amputation    
Ulcer or infection    
Gangrene    
Acute ischemic foot     
Bypass for PVD     
Diminished sensation    
Intermittent claudication    
Abnormal NIVS, noninvasive vascular 
studies;  
   
Eye d i s ease  compl i ca t ions :     
 
 
 
   
Renal  d i s ease  compl i ca t ions :  
 
 
   
Proteinuria    
Microalbuminuria    
 !
 
 
 
 
